|
177Lu-EVS459
|
|
[177Lu]Lu-EVS459|Lutetium Lu 177 EVS459 |
|
177Lu-EVS459 is a radioconjugate comprising the radionuclide Lutetium-177 linked to EVS459, a FOLR1-targeting ligand, which delivers radiation to FOLR1-expressing tumor cells, potentially resulting in tumor cell death (NCI Drug Dictionary). |
|
177Lu-FF58
|
|
177LuFF58|[177Lu]-FF58|Lutetium Lu 177 FF58 |
|
177Lu-FF58 is a radioconjugate comprising a non-RGD small molecule that targets integrins alphaVbeta3 and alphaVbeta5 conjugated to the radionuclide lutetium-177, which delivers beta radiation to tumor cells expressing integrin alphaVbeta3 or alphaVbeta5, potentially resulting in antitumor activity (NCI Drug Dictionary). |
|
177Lu-RAD204
|
|
177Lu RAD204|177LuRAD204 |
PD-L1/PD-1 antibody
137
|
177Lu-RAD204 is a radioconjugate comprising the radionuclide lutetium-177 conjugated to a nanobody targeting CD274 (PD-L1), which potentially delivers beta radiation to tumor cells expressing CD7274 (PD-L1), resulting in tumor cell cytotoxicity (NCI Drug Dictionary). |
|
177Lu-edotreotide
|
|
177LuDOTATOC|177Lu-DOTA-Tyr3-octreotide|177Lu-Edo |
|
177Lu-edotreotide is a radioconjugate comprising the somatostatin analog edotreotide linked to Lu 177, which may have anti-tumor activity (NCI Drug Dictionary). |
|
177Lu-rhPSMA-10.1
|
|
177Lu rhPSMA-10.1|(177Lu) rhPSMA-10.1|Lutetium Lu 177 PSMA-10.1 |
|
177Lu-rhPSMA-10.1 is a radioconjugate comprising the radionuclide lutetium-177 linked to a PSMA-targeted ligand, PSMA-10.1, which delivers radiation to PSMA-expressing tumor cells, potentially resulting in increased tumor cell death and antitumor activity (PMID: 36692961, NCI Drug Dictionary). |
|
1A46
|
|
CMG1A46|CMG 1A46|CMG-1A46 |
CD19 Antibody
22
CD20 Antibody
28
CD3 Antibody
123
|
1A46 is a trispecific antibody that targets tumor-expressed CD19 and CD20, and T cell-expressed CD3, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD19 and CD20 (NCI Drug Dictionary). |
|
212Pb-Pentixather
|
|
212-Lead Pentixather |
|
212Pb-Pentixather is a radioconjugate comprising the radionuclide 212Pb linked to pentixather, a CXCR4-targeting ligand, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 5034, NCI Drug Dictionary). |
|
212Pb-VMT-alpha-NET
|
|
[212Pb] VMT-a-NET |
|
212Pb-VMT-alpha-NET is a radioconjugate comprising the radionuclide 212Pb linked to a SSTR2 peptide analogue peptide, which delivers radiation to SSTR2-expressing tumor cells, potentially resulting in decreased tumor growth (J Nucl Med June 2023, 64 (supplement 1) P772, NCI Drug Dictionary). |
|
225Ac-DOTA-Daratumumab
|
|
[225Ac]-DOTA-Daratumumab |
|
225Ac-DOTA-Daratumumab is a radioconjugate comprising daratumumab, a monoclonal antibody that targets CD38, linked to the radionuclide Actinium-225, which delivers radiation to tumor cells, potentially resulting in cytotoxic effects and inhibition of tumor growth (PMID: 31413916, NCI Drug Dictionary). |
|
225Ac-FPI-1966
|
|
225Ac-Vofatamab|[225Ac]-FPI-1966|actinium-225 vofatamab |
|
225Ac-FPI-1966 is a radioconjugate comprising vofatamab, a monoclonal antibody that targets FGFR3, linked to the radionuclide Actinium-225, which delivers radiation to tumor cells, potentially resulting in cytotoxic effects (NCI Drug Dictionary). |
|
225Ac-PSMA-R2
|
|
225AcPSMA-R2|Ac225-PSMA-R2|[225Ac]Ac-PSMA-R2 |
PSMA Antibody
24
|
225Ac-PSMA-R2 is a radioconjugate comprising the PSMA-targeting ligand PSMA-R2 linked to the radionuclide actinium-225, which delivers alpha radiation to PSMA-expressing tumor cells, potentially inducing cell killing (NCI Drug Dictionary). |
|
27T51
|
|
27T-51|27T 51|bbT 4015|bbT-4015|bbT4015 |
MUC16 Targeted Therapy
11
|
27T51 comprises T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets MUC16, which potentially induces toxicity in tumor cells expressing MUC16 (NCI Drug Dictionary). |
|
2B3-101
|
|
2B3101|2B3 101 |
|
2B3-101 is a glutathione pegylated liposomal doxorubicin hydrochloride formulation (NCI Drug Dictionary). |
|
4SC-205
|
|
LH031|4SC205|4SC 205|SC-205 |
|
4SC-205 inhibits human kinesin-related motor protein Eg5, which may lead to cell cycle arrest and apoptosis in tumor cells (NCI Drug Dictionary). |
|
8-Chloroadenosine
|
|
8-Chloro-adenosine|8-Cl-Ado|8-Cl-adenosine |
Chemotherapy - Antimetabolite
14
|
8-Chloroadenosine is an adenosine derivative that acts as a ribonucleoside analog following phosphorylation, potentially resulting in inhibition of transcription and decreased cell proliferation (NCI Drug Dictionary). |
|
A2B395
|
|
A-2B395|A 2B395 |
EGFR Immune Cell Therapy
5
|
A2B395 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting EGFR, and containing an HLA-A*02-targeted LIR-1-based inhibitory receptor, and shRNA targeting beta2 microglobulin (B2M), which potentially induce killing of tumor cells expressing EGFR with loss of heterozygosity for HLA-A*02 (J Clin Oncol 2025 43: 16_suppl, TPS2677, NCI Drug Dictionary). |
|
AB-101
|
|
AB101|AB 101 |
|
AB-101 are umbilical cord blood-derived NK cells expressing a high-affinity CD16 variant, which may lead to antibody-dependent cellular cytotoxicity and increased anti-tumor immune response (NCI Drug Dictionary). |
|
AB-110
|
|
CD34-positive Enriched HPCs Mixed with Engineered Human ECs AB-110 |
|
AB-110 is a preparation of umbilical cord blood-derived CD34-positive hematopoietic progenitor cells mixed with endothelial cells engineered to express the adenovirus E4ORF1 gene, potentially resulting in increased engraftment upon transplantation (NCI Drug Dictionary). |
|
AB-205
|
|
AB205|AB 205|engineered HUVEC AB-205 |
|
AB-205 consists of engineered CD31 (PECAM-1) positive human umbilical vein-derived endothelial cells, which potentially improve transplant engraftment and enhance recovery of blood cells (NCI Drug Dictionary). |
|
AB308
|
|
AB-308|AB 308 |
TIGIT Antibody
21
|
AB308 is a monoclonal antibody that targets and binds to T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (NCI Drug Dictionary). |
|
ABBV-368
|
|
ABBV368|ABBV 368 |
OX40 Antibody
15
|
ABBV-368 is an activating monoclonal antibody to the T-cell receptor, TNFRSF4 (OX40, CD134) (NCI Drug Dictionary). |
|
ABBV-453
|
|
ABBV 453|ABBV453 |
BCL2 inhibitor
29
|
ABBV-453 inhibits BCL2, potentially leading to increased tumor cell apoptosis (NCI Drug Dictionary). |
|
ABBV-461
|
|
ABBV 461|ABBV461 |
|
ABBV-461 comprises an antibody fragment targeting an undisclosed tumor-associated antigen linked to a peptide epitope that is recognized by CRBL001 CAR-T cells, which potentially induces activation of CRBL001 CAR-T cells and tumor cell killing (NCI Drug Dictionary). |
|
ABBV-467
|
|
ABBV467|ABBV 467 |
MCL1 Inhibitor
18
|
ABBV-467 inhibits MCL1, potentially leading increased apoptosis of Mcl1-expressing tumor cells (NCI Drug Dictionary) |
|
ABBV-525
|
|
ABBV 525|ABBV525 |
MALT1 Inhibitor
6
|
ABBV-525 inhibits MALT1 and leads to decreased CARD11-BCL10-MALT1 (CBM) signaling, potentially resulting in reduced immunosuppressionin the tumor microenvironment and inhibition of tumor cell growth (NCI Drug Dictionary). |
|
ABBV-787
|
|
ABBV 787|ABBV787 |
BET Inhibitor (Pan)
33
CD33 Antibody
17
|
ABBV-787 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD33 linked to a BET degrader, which potentially inhibits proliferation of CD33-positive tumor cells overexpressing BET (NCI Drug Dictionary). |
|
ABBV-927
|
|
ABBV 927|ABBV927 |
CD40 Antibody
16
|
ABBV-927 is a monoclonal antibody to TNFRSF5 (CD40), which mimics the binding of the ligand, CD40LG (CD40L), to stimulate proliferation of T-cells and enhance an anti-tumor response (NCI Drug Dictionary). |
|
ABD-3001
|
|
ABD 3001|ABD3001 |
|
ABD-3001 irreversibly inhibits ALDH1 and ALDH3, which potentially results in impaired tumor cell proliferation (NCI Drug Dictionary). |
|
ABSK021
|
|
ABSK 021|ABSK-021|CSF-1R Inhibitor ABSK021|Pimicotinib |
CSF1R Inhibitor
28
|
ABSK021 selectively inhibits CSF1R, potentially leading to inhibition of tumor cell proliferation, enhanced T cell immune response, and antitumor activity (NCI Drug Dictionary, J Clin Oncol 41, 2023 (suppl 16; abstr 11559). |
|
AC0676
|
|
AC 0676|AC-0676|AC-676|AC 676|AC676 |
BTK inhibitor
39
|
AC0676 is a BTK degrader, with activity against wild-type and mutant BTK, which reduces downstream signaling and potentially inhibits tumor growth (NCI Drug Dictionary). |
|
AC699
|
|
AC-699|AC 699 |
Hormone - Anti-estrogens
31
|
AC699 is a protein degrader comprising ESR1 ligands and E3 ligase, which targets and degrades ESR1, potentially leading to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3074, NCI Drug Dictionary). |
|
ADA-011
|
|
ADA 011|ADA011 |
Immune Checkpoint Inhibitor
150
LILRB2 Antibody
12
|
ADA-011 is a monoclonal antibody targeting leukocyte immunoglobulin-like receptors B (LILRB), which potentially induces antitumor immune response (NCI Drug Dictionary). |
|
ADG106
|
|
ADG-106|ADG 106 |
TNFRSF9 Antibody
36
|
ADG106 is a monoclonal antibody targeting CD137, which potentially enhances antitumor immune response (J Clin Oncol 42, 2024 (suppl 16); e14507). |
|
ADXS-NEO
|
|
ADXS NEO |
|
ADXS-NEO is a Listeria monocytogenes-based plasmid vaccine that contains a truncated form of listeriolysin O fused to patient-specific immunogenic neoepitopes, potentially resulting in a personalized immunogenic response and antitumor efficacy (NCI Drug Dictionary). |
|
AFPc332T
|
|
Autologous genetically modified AFPc332 T cells|AFP-c332T|AFP c332T |
|
AFPc332T comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting alpha-fetoprotein (AFP), which potentially induces killing of AFP-expressing tumor cells (PMID: 30561769, NCI Drug Dictionary). |
|
AG-270
|
|
AG270|AG 270 |
MAT2A Inhibitor
5
|
AG-270 inhibits methionine adenosyltransferase II alpha (MAT2A), to induce cell death of tumor cells reliant on S-Adenosyl-L-methionine (SAM) synthesis (NCI Drug Dictionary). |
|
AGX101
|
|
AGX-101|AGX 101 |
|
AGX101 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TM4SF1 linked to a tubulin inhibitor, which potentially inhibits growth of tumors expressing TM4SF1 (NCI Drug Dictionary, J Clin Oncol 2025 43: 16_suppl, 829). |
|
AI-061
|
|
AI 061|AI061 |
CTLA4 Antibody
33
PD-L1/PD-1 antibody
137
|
AI-061 is a coformulation of the anti-PDCD1 (PD-1) antibody AI-025 and the anti-CTLA4 antibody gotistobart (ONC-392), which potentially enhances antitumor immune response (NCI Drug Dictionary). |
|
AI-081
|
|
AI081|AI 081 |
PD-L1/PD-1 antibody
137
VEGF Antibody
17
|
AI-081 is a bispecific antibody that targets PDCD1 (PD-1) expressed on T-lymphocytes and VEGF expressed on tumor cells, which potentially inhibits VEGFR signaling, decreases tumor cell proliferation, and enhances antitumor immune response (NCI Drug Dictionary). |
|
AIC100
|
|
AIC-100|AIC 100 |
|
AIC100 is a cell therapy consisting of T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the intercellular adhesion molecule-1 (ICAM-1), and CD28, potentially leading to activation of inhibitory T cells, inhibition of cell proliferation and inhibition of tumor growth (PMID: 31337787, NCI Drug Dictionary). |
|
AIP-303
|
|
AIP303|AIP 303 |
HER2 Inhibitor
45
|
AIP-303 targets and binds to ERBB2 (HER2) expressed on tumor cells, and may lead to inhibition of ERBB2 (HER2) signaling and tumor cell growth (NCI Drug Dictionary). |
|
AK114
|
|
AK-114|AK 114 |
|
AK114 is a monoclonal antibody that targets IL-1b leading to inhibition of downstream signaling pathways and potentially resulting in decreased inflammatory response, angiogenesis, and tumor growth (NCI Drug Dictionary). |
|
AK127
|
|
AK-127|AK 127 |
TIGIT Antibody
21
|
AK127 is a monoclonal antibody that targets and binds to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), thereby inhibiting binding with ligands CD112 and CD155, and potentially resulting in an enhanced immune response against tumor cells (NCI Drug Dictionary). |
|
AL8326
|
|
AL-8326|AL 8326 |
Aurkb Inhibitors
21
FGFR Inhibitor (Pan)
26
VEGFR Inhibitor (Pan)
36
|
AL8326 is a tyrosine kinase inhibitor that inhibits Aurora B, Fgfr, and Vegfr, potentially leading to disrupted chromosome segregation, impaired cell division, decreased tumor cell proliferation, and antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 8585), NCI Drug Dictionary). |
|
ALLO-501A
|
|
ALLO 501A|ALLO501A|Cemacabtagene ansegedleucel |
CD19 Immune Cell Therapy
74
|
ALLO-501A comprises allogeneic T-lymphocytes engineered to remove the TCR alpha chain and CD52 and to express a chimeric antigen receptor (CAR) targeting CD19, which potentially induce lysis of CD19-expressing tumor cells (NCI Drug Dictionary). |
|
ALLO-647
|
|
ALLO 647|ALLO 647 |
|
ALLO-647 is a monoclonal antibody that targets CD52 (CAMPATH-1), which activates host immune response, potentially resulting in the lysis of CD52-positive tumor cells (NCI Drug Dictionary). |
|
AMG 199
|
|
AMG199|AMG-199 |
CD3 Antibody
123
|
AMG 199 is a bi-specific T-cell engager (BiTE) antibody that binds to MUC17 and CD3, thereby crosslinking MUC17-expressing tumor cells and T-lymphocytes, potentially resulting in enhanced T-cell response against tumor cells expressing MUC17 (NCI Drug Dictionary). |
|
AMG 355
|
|
AMG355|AMG-355 |
CCR8 Antibody
13
|
AMG 355 is a monoclonal antibody that targets CCR8 expressed on regulatory T-cells and inhibits downstream signaling, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
|
AMG 397
|
|
AMG-397|AMG397|Murizatoclax |
MCL1 Inhibitor
18
|
AMG 397 is a small molecule inhibitor of MCL1 that selectively disrupts the interaction with members of the Bcl2 family, potentially resulting in increased cellular apoptosis, decreased cell viability, and reduced tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6218). |
|
AMG 404
|
|
AMG404|AMG-404|zeluvalimab |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
AMG 404 is a monoclonal antibody that binds to and inhibits PD-1 signaling, potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary). |
|
AMG 427
|
|
AMG-427|AMG427|BiTE Antibody AMG 427|Anti-FLT3 x Anti-CD3 BiTE AMG 427 |
CD3 Antibody
123
FLT3 Antibody
5
|
AMG 427 is a bi-specific T-cell engager (BiTE) antibody that binds to FLT3 and CD3, which activates cytotoxic T-lymphocytes against tumor cells expressing FLT3, potentially resulting in increased death of FLT3-expressing tumor cells (NCI Drug Dictionary). |
|
AMG 596
|
|
AMG596|AMG-596 |
EGFR Antibody
74
|
AMG 596 is a bispecific antibody that targets CD3 on T-cells and the Egfr variant, EGFRvIII, expressed by tumor cells (NCI Drug Dictionary). |
|
AMG 701
|
|
AMG-701|AMG701|BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody AMG 701 |
CD3 Antibody
123
TNFRSF17 Antibody
22
|
AMG 701 is a bi-specific T-cell engager (BiTE) antibody that simultaneously binds to BCMA (TNFRSF17) and CD3, and activates cytotoxic T-lymphocytes against tumor cells expressing BCMA, potentially inducing death of BCMA expressing tumor cells (NCI Drug Dictionary). |
|
AMG 994
|
|
AMG994|AMG-994|Inezetamab |
|
AMG 994 is a bispecific antibody with undisclosed targets that potentially inhibits tumor cell proliferation (NCI Drug Dictionary). |
|
AMG193
|
|
AMG-193|AMG 193 |
PRMT5 Inhibitor
21
|
AMG193 inhibits protein arginine methyltransferase 5 (PRMT5), potentially leading to inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
AMG562
|
|
AMG 562|AMG-562 |
CD19 Antibody
22
CD3 Antibody
123
|
AMG562 is a bi-specific T-cell engager (BiTE) antibody that binds to CD19 and CD3, potentially resulting in increased T-cell response to CD19-expressing tumor cells (NCI Drug Dictionary). |
|
AMT-151
|
|
AMT 151|AMT151 |
FOLR1-targeted Therapy
24
|
AMT-151 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against folate receptor alpha (FRa) linked to an undisclosed cytotoxic agent, which potentially leads to decreased proliferation of tumor cells expressing FRa (NCI Drug Dictionary). |
|
AND019
|
|
AND-019|AND 019 |
Hormone - Anti-estrogens
31
|
AND019 is a selective estrogen receptor degrader (SERD) that may inhibit growth of ESR1 (ER alpha)-positive tumor cells (NCI Drug Dictionary). |
|
AP-002
|
|
AP002|AP 002 |
|
AP-002 is a small molecule that prevents bone resorption and has potential anti-tumor activity (NCI Drug Dictionary). |
|
AP-160
|
|
AP160|AP 160|nab-paclitaxel/STI-3031 complex|nab-paclitaxel/danburstotug complex |
PD-L1/PD-1 antibody
137
|
AP-160 is a complex composed of nab-paclitaxel and the PD-L1 (CD274)-targeting antibody danburstotug, which potentially induces death of PD-L1 (CD274)-expressing tumor cells (NCI Drug Dictionary). |
|
APL-4098
|
|
APL 4098|APL4098 |
|
APL-4098 inhibits GCN2, which potentially results in decreased downstream signaling, increased antitumor immune response, and enhanced apoptosis in tumor cells (NCI Drug Dictionary). |
|
APL-5125
|
|
APL 5125|APL5125 |
WNT Inhibitor
17
|
APL-5125 is a small molecule inhibitor of Wnt signaling that inhibits an undisclosed kinase in the Wnt pathway, potentially resulting in decreased tumor cell growth (NCI Drug Dictionary). |
|
ART0380
|
|
ART-0380|ART 0380 |
ATR Inhibitor
16
|
ART0380 inhibits ATR activity leading to decreased phopshorylation of Chk1, which may result in impaired DNA damage repair, induction of apoptosis in tumor cells, and antitumor activity (NCI Drug Dictionary, (Ann Oncol 34 (2023): S475-S476). |
|
ART4215
|
|
ART-4215|ART 4215 |
|
ART4215 inhibits DNA polymerase theta and prevents DNA damage repair, potentially leading to enhanced sensitivity to DNA damaging agents (NCI Drug Dictionary). |
|
ART6043
|
|
ART-6043|ART 6043 |
|
ART6043 selectively inhibits DNA polymerase theta, which potentially induces apoptosis and decreases growth of tumor cells (NCI Drug Dictionary). |
|
ASCA101
|
|
ASCA-101|ASCA 101 |
|
ASCA101 interferes with tumor cell metabolism, potentially resulting in increased production of reactive oxygen species (ROS) and apoptosis of tumor cells (NCI Drug Dictionary). |
|
ASP-1929
|
|
Cetuximab sarotalocan|Cetuximab-IRDye-700DX|RM-1929|Cet-IR700|ASP1929 |
EGFR Antibody
74
|
ASP1929 (RM-1929) is comprised of the EGFR antibody cetuximab conjugated to the dye IR700, which binds to EGFR-expressing cells and disrupts the cell membrane upon exposure to near-infared light, and may induce antitumor activity (NCI Drug Dictionary, J Clin Oncol 42, 2024 (suppl 16; abstr 6083)). |
|
ASP1012
|
|
ASP-1012|ASP 1012|VET2 L2|VET2-L2|VET2L2 |
|
ASP1012 is an oncolytic vaccinia virus modified to express a leptiin/IL-2 fusion protein, which potentially enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_2): CT122, NCI Drug Dictionary). |
|
ASP1570
|
|
ASP-1570|ASP 1570 |
DGKZ Inhibitor
4
|
ASP1570 is a DGKzeta inhibitor, which potentially reduces tumor cell proliferation and tumor growth (NCI Drug Dictionary). |
|
ASP1948
|
|
ASP 1948|ASP-1948|PTZ 329|PTZ329|PTZ-329 |
|
ASP1948 is a monoclonal antibody that targets an undisclosed immune receptor, which potentially results in anti-tumor immune response (NCI Drug Dictionary). |
|
ASP2802
|
|
ASP-2802|ASP 2802 |
|
ASP2802 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting a modified form of NKG2D, which upon activation by the CD20-targeted bispecific adaptor ASP101G potentially induce killing of tumor cells expressing CD20 (NCI Drug Dictionary). |
|
ASP4396
|
|
ASP-4396|ASP 4396 |
KRAS G12D Inhibitor
25
|
ASP4396 comprises a E3 ubiquitin ligase-binding moiety linked to a moiety targeting KRAS G12D, which potentially targets KRAS G12D for proteasomal degradation, resulting in decreased growth of KRAS G12D-expressing tumor cells (NCI Drug Dictionary). |
|
ASP5541
|
|
PRL02|PRL 02|Abiraterone Decanoate Depot|PRL-02 |
Hormone - Anti-androgens
58
|
ASP5541 (PRL-02) is a long-acting formulation of abiraterone, which may lead to suppression of testosterone levels and decreased tumor cell proliferation (J Clin Oncol 39, 2021 (suppl 15; abstr TPS5090), NCI Drug Dictionary). |
|
ASP7517
|
|
ASP 7517|ASP-7517 |
|
ASP7517 comprises artificial adjuvant vector cells engineered to express CD1d, which are loaded with the Wilms' tumor 1 (WT1) antigen and the CD1d ligand alpha-galactosylceramide on the cell surface, which may result in the activation of antitumor immune response against tumor cells expressing WT1 (NCI Drug Dictionary). |
|
ASP8374
|
|
ASP-8374|ASP 8374 |
Immune Checkpoint Inhibitor
150
|
ASP8374 is an immune checkpoint inhibitor, which may activate anti-tumor immunity (NCI Drug Dictionary). |
|
ASP9801
|
|
ASP 9801|ASP-9801 |
|
ASP9801 is an oncolytic virus that selectively infects tumor cells, which may induce cytotoxicity and anti-tumor immune response (NCI Drug Dictionary). |
|
ASTX295
|
|
ASTX 295|ASTX-295 |
MDM2 Inhibitor
23
|
ASTX295 is an inhibitor of murine double minute 2 (MDM2; HDM2) that binds to Mdm2 and inhibits proteasomal degradation of Tp53 by Mdm2, thereby restoring wild-type Tp53 and potentially leading to induction of apoptosis in tumor cells (NCI Drug Dictionary). |
|
ATI-2231
|
|
ATI2231|ATI 2231 |
|
ATI-2231 inhibits MAPKAPK2 (MK2), potentially resulting in decreased downstream signaling, impaired DNA damage repair, and tumor cell apoptosis (J Bone Oncol 45 (2024): 100569, NCI Drug Dictionary). |
|
ATL001
|
|
ATL 001|ATL-001 |
|
ATL001 are personalized patient-derived tumor infiltrating lymphocytes that target tumor neoantigens, which may result in the induction of an antitumor immune response (NCI Drug Dictionary). |
|
ATLCAR.CD30 cells
|
|
CAR.CD30-expressing autologous T lymphocytes |
CD30 (TNFRSF8) Immune Cell Therapy
5
|
ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets TNFRSF8 (CD30), which may induce lysis of TNFRSF8 (CD30)-positive tumor cells (PMID: 32701411, NCI Drug Dictionary). |
|
ATLCAR.CD30.CCR4 cells
|
|
ATLCAR.CD30-CD28zeta-CCR4 cells |
CD30 (TNFRSF8) Immune Cell Therapy
5
|
ATLCAR.CD30.CCR4 cells are autologous T-lymphocytes engineered to express CCR4 linked to a chimeric antigen receptor (CAR) targeting CD30 and the CD28 and CD3zeta co-stimulatory domains, which potentially increase antitumor immune response (NCI Drug Dictionary). |
|
ATP128
|
|
ATP 128|ATP-128 |
|
ATP128 is a chimeric protein vaccine that potentially modify antigen presentation of dendritic cells, leading to activation of immune response against tumor cells (NCI Drug Dictionary). |
|
ATP150
|
|
ATP-150|ATP 150 |
|
Limited information is currently available on ATP150 (Feb 2025). |
|
AU409
|
|
AU-409|AU 409 |
|
AU409 is an RNA transcription modulator, which potentially alters gene expression leading to decreased tumor cell proliferation (NCI Drug Dictionary). |
|
AUTO4
|
|
AUTO-4|AUTO 4 |
|
AUTO4 are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets the T-cell receptor beta constant 1 (TRBC1), potentially resulting in killing of TRBC1-expressing tumor cells (NCI Drug Dictionary). |
|
AZD5492
|
|
AZD-5492|AZD 5492 |
CD20 Antibody
28
CD3 Antibody
123
|
AZD5492 is a trispecific target-induced T-cell activating nanobody targeting CD20 on tumor cells, TCR, and CD8, which potentially induces activation of T-cells and enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
|
AZD7789
|
|
AZD 7789|AZD-7789 |
PD-L1/PD-1 antibody
137
TIM-3 Antibody
9
|
AZD7789 is a bispecific antibody that targets both programmed cell death protein 1 (PDCD1) and TIM3, potentially leading to altered antitumor response including enhanced T-cell mediated cell lysis, and inhibition of tumor growth (NCI Drug Dictionary). |
|
AbGn-107
|
|
AbGn 107 |
|
AbGn-107 is an antibody drug conjugate comprised of a monoclonal antibody that targets AG7 linked to a proprietary cytotoxic therapy, which binds to cancer cells expressing AG7 and potentially induces cell death (NCI Drug Dictionary). |
|
Acyclovir
|
Zovirax |
Virorax|Cargosil|BW-248U|acycloguanosine|aclovir|aciclovir |
|
Acyclovir is a synthetic analog of guanosine, which functions as an antiviral agent by inhibiting viral DNA polymerase (NCI Drug Dictionary). |
|
Ad-MAGEA3
|
|
Adenovirus MAGE-A3|AdMA3|MAGE-A3-expressing Adenovirus Type 5 Vaccine |
|
Ad-MAGEA3 is a cancer vaccine comprising a replication-defective adenovirus engineered to express MAGE-A3, which may result in enhanced immune response against MAGE-A3 expressing tumors (NCI Drug Dictionary). |
|
Ad-RTS-IL-12 plus AL
|
|
adenovirus-mediated human interleukin-12 INXN-2001 plus veledimex |
|
Ad-RTS-IL-12 plus AL is a replication incompetent adenovirus that initiates interleukin-12 (IL-12) production upon veledimex induction, which may stimulate anti-tumor immunity (NCI Drug Dictionary). |
|
Ad5-survivin-transduced autologous DC vaccine
|
|
Autologous DC:AdmS |
|
Ad5-survivin-transduced autologous DC vaccine consists of autologous dendritic cells engineered to carry a replication defective adenovirus type 5 vector (Ad5) that encodes a survivin antigen, which potentially activates a cytotoxic T-lymphocyte response against survivin-expressing tumor cells, resulting in cell death (NCI Drug Dictionary). |
|
Aldesleukin
|
Proleukin |
IL-2|Interleukin-2|IL2 |
|
Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). |
|
Allogeneic CD19-CD28-CD3-zeta CAR-T cells
|
|
Allogeneic 19-28z CAR T-cells|Allogeneic CD19-28z CAR T Cells |
CD19 Immune Cell Therapy
74
|
Allogeneic CD19-CD28-CD3-zeta CAR-T cells are allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to the CD28 co-stimulatory receptor and CD3zeta, which potentially induce toxicity in CD19-expressing tumor cells (NCI Drug Dictionary). |
|
Allogeneic HPV-specific CD4+ T cells
|
|
|
|
Allogeneic HPV-specific CD4+ T cells comprises patient-derived CD4+ T-lymphocytes harvested post-HPV vaccination, which potentially induce cytotoxicity in HPV-positive cancer cells (NCI Drug Dictionary). |
|
Allogeneic NAM NK cells
|
|
allogeneic NAM NKs|donor nicotinamide-expanded natural killer cells |
|
Allogeneic NAM NK cells are donor-derived natural killer cells that have been grown in the presence of nicotinamide (NAM), which potentially induce tumor cell lysis (NCI Drug Dictionary). |
|
Alpha 2 Interferon
|
Roferon-A |
AlferonIinterferon alfa 2a|interferon alpha 2a |
|
Roferon-A (alpha 2 Interferon) is a recombinant form of human interferon alfa-2a, which binds to its receptor, activating anti-viral, anti-proliferative, anti-cancer, and immune modulating downstream effectors (NCI Drug Dictionary). |
|
Amcasertib
|
|
BBI-503|BBI503 |
|
Amcasertib (BBI503) is a kinase inhibitor that inhibits signaling pathways that regulate survival of cancer stem cells, resulting in decreased cancer cell growth (NCI Drug Dictionary). |
|
Anti-CD22 CAR T cells
|
|
CD22 CAR-T|anti-CD22 CAR-expressing T lymphocytes |
CD22 Immune Cell Therapy
13
|
Anti-CD22 CAR T cells are T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in enhanced anti-tumor immune response against CD22-expressing tumor cells (NCI Drug Dictionary). |
|
Anti-GPC3-scFvGC33-CAR autologous T lymphocytes
|
|
GAP T cells|GLYCAR T cells |
GPC3 Immune Cell Therapy
8
|
Anti-GPC3-scFvGC33-CAR autologous T lymphocytes are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) based on an antibody (GC33) that targets GPC3, which may induce lysis of GPC3-expressing tumor cells (NCI Drug Dictionary). |
|
Anti-HER2/HER3 DC vaccine
|
|
Anti-HER2/3 dendritic cell vaccine |
HER2 (ERBB2) Vaccine
15
|
Anti-HER2/HER3 DC vaccine is a dendritic cell vaccine that targets ERBB2 (HER2) and HER3, which potentially stimulates cytotoxic immune response against tumor cells expressing ERBB2 (HER2) and HER3, and may reduce tumor growth (NCI Drug Dictionary). |
|
Anti-VEGFR2 CAR CD8 lymphocytes
|
|
|
VEGFR2 Immune Cell Therapy
1
|
Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary). |
|
Asparaginase
|
Elspar |
L-asparaginase|ASP-1 |
|
Elspar (asparaginase) is an enzyme that converts L-asparagine to L-aspartic acid and ammonia, reducing the available L-asparagine, which may result in cell-cycle arrest and apoptosis in leukemia cells (NCI Drug Dictionary). |
|
Autologous CD19t T-APC
|
|
Autologous CD19t T-antigen presenting cells |
|
Autologous CD19t T-APC are CD4 and CD8-positive antigen presenting cells (APCs) isolated from patients and engineered to express a truncated version of CD19, which may induce activation of CD19 chimeric antigen receptor (CAR)-expressing T-cells (NCI Drug Dictionary). |
|
Autologous Dendritic Cells Pulsed with MART-1
|
|
|
|
Autologous Dendritic Cells Pulsed with MART-1 consists of dendritic cells pulsed with a peptide vaccine against melanocyte differentiation antigen Melan-A (MART-1), which may enhance the humoral and cytotoxic immune responses against tumor cells expressing Melan-A (NCI Drug Dictionary). |
|
Autologous TAPA-pulsed dendritic cell vaccine
|
|
KiroVAX |
|
Autologous TAPA-pulsed dendritic cell vaccine (KiroVAX) is a vaccine comprised of autologous dendritic cells that have been pulsed with tumor-associated peptide antigens, which may initiate an immune response against tumor cells expressing the specific tumor associated peptide antigens (NCI Drug Dictionary). |
|
Autologous TGF beta resistant HER2 EBV CTLs
|
|
|
HER2 (ERBB2) Immune Cell Therapy
9
|
Autologous TGF beta resistant HER2 EBV CTLs are EBV-specific autologous cytotoxic T lymphocytes that express a chimeric ERBB2 (HER2) antigen receptor as well as a dominant negative TGF-beta receptor, which target ERBB2 (HER2) expressing tumor cells, potentially resulting in increased CTL-mediated tumor cell death (NCI Drug Dictionary). |
|
Autologous TIL 1383I TCR transduced T-cells
|
|
TIL 1383I T Cell Receptor-Transduced Autologous T cells |
|
Autologous TIL 1383I TCR transduced T-cells are patient-derived peripheral blood mononuclear cells engineered to express a T-cell receptor (TCR) targeting melanoma-specific tyrosinase, which potentially induce an increased immune response against tyrosinase-expressing tumors (Journal for ImmunoTherapy of Cancer 2013;1:P31; NCI Drug Dictionary). |
|
Autologous anti-HLA-A2/NY-ESO-1 TCR T cells
|
|
A2-ESO-1 TCR-T cells |
|
Autologous anti-HLA-A2/NY-ESO-1 TCR T cells are T-lymphocytes engineered to express a T-cell receptor (TCR) targeting HLA-A2/NY-ESO-1 expressed on tumor cells, which potentially induce killing of tumor cells expressing NY-ESO-1 (NCI Drug Dictionary). |
|
B003
|
|
B 003|B-003|ADC B003|anti-HER2-DM1 ADC B003 |
HER2 (ERBB2) Antibody
80
HER2 (ERBB2) Antibody-Drug Conjugate
36
|
B003 is an antibody-drug conjugate (ADC) comprising a monoclonal ERBB2 (HER2) antibody linked to DM1, which delivers the anti-microtubule agent to ERBB2 (HER2)-overexpressing cells, potentially inducing cell cycle arrest and inhibiting proliferation of tumor cells overexpressing ERBB2 (HER2) (NCI Drug Dictionary). |
|
BA3071
|
|
BA-3071|BA 3071 |
CTLA4 Antibody
33
Immune Checkpoint Inhibitor
150
|
BA3071 is a monoclonal antibody that targets CTLA4, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
|
BA3182
|
|
BA-3182|BA 3182 |
|
BA3182 is a bispecific antibody targeting EpCAM and CD3E that redirects cytotoxic T-lymphocytes towards EpCAM-expressing tumor cells, potentially resulting in increased tumor cell killing (PMID: 38445633; NCI Drug Dictionary). |
|
BAT1308
|
|
BAT-1308|BAT 1308 |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
BAT1308 is a humanized monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in the restoration of T-cell mediated antitumor immune response (NCI Drug Dictionary). |
|
BAT6021
|
|
BAT-6021|BAT 6021 |
Immune Checkpoint Inhibitor
150
TIGIT Antibody
21
|
BAT6021 is a monoclonal antibody that targets T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and prevents its interaction with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
|
BAT7104
|
|
BAT-7104|BAT 7104 |
CD47 Antibody
31
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
BAT7104 is a bispecific antibody that targets both CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
|
BAT8001
|
|
BAT-8001|BAT 8001|anti-HER2 ADC BAT8001 |
HER2 (ERBB2) Antibody
80
HER2 (ERBB2) Antibody-Drug Conjugate
36
|
BAT8001 is an antibody-drug conjugate (ADC) comprising the Erbb2 (Her2)-targeting monoclonal antibody, Trastuzumab, linked to a maytansine-derivative, which delivers the cytotoxic agent to Erbb2-expressing tumor cells, potentially resulting in increased apoptosis and reduced proliferation of tumor cells expressing Erbb2, and decreased tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr CT053; NCI Drug Dictionary). |
|
BAY2416964
|
|
BAY-2416964|BAY 2416964 |
|
BAY2416964 binds to and inhibits aryl hydrocarbon receptor (AhR) signaling, which may restore anti-tumor immune response in the tumor microenvironment (NCI Drug Dictionary). |
|
BAY2862789
|
|
BAY 2862789|BAY-2862789 |
|
BAY2862789 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
|
BCG Tokyo-172 Strain Solution
|
|
Bacillus Calmette-Guerin Tokyo-172 strain solution |
|
BCG Tokyo-172 strain solution contains an attenuated live culture of the BCG strain of Mycobacterium bovis, which induces an immune response in bladder cancer cells (NCI Drug Dictionary). |
|
BDB018
|
|
BDB 018|BDB-018 |
TLR7 Agonist
14
TLR8 Agonist
10
|
BDB018 acts an an agonist of TLR7 and TLR8, potentially resulting in activation of the anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary). |
|
BG-60366
|
|
BG60366|BG 60366 |
EGFR Inhibitor (Pan)
63
|
BG-60366 is a chimeric degradation activation compound (CDAC) comprising a ligand that binds to E3 ubiquitin ligase linked to a ligand targeting mutant EGFR, which potentially induces proteasome-mediated degradation of mutant EGFR and decreased growth of tumor cells (NCI Drug Dictionary). |
|
BG-68501
|
|
BG 68501|BG68501|ENS 791|ENS-791|ENS791 |
CDK2 Inhibitor
31
|
BG-68501 inhibits CDK2, which potentially induces apoptosis and decreases proliferation of tumor cells (NCI Drug Dictionary). |
|
BG-C9074
|
|
BG C9074|BGC9074 |
B7-H4 (VTCN1) Antibody
13
|
BG-C9074 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting VTCN1 (B7-H4) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in VTCN1 (B7-H4)-expressing tumor cells (J Clin Oncol 2025 43: 16_suppl, 3033, NCI Drug Dictionary). |
|
BGB-16673
|
|
BGB16673|BGB 16673 |
BTK inhibitor
39
|
BGB-16673 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition of BTK-expressing tumor cells (NCI Drug Dictionary). |
|
BGB-21447
|
|
BGB 21447|BGB21447 |
BCL2 inhibitor
29
|
BGB-21447 inhibits BCL2, potentially resulting in enhanced tumor cell apoptosis (NCI Drug Dictionary). |
|
BGB-24714
|
|
BGB 24714|BGB24714 |
|
BGB-24714 is a mimetic of second mitochondrial-derived activator of caspases (Smac), which inhibits the activities of inhibitor of apoptosis (IAP) proteins, potentially leading to apoptosis of tumor cells (NCI Drug Dictionary). |
|
BGB-26808
|
|
BGB26808|BGB 26808 |
MAP4K1 Inhibitor
8
|
BGB-26808 inhibits MAP4K1 (HPK1), which may decrease immunosuppression in the tumor microenvironment and increase cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
|
BGB-30813
|
|
BGB 30813|BGB30813 |
DGKZ Inhibitor
4
|
BGB-30813 inhibits DGKzeta, which potentially decreases proliferation of tumor cells (NCI Drug Dictionary). |
|
BGB-43395
|
|
BGB43395|BGB 43395 |
CDK4 Inhibitor
19
|
BGB-43395 selectively inhibits CDK4, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). |
|
BGB-53038
|
|
BGB 53038|BGB53038 |
KRAS Inhibitor
31
|
BGB-53038 is a pan-KRAS inhibitor, which potentially induces apoptosis and decreases proliferation in tumor cells harboring KRAS mutations (NCI Drug Dictionary). |
|
BGB-58067
|
|
BGB58067|BGB 58067 |
PRMT5 Inhibitor
21
|
BGB-58067 selectively inhibits PRMT5 in MTAP-deleted cells, which potentially leads to decreased tumor cell growth (Cancer Res (2025) 85 (8_Supplement_2): CT193, NCI Drug Dictionary). |
|
BGB-A3055
|
|
BGBA3055|BGB A3055 |
CCR8 Antibody
13
|
BGB-A3055 is a monoclonal antibody that targets CCR8 expressed on regulatory T-cells and inhibits downstream signaling, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
|
BGC515
|
|
BGC-515|BGC 515 |
|
BGC515 inhibits TEAD, which potentially increases apoptosis in tumor cells (NCI Drug Dictionary). |
|
BI 1821736
|
|
BI-1821736|BI1821736 |
|
BI 1821736 is an oncolytic vesicular stomatitis virus engineered to express the non-neurotopic GP glycoprotein and a CD80 Fc fragment, which may induce a cytotoxic response in tumor cells and an antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr TPS2688), NCI Drug Dictionary). |
|
BI 765179
|
|
BI765179|BI-765179 |
TNFRSF9 Antibody
36
|
BI 765179 is a bispecific antibody that targets TNFRSF9 (CD137; 4-1BB) expressed on immune cells and fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts, which potentially results in activation of immune cells and a T-lymphocyte mediated immune response against tumor cells (NCI Drug Dictionary). |
|
BI 905681
|
|
BI905681|BI-905681|LRP5 Antagonist BI 905681 |
|
BI 905681 is an antagonist of lipoprotein receptor-related protein 5 (LRP5), that binds to LRP5 and inhibits the Wnt/beta-catenin signaling pathway, potentially leading to inhibition of tumor cell proliferation and activation of cytotoxic T lymphocytes (PMID: 39617535, NCI Drug Dictionary). |
|
BIO-106
|
|
BIO 106|BIO106 |
TROP2 Antibody
19
|
BIO-106 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to an undisclosed tubulin inhibitor, potentially resulting in cell cycle arrest, apoptosis, and decreased proliferation of tumor cells expressing TROP2 (NCI Drug Dictionary). |
|
BJ-005
|
|
BJ 005|BJ005 |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
BJ-005 is a fusion protein comprising an anti-PD-L1 (CD274) antibody linked to the extracellular domain of Tgfbr2, which may decrease TGFbeta- and PD-L1-mediated immunosuppression, leading to increased antitumor immune response and reduced tumor cell proliferation (NCI Drug Dictionary). |
|
BLU-451
|
|
BLU451|BLU 451|LNG-451|LNG451|LNG 451 |
EGFR Exon 20 Insertion Inhibitor
16
|
BLU-451 is a blood-brain-barrier penetrant, mutant-selective, EGFR inhibitor with activity against exon 20 insertions, which blocks downstream signaling potentially resulting in decreased tumor growth (NCI Drug Dictionary). |
|
BMS-986207
|
|
BMS986207|BMS 986207 |
Immune Checkpoint Inhibitor
150
TIGIT Antibody
21
|
BMS-986207 is a human monoclonal antibody against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary). |
|
BMS-986226
|
|
BMS986226|BMS 986226 |
ICOS Antibody
6
|
BMS-986226 is a monoclonal antibody that targets ICOS (inducible T-cell costimulator, CD278) to activate T-cells in the immune anti-tumor response (NCI Drug Dictionary). |
|
BMS-986299
|
|
BMS986299|BMS 986299 |
|
BMS-986299 is an NLRP3 agonist that induces IL8 release to activate natural killer (NK) cells (NCI Drug Dictionary). |
|
BMS-986310
|
|
ONO-4578 |
|
BMS-986310 (ONO-4578) is an antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4), which may prevent tumor cell proliferation (NCI Drug Dictionary). |
|
BMS-986403
|
|
BMS986403|BMS 986403 |
ROR1 Immune Cell Therapy
5
|
BMS-986403 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets ROR1, which potentially induce toxicity in ROR1-expressing tumor cells (NCI Drug DIctionary). |
|
BMS-986406
|
|
BMS986406|BMS 986406 |
LILRB2 Antibody
12
|
BMS-986406 is a monoclonal antibody that targets LILRB2 (ILT4), resulting in decreased downstream signaling and potentially leading to reduced immunosuppressive effects in the tumor microenvironment, and enhanced antitumor immune response (NCI Drug Dictionary). |
|
BMS-986408
|
|
BMS 986408|BMS986408 |
|
BMS-986408 inhibits DGKalpha and DGKzeta, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). |
|
BMS-986449
|
|
BMS 986449|BMS986449 |
|
BMS-986449 is a molecular glue degrader that induces CRBN-dependent proteasomal degradation of IKZF2 (Helios) and IKZF4 (Eos) in regulatory T-cells (Treg), which potentially induces Treg reprogramming and enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_2): ND05, NCI Drug Dictionary). |
|
BMS-986453
|
|
BMS986453|BMS 986453 |
GPRC5D Immune Cell Therapy
4
TNFRSF17 Immune Cell Therapy
28
|
BMS-986453 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting TNFRSF17 (BCMA) and GPRC5D, which potentially induces toxicity in TNFRSF17 (BCMA) and GPRC5D-expressing tumor cells (NCI Drug Dictionary). |
|
BMS-986460
|
|
BMS986460|BMS 986460 |
|
BMS-986460 is a ligand-directed degrader comprising a E3 ubiquitin ligase-binding moiety linked to a moiety targeting a prostate-specific tumor-associated antigen (TAA), which potentially inhibits growth of TAA-expressing tumor cells (NCI Drug Dictionary). |
|
BNT112
|
|
BNT 112|BNT-112|W_pro1 |
|
BNT112 is an mRNA-based cancer vaccine that encodes prostate cancer antigens, which may activate anti-tumor immune response (NCI Drug Dictionary). |
|
BNT113
|
|
BNT-113|BNT 113|E6/E7 RNA(LIP) BNT113|RNA-lipoplex Cancer Vaccine BNT113 |
|
BNT113 is an RNA vaccine that consists of liposome encapsulated HPV-16 viral proteins E6 and E7, which may lead to activation of T lymphocyte mediated immune response against HPV-16 E6 and E7-positive tumor cells (NCI Drug Dictionary) |
|
BNT141
|
|
BNT-141|BNT 141 |
|
BNT141 consists of an mRNA encoding an anti-CLDN18.2 monoclonal antibody contained within a lipid nanoparticle, which may lead to inhibition of tumor-expressed CLDN18.2, potentially resulting in tumor cell death (NCI Drug Dictionary). |
|
BNT151
|
|
BNT 151|BN-T151 |
|
BNT151 comprises a formulation of messenger RNA encoding modified IL-2, which may lead to activation of antitumor immune response (NCI Drug Dictionary). |
|
BNT152
|
|
BNT-152|BNT 152 |
|
BNT152 consists of a modified mRNA for IL-7 contained within a lipid nanoparticle, which leads to expression of IL-7 and activation of downstream signaling, potentially resulting in increased antitumor immune response (NCI Drug Dictionary). |
|
BNT153
|
|
BNT-153|BNT 153 |
|
BNT153 consists of an mRNA for IL-2 contained within a lipid nanoparticle, which activates IL2Rb-dependent signaling, potentially resulting in increased antitumor response and tumor cell killing (NCI Drug Dictionary). |
|
BNT411
|
|
BNT 411|BNT-411 |
TLR7 Agonist
14
|
BNT411 is a TLR7 agonist, which activates B cells and CD8-positive T-lymphocytes as well as innate immune cells, potentially resulting in antitumor activity (NCI Drug Dictionary). |
|
BPX-603
|
|
HER-2 Autologous GoCAR-T|BPX603|BPX 603 |
HER2 (ERBB2) Immune Cell Therapy
9
|
BPX-603 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) for ERBB2 (HER2) and a dual-switch consisting of chemical inducer of dimerization (CID)-inducible co-activation domain (MyD88/CD40) and an inducible caspase 9 safety switch (CaspaCIDe), which may lead to activation of anti-tumor immune responses in the tumor microenvironment (NCI Drug Dictionary). |
|
BPX-701
|
|
|
|
BPX-701 is an autologous T-cell therapy that targets HLA-A201, PRAME (preferentially-expressed antigen in melanoma), and contains a drug binding domain for caspase 9 (CASP9) initiation, thereby potentially inducing cell death (NCI Drug Dictionary). |
|
BTX-A51
|
|
BTXA51 |
CDK7 Inhibitor
16
CDK9 Inhibitor
21
|
BTX-A51 is a small molecule inhibitor of CSNK1A1, CDK7, and CDK9, which may lead to Tp53 stabilization and apoptotic induction, inhibition of colony formation, and antitumor activity (NCI Drug Dictionary). |
|
Buserelin
|
|
Buserelin acetate|HOE 766|ICI 123215|S74-6766 |
|
Buserelin is a gonadotropin-releasing hormone (GnRH) analog that activates pituitary GnRH receptors, potentially resulting in reduced synthesis of gonadotropin and decreased levels of circulating gonadotropin and gonadal steroids (NCI Drug Dictionary). |
|
CAR.70/IL15-transduced CB-NK cells
|
|
|
CD70 Immune Cell Therapy
11
|
CAR.70/IL15-transduced CB-NK cells are cord blood-derived natural killer (NK) cells expressing a chimeric antigen receptor (CAR) targeting CD70 and IL15, which potentially induce cytotoxicity in tumor cells expressing CD70 (NCI Drug Dictionary). |
|
CAR.B7-H3T cells
|
|
|
CD276 Immune Cell Therapy
12
|
CAR.B7-H3T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3), which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) (NCI Drug Dictionary). |
|
CAR.k.28 cells
|
|
ATLCAR.k.28|ATLCAR.kappa.28 |
|
CAR.k.28 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the kappa-light chain antibody linked to CD28 endodomain, which potentially induce cytotoxicity against Kappa-positive tumor cells (PMID: 16926291, NCI Drug Dictionary). |
|
CART-EGFR-IL13Ra2 cells
|
|
|
IL13RA2 Immune Cell Therapy
7
|
CART-EGFR-IL13Ra2 cells are autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) that target EGFR epitope 806 and IL13Ra2, which potentially induce toxicity in tumor cells expressing EGFR or IL13Ra2 (PMID: 40451950, NCI Drug Dictionary). |
|
CART22-65s cells
|
|
anti-CD22 CAR T cells CART22-65s|anti-CD22 CAR 4-1BB-TCRz CART22-65s |
CD22 Immune Cell Therapy
13
|
CART22-65s cells consist of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, and linked to 4-1BB (CD137) co-stimulatory domain and CD3 zeta chain, which potentially leads to lysis of tumor cells expressing CD22 and antitumor activity (NCI Drug Dictionary; Blood (2022) 140 (Supplement 1): 2376-2377). |
|
CB-010
|
|
CB 010|CB010 |
CD19 Immune Cell Therapy
74
|
CB-010 cells are allogeneic T lymphocytes that are engineered to eliminate expression of the endogenous T cell receptor and PDCD1, and also to express a chimeric antigen receptor (CAR) specific for CD19, a tumor cell surface protein, and potentially result in cytotoxic T-cell mediated killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
|
CC-91633
|
|
CC 91633|CC91633|BMS-986397|BMS986397|BMS 986397 |
|
CC-91633 (BMS-986397) degrades and inhibits the activity of casein kinase 1 alpha, resulting in impaired interaction of MDM2 with p53 and thereby leading to elevated p53 activity, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). |
|
CC-93269
|
|
CC 93269|CC93269|EM901|BCMAxCD3 TCB CC-93269|Alnuctamab|BMS-986349 |
CD3 Antibody
123
TNFRSF17 Antibody
22
|
CC-93269 is a bispecific T-cell engager (BiTE) that targets the human B-cell maturation antigen (BCMA; TNFRSF17) on tumor cells, and the CD3 antigen on cytotoxic T cell lymphocytes, potentially resulting in tumor cell killing (NCI Drug Dictionary). |
|
CC-97540
|
|
CC 97540|CC97540 |
CD19 Immune Cell Therapy
74
|
CC-97540 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, a cell surface tumor antigen, potentially leading to an immune response against CD19-expressing tumor cells and inducing cytotoxicity (NCI Drug Dictionary). |
|
CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs
|
|
|
|
CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs are patient hematopoietic progenitor cells that have been transduced using a lentiviral vector containing HIV genes for a short hairpin RNA that interferes with CCR5 expression, TRIM5a, and a TAT activation response (TAR) decoy as well as a mutated version of human CD25, which may result in resistance to HIV infection and HIV-related tumors (NCI Drug Dictionary). |
|
CCT301-38
|
|
CCT301 38|CCT30138 CAR-T cells|autologous anti-AXL CAR-T Cells CCT30138 |
|
CCT301-38 consists of autologous T cells engineered to express an AXL-targeting chimeric antigen receptor (CAR), which are activated in the tumor microenvironment, potentially resulting in the killing of tumor cells expressing AXL (NCI Drug Dictionary). |
|
CCW702
|
|
CCW-702|CCW 702 |
CD3 Antibody
123
PSMA Antibody
24
|
CCW702 is a bispecific antibody that binds PSMA and CD3, potentially resulting in increased cytotoxic T-cell response against PSMA-expressing tumor cells (NCI Drug Dictionary). |
|
CD11301
|
|
CD-11301|CD 11301 |
|
CD11301 is a topical gel containing resiquimod, a Toll-like receptor (TLR) agonist that may activates TLR signaling, leading to enhanced T-cell immune response (NCI Drug Dictionary). |
|
CD19-CD34 CAR transduced T-cells
|
|
CD19-CD34t Metabolically Programmed CAR T-cells |
CD19 Immune Cell Therapy
74
|
CD19-CD34 CAR transduced T-cells are metabolically enhanced T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and selected for CD34 expression, which potentially induce toxicity in CD19-expressing tumor cells (NCI Drug Dictionary). |
|
CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells
|
|
|
CD19 Immune Cell Therapy
74
|
Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells are engineered T cells expressing chimeric antigen receptor consisted of CD19 linked to CD8, CD28, and TCR/CD3-zeta, a co-expressing membrane-bound IL-15 and IL-15 receptor fusion protein (mbIL15), and a truncated EGFR (HER1t), which may lead to cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
|
CD19CAR(2G)-T2A-HER2tG
|
|
|
CD19 Immune Cell Therapy
74
|
CD19CAR(2G)-T2A-HER2tG comprises CD4+ and CD8+ T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to the intracellular domain of TNFRSF9 (4-1BB), CD3zeta, and a truncated form of ERBB2 (HER2), which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
|
CD19R(EQ)28zetaEGFRt+ Tn/mem cells
|
|
CD19R(EQ)28zeta/EGFRt-expressing naive and memory T cells |
CD19 Immune Cell Therapy
74
|
CD19R(EQ)28zetaEGFRt+ Tn/mem cells consist of a preparation of CD62L-positive naive and memory T-lymphocytes engineered to express a modified CD19-targeting (CD19R(EQ)) chimeric antigen receptor (CAR) as well as CD28 and CD3-zeta signaling domains, as well as a truncated EGFR (EGFRt), which potentially induces toxicity against tumor cells expressing CD19 (NCI Drug Dictionary). |
|
CD3/CD28 stimulated/primed autologous Ts
|
|
ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells |
|
T cells that have been sensitized to vaccine tumor antigen(s) in vivo, then collected from the patient, costimulated with antibodies to the T-cell cell surface proteins CD3 and CD28 and expanded, then re-infused to the same patient (NCI Drug Dictionary). |
|
CD38-SADA
|
|
Anti-CD38 scFv/Anti-DOTA scFv Fusion Protein CD38-SADA |
CD38 Antibody
21
|
CD38-SADA is a fusion protein comprising a single chain variable fragment targeting CD38, a single chain variable fragment targeting the chelating agent DOTA, and a self-assembling and disassembling (SADA) domain, which potentially allows selective delivery of a radioactive payload to CD38-expressing tumor cells (NCI Drug Dictionary). |
|
CD40L-augmented TILs
|
|
|
|
CD40L-augmented TILs are autologous tumor infiltrating lymphocytes that have been activated with the CD40 ligand (CD40L; CD40LG), which potentially increase tumor cell killing (NCI Drug Dictionary). |
|
CGT4859
|
|
CGT-4859|CGT 4859 |
FGFR2 Inhibitor
24
FGFR3 Inhibitor
21
|
CGT4859 is a selective reversible inhibitor of FGFR2 and FGFR3, with activity against mutant FGFR2, which potentially reduces proliferation of tumor cells overexpressing FGFR2 or FGFR3 (Cancer Res (2025) 85 (8_Supplement_1): 4729, NCI Drug Dictionary). |
|
CHM-2101 CAR-T cells
|
|
CHM 2101|CHM2101 |
|
CHM-2101 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CDH17, which potentially induce toxicity in CDH17-expressing tumor cells (NCI Drug Dictionary). |
|
CHO-H01
|
|
CHO H01|CHOH01 |
CD20 Antibody
28
|
CHO-H01 is a monoclonal antibody targeting CD20, which potentially induces apoptosis and inhibits tumor cell proliferation (NCI Drug Dictionary). |
|
CID-103
|
|
CID 103|CID103 |
CD38 Antibody
21
|
CID-103 is a monoclonal antibody that binds CD38, a cell surface glycoprotein expressed on tumor cells, potentially resulting in antibody-dependent cellular cytotoxicity (ADCC) and tumor cell lysis (NCI Drug Dictionary). |
|
CIML-NK cells
|
|
|
|
CIML-NK cells are allogeneic cytokine-induced memory-like natural killer (CIML-NK) cells, which potentially enhance cytotoxic anti-tumor immune response (NCI Drug Dictionary). |
|
CK-101
|
|
CK101|CK 101 |
EGFR Inhibitor 3rd gen
28
|
CK-101 is a third generation EGFR inhibitor that preferentially binds to and inhibits mutant EGFR, particularly T790M, resulting in anti-tumor activity (NCI Drug Dictionary). |
|
CLBR001
|
|
CLBR-001|CLBR 001|Autologous alpha-PNE CAR T-cells CLBR001 |
|
CLBR001 is a switchable CAR-T therapy that comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets a unique peptide epitope on a tumor antigen-specific switch molecule, which potentially results in activation of CAR-T cells and tumor cell killing in the presence of the switch molecule (Blood (2021) 138 (Supplement 1): 1695, NCI Drug Dictionary). |
|
CLIC-2201
|
|
CLIC 2201|CLIC2201 |
CD22 Immune Cell Therapy
13
|
CLIC-2201 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, which potentially induce killing of tumor cells expressing CD22 (NCI Drug Dictionary). |
|
CM-24
|
|
MK-6018 |
|
CM-24 (MK-6018) is a monoclonal antibody that binds to CEA-related cell adhesion molecule 1 (CEACAM1) and blocks immune suppression mediated by CEACAM1, resulting in enhanced anti-tumor immunity (NCI Drug Dictionary). |
|
CM93
|
|
CM 93|CM-93 |
EGFR Inhibitor 3rd gen
28
|
CM93 is a blood-brain-barrier penetrant third-generation EGFR inhibitor, with activity against EGFR mutations, which decreases downstream signaling potentially resulting in increased death of EGFR-expressing tumor cells (NCI Drug Dictionary). |
|
CMD-003
|
|
Baltaleucel-T |
|
CMD-003 (baltaleucel-T) comprises autologous Epstein-Barr virus (EBV) specific T-cells, which potentially leads to increased death of EBV-associated tumor cells (NCI Drug Dictionary). |
|
CPI-100
|
|
|
|
CPI-100 is a preparation of nanoparticles containing an undisclosed payload, which may stimulate immune response or inhibit tumor growth (NCI Drug Dictionary). |
|
CPO107
|
|
CPO 107|CPO-107|JMT601 |
CD20 Antibody
28
CD47 Antibody
31
|
CPO107 is a bispecific fusion protein consisting ofatumumab, an anti-CD20 antibody, linked to signal regulatory protein alpha (SIRPalpha), which targets CD20 and CD47 expressed on tumor cells, potentially leading to antibody-dependent and complement-mediated tumor cell cytotoxicity and increased tumor cell phagocytosis and anti-tumor T-cell response (NCI Drug Dictionary). |
|
CPO301
|
|
CPO-301|CPO 301|SYS6010|SYS 6010|SYS-6010 |
EGFR Antibody
74
|
CPO301 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting EGFR linked to JS-1, which potentially induces killing of EGFR-expressing tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT008, NCI Drug Dictionary). |
|
CRG-022
|
|
CRG 022|CRG022 |
CD22 Immune Cell Therapy
13
|
CRG-022 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD22, which potentially induce tumor cell lysis (NCI Drug Dictionary). |
|
CT3001
|
|
CT-3001|CT 3001 |
|
CT3001 inhibits GPR35, which potentially leads to decreased YAP/TAZ signaling, enhanced antitumor immune response, and reduced tumor cell proliferation (NCI Drug Dictionary). |
|
CT7/MAGE-A3/WT1 mRNA-electroporated LCs
|
|
|
|
CT7/MAGE-A3/WT1 mRNA-electroporated LCs are autologous patient-derived Langerhans cells that are modifed to induce a cytotoxic T-cell response against cancer cells expressing MAGEC1 (CT7), MAGEA3, and WT1 (NCI Drug Dictionary). |
|
CTX110
|
|
CTX-110|CTX 110|anti-CD19 CAR CRISPR-edited CTX110 |
CD19 Immune Cell Therapy
74
|
CTX110 consists of a preparation of allogeneic T-lymphocytes engineered with CRISPR/Cas9 to express a chimeric antigen receptor (CAR) targeting CD19 and to simultaneously remove the endogenous T cell receptor, which potentially reduces GVHD and induces killing of tumor cells overexpressing CD19 (NCI Drug Dictionary). |
|
CX-188
|
|
CX188|CX 188 |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
CX-188 is a PD-1 (PDCD1) probody, consisting of a monoclonal antibody conjugated to a linker that is cleaved by tumor proteases to unmask the antibody and inhibit signaling by PD-1 (NCI Drug Dictionary). |
|
CX-2029
|
|
PDC-targeting CD71 CX-2029|CX 2029 |
|
CX-2029 is a probody-drug conjugate that consists of CD71-targeted monoclonal antibody linked to a antigen-binding site masking peptide that is conjugated to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cell cycle arrest and apoptosis of CD71-expressing tumor cells (NCI Drug Dictionary). |
|
CX-2051
|
|
CX2051|CX 2051 |
|
CX-2051 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets EpCAM linked to a camptothecin derivative, which potentially induces apoptosis in in EpCAM-expressing tumor cells (NCI Drug Dictionary). |
|
CX-904
|
|
CX 904|CX904|AMG 651|AMG651|AMG-651 |
CD3 Antibody
123
EGFR Antibody
74
|
CX-904 comprises a bispecific antibody targeting both EGFR and CD3 linked to masking peptide that is cleaved by tumor-specific proteases in the tumor microenvironment, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
|
CYAD-211
|
|
CYAD211|CYAD 211 |
TNFRSF17 Immune Cell Therapy
28
|
CYAD-211 is a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor T cell (CAR-T) therapy that coexpresses an shRNA targeting CD3z, which potentially induces killing of BCMA-expressing tumor cells (Blood 2021 138:2817, NCI Drug Dictionary). |
|
Carboplatin
|
Paraplatin |
CBDCA |
Chemotherapy - Platinum
7
|
Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
|
Carmustine
|
Becenun |
BCNU |
Chemotherapy - Alkylating
18
|
Becenun (carmustine) is an antineoplastic alkylating agent, which cross-links DNA and disrupts the cell-cycle (NCI Drug Dictionary). |
|
Cisplatin
|
Platinol |
CDDP |
Chemotherapy - Platinum
7
|
Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
|
Cladribine
|
Leustatin |
2-CdA |
|
Leustatin (cladribine) is a purine analog that is incorporated into DNA, resulting in DNA single strand breaks and apoptosis (NCI Drug Dictionary). |
|
Clofarabine
|
Clolar |
Clofarex |
|
Clolar (clofarabine) is a purine nucleoside analog that inhibits ribonucleotide reductase and DNA polymerase, preventing DNA synthesis and repair, and induces apoptosis by inhibiting mitochondrial function (NCI Drug Dictionary). |
|
Conjugated estrogens-bazedoxifene
|
Duavee |
|
|
Duavee (conjugated estrogens-bazedoxifene) is a drug combined of conjugated estrogens and a selective estrogen receptor modulator, which stimulates estrogen levels and prevents proliferation via estrogen antagonism (NCI Drug Dictionary). |
|
Cyclophosphamide
|
Cytoxan |
CPM |
Chemotherapy - Alkylating
18
|
Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
|
Cyproterone
|
Androcur |
Cyproterone acetate |
Hormone - Anti-androgens
58
|
Androcur (cyproterone) is a steroidal androgen receptor (AR) antagonist, which reduces AR activation and growth of androgen-sensitive tumors (NCI Drug Dictionary). |
|
DCBY02
|
|
DCBY-02|DCBY 02 |
|
DCBY02 is a monoclonal antibody that binds to CD93 expressed on endothelial cells and blocks its interaction IGFBP7, potentially leading to increased infiltration of immune cells into the tumor microenvironment and enhanced antitumor activity (NCI Drug Dictionary). |
|
DCSZ11
|
|
DCSZ-11|DCSZ 11 |
|
DCSZ11 is a monoclonal antibody that targets an epitope of C1QR1 (CD93) and prevents the interaction of C1Q1R and its ligand IGFBP7, potentially resulting in decreased tumor cell proliferation and increased immune cell infiltration in the tumor microenvironment (NCI Drug DIctionary). |
|
DF6002
|
|
DF-6002|DF 6002 |
|
DF6002 is a fusion protein consisting of interleukin-12 (IL-12) linked to an Fc fragment, which binds to the IL-12 receptor and may lead to activation of the immune response, inhibition of tumor cell proliferation and tumor cell killing (NCI Drug Dictionary). |
|
DFF332
|
|
DFF 332|DFF-332 |
HIF2A Inhibitor
6
|
DFF332 inhibits HIF-2alpha and blocks its DNA binding, which may lead to downregulation of HIF-2alpha target genes involved in tumor cell growth and survival (NCI Drug Dictionary). |
|
DFP-14927
|
|
DFP14927|DFP 14927|PEGylated DFP-10917 |
|
DFP-14927 is a pegylated version of DFP-10917, which is a deoxycytidine analogue that gets incorporated into DNA and inhibits DNA replication, potentially resulting in increased cell cycle arrest and apoptosis in tumor cells (NCI Drug Dictionary). |
|
DK210
|
|
DK-210|DK 210 |
|
DK210 is a dual cytokine fusion protein comprising high-affinity IL-10 linked to IL-2 by an anti-EGFR single chain variable fragment, which binds to EGFR and potentially induces a cytotoxic T-lymphocyte (CTL) response against tumor cells (J Clin Oncol 42, 2024 (suppl 16; abstr 2584), NCI Drug Dictionary). |
|
DN1508052
|
|
DN 1508052|DN1508052-01|DN A1|DN-A1|DN-1508052 |
TLR8 Agonist
10
|
DN1508052 acts as an agonist of TLR8, potentially resulting in activation of NFkappaB signaling and increased anti-tumor immune response (NCI Drug Dictionary). |
|
DNAJB1-PRKACA peptide vaccine
|
|
DNAJB1-PRKCA peptide vaccine |
|
DNAJB1-PRKACA peptide vaccine consists of a fusion peptide derived from the DNAJB1-PRKACA fusion gene, which may lead to activation of immune response against DNAJB1-PRKACA -expressing tumor cells and decreased tumor cell proliferation (NCI Drug Dictionary). |
|
DNX-2440
|
|
DNX 2440|DNX2440 |
|
DNX-2440 is the replication component of an engineered adenovirus that expresses human OX40 ligand, which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
|
DO-2
|
|
DO2|DO 2 |
MET Inhibitor
59
|
DO-2 is a selective MET inhibitor, which potentially induces cell death in tumor cells overexpressing MET (PMID: 38211518, NCI Drug Dictionary). |
|
DPX-E7
|
|
DPXE7|DPX E7 |
|
DPX-E7 is a vaccine that contains a synthetic peptide of the human papilloma virus subtype 16 (HPV16) amino acids 7 through 19, which may lead to an immune response against cancer cells expressing HPV16 (NCI Drug Dictionary). |
|
DR-01
|
|
DR01|DR 01 |
|
ADR-01 is a non-fucosylated monoclonal antibody that targets an undisclosed cell surface receptor on cytotoxic cells, potentially leading to antitumor activity (NCI Drug Dictionary). |
|
DR-0201
|
|
DR 0201|DR0201|SAR448501 |
CD20 Antibody
28
|
DR-0201 is a bispecific antibody targeting CD20, which potentially induces phagocytosis tumor cells expressing CD20 (NCI Drug Dictionary). |
|
DS-1594b
|
|
DS 1594b|DS1594b |
MEN1-KMT2A Inhibitor
8
|
DS-1594b is a menin inhibitor that blocks the interaction of menin with MLL (KMT2A), leading to decreased expression of target genes, potentially resulting in reduced cell proliferation of leukemic cells harboring MLL rearrangements (NCI Drug Dictionary). |
|
DS-2243a
|
|
DS 2243a|DS2243a |
|
DS-2243a is a bispecific T-cell engager targeting NY-ESO-1 presented by the HLA-A*02 complex on tumor cells and an undisclosed antigen on cytotoxic T-lymphocytes, which redirects cytotoxic T-lymphocytes towards tumor cells expressing NY-ESO-1, potentially resulting in increased tumor cell killing (NCI Drug Dictionary). |
|
DS-2248
|
|
|
HSP90 Inhibitor
35
|
DS-2248 inhibits Heat Shock Protein 90, potentially resulting in decreased proliferation of tumor cells (NCI Drug Dictionary). |
|
DS-9606a
|
|
DS9606a|DS 9606a|DS9606|DS 9606|DS-9606 |
CLDN6 Antibody
10
|
DS-9606a is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting CLDN6 linked to the cytotoxic agent pyrrolobenzodiazepine, which potentially induces killing of CLDN6-expressing tumor cells (Ann Oncol (2024) 35 (Suppl_2): S488 - S489, NCI Drug Dictionary). |
|
DSP-0337
|
|
|
|
DSP-0337 is a prodrug of napabucasin, which inhibits Stat3 signaling and may potentially lead to tumor growth inhibition (NCI Drug Dictionary). |
|
DSP-7888
|
|
Ombipepimut-s|DSP 7888|DSP7888 |
|
Ombipepimut-s (DSP-7888) is a peptide vaccine that potentially induces anti-tumor immune response against tumor cells with WT1 over expression (NCI Drug Dictionary). |
|
DST-2970
|
|
DST2970|DST 2970 |
Hormone - Anti-androgens
58
|
DST-2970 is a solid dispersion formulation of abiraterone, which inhibits the cytochrome p450 family enzyme Cyp17a1 potentially leading to inhibition of testosterone production (NCI Drug Dictionary). |
|
DTRMWXHS-12
|
|
DTRM-12|DTRMWXHS 12 |
BTK inhibitor
39
|
DTRMWXHS-12 inhibits BTK, resulting in decreased B-cell receptor (BCR) signaling and potentially leading to reduced tumor cell growth (NCI Drug Dictionary). |
|
DUK-CPG-001
|
|
|
TLR9 Agonist
9
|
DUK-CPG-001 act as an agonist of TLR9, resulting in activation of dendritic cells, natural killer cells and B-cells, production of T-helper cells, and induction of immune signaling (NCI Drug Dictionary). |
|
DZD1516
|
|
DZD-1516|DZD 1516 |
HER2 Inhibitor
45
|
DZD1516 is an ERBB2 (HER2) inhibitor that penetrates the blood brain barrier, and upon binding to ERRB2 (HER2), prevents ERBB2 (HER2)-dependent signaling, potentially leading to tumor cell death (NCI Drug Dictionary). |
|
Dargistotug
|
|
M-6223|M 6223|M6223 |
TIGIT Antibody
21
|
Dargistotug (M6223) targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary). |
|
Daromun
|
|
L19-IL2/L19-TNF-alpha|Darleukin/Fibromun|L19IL2/L19TNF |
|
Daromun consists of a mixture of darleukin, a recombinant IL2 linked to the fibronectin extra domain B (EDB) targeting single-chain variable fragment (L19), and fibromun, a human TNF-alpha linked to L19, which binds to cells expressing fibronectin EDB in tumor neovasculature, potentially resulting in the induction of antitumor immune response against tumor cells expressing EDB-containing fibronectin (NCI Drug Dictionary). |
|
Deazauridine
|
|
3-deazauridine |
|
Deazauridine is a nucleoside analog that inhibits cytidine synthase, potentially resulting in inhibition of DNA synthesis and increased tumor cell apoptosis (NCI Drug Dictionary). |
|
Debio 4126
|
|
Debio-4126|Debio4126 |
|
Debio 4126 comprises the somatostatin analog octreotide formulated for sustained release, which potentially activates somatostatin receptors leading to decreased angiogenesis and tumor cell proliferation, and increased tumor cell death (NCI Drug Dictionary). |
|
Dexamethasone intravitreal implant
|
Ozurdex |
|
|
Ozurdex (dexamethasone intravitreal implant) is matrix-encapsulated dexamethasone designed for implantation into the vitreous cavity. Within the eye, dexamethasone acts as an anti-inflammatory steroid that will reduce edema and may prevent vision loss (NCI Drug Dictionary). |
|
Dupilumab
|
|
REGN 668|REGN-668|REGN668|SAR 231893|SAR231893|SAR-231893 |
|
Dupilumab is a monoclonal antibody that targets IL-4Ralpha, resulting in decreased IL-4 and IL-13 signaling and potentially leading to decreased tumor cell survival (NCI Drug Dictionary). |
|
E-SYNC T cells
|
|
Anti-EGFRvIII synNotch Receptor-induced Anti-EphA2/IL-13Ralpha2 CAR-T Cells |
IL13RA2 Immune Cell Therapy
7
|
E-SYNC T cells are autologous T cells engineered to express a modified Notch receptor that binds to EGFRvIII expressed on tumor cells and induces the expression of an anti-EphA2 and anti-IL13Ra2 chimeric antigen receptor (CAR), which potentially leads to selective killing of tumor cells expressing EphA2 or IL13Ra2 (PMID: 33910979, NCI Drug Dictionary). |
|
EB103
|
|
EB 103|EB-103 |
CD19 Immune Cell Therapy
74
|
EB103 comprises autologous T-lymphocytes engineered to express an antibody T-cell receptor (TCR) targeting CD19, as well as a co-stimulatory molecule comprising a CD19-targeted binding domain and human co-stimulatory receptor-derived domain, which potentially induces killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
|
EC17
|
|
Folate-FITC|EC-17 |
FOLR1-targeted Therapy
24
|
EC17 (Folate-FITC ) is composed of folate conjugated to fluorescein isothiocyanate, which binds to folate receptors and induces an immune response towards folate receptor-expressing cells (NCI Drug Dictionary). |
|
ECT-001 cord blood cells
|
|
UM171 expanded cord blood |
|
ECT-001 cord blood cells consist of a preparation of expanded umbilical cord blood cells, which may result in improved restoration of blood cells (NCI Drug Dictionary). |
|
ECT204
|
|
ECT-204|ECT 204 |
|
ECT204 are autologous human T-lymphocytes engineered to express an antibody-based antigen-binding domain targeting GPC3 and an effector-binding domain, which potentially lead to cytotoxic T-lymphocyte (CTL)-dependent killing of GPC3 expressing tumor cells (NCI Drug Dictionary). |
|
EGFR Antisense DNA
|
|
|
EGFR Inhibitor (Pan)
63
|
EGFR antisense DNA is synthetic DNA that runs antisense to the EGFR sequence and suppresses endogenous EGFR expression, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary). |
|
EGFR FPBMC
|
|
EGFRBi Armed Fresh PBMC|autologous anti-CD3/EGFR bispecific antibody armed PBMCs |
EGFR Immune Cell Therapy
5
|
EGFR FPBMC are autologous peripheral blood mononuclear cells armed with a bispecific antibody targeting EGFR and CD3, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
|
EGFR806CAR(2G)-EGFRt
|
|
autologous CD4+/CD8+ T cells expressing EGFR806-specific CAR/EGFRt |
EGFR Immune Cell Therapy
5
|
EGFR806CAR(2G)-EGFRt comprises CD4+ and CD8+ T-lymphocytes engineered to express a chimeric antigen receptor (CAR) composed of a depatuxizumab-derived binding domain, which targets EGFR linked to the intracellular domain of TNFRSF9 (4-1BB), CD3zeta, and a truncated form of EGFR, which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing EGFR (NCI Drug Dictionary, J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9116). |
|
EGFRBi-armed autologous activated T cells
|
|
EGFR BATs |
EGFR Antibody
74
|
EGFRBi-armed autologous activated T cells are autologous T-cells that have been armed with a bispecific antibody that binds EGFR and CD3, potentially enhancing T-cell mediated response to EGFR-expressing cells upon antibody binding (NCI Drug Dictionary). |
|
EGFRt/19-28z/IL-12 CAR-T cells
|
|
EGFRt/19-28z/IL-12 CAR T cells |
CD19 Immune Cell Therapy
74
|
EGFRt/19-28z/IL-12 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to CD3zeta and CD28 signaling domains, truncated EGFR, and the cytokine IL-12, which potentially induce cytotoxicity against CD19-expressing tumor cells (NCI Drug Dictionary). |
|
EIS-12656
|
|
EIS12656|EIS 12656 |
|
EIS-12656 inhibits CHD1L (ALC1), which potentially results in decreased PARP-mediated DNA damage repair and tumor cell apoptosis (PMID: 39096699, NCI Drug Dictionary). |
|
EMB-02
|
|
EMB 02|EMB02 |
Immune Checkpoint Inhibitor
150
LAG3 Antibody
19
PD-L1/PD-1 antibody
137
|
EMB-02 is a bispecific antibody that targets both PD-1 (CD279) and lymphocyte activation gene 3 protein (LAG-3), which degrades PD-1- and LAG-3 to induce T cell effector function, potentially leading to a cytotoxic T lymphocyte response against tumor cells (NCI Drug Dictionary, Ann Oncol 34 (2023): S625). |
|
EMB-06
|
|
EMB06|EMB 06 |
CD3 Antibody
123
TNFRSF17 Antibody
22
|
EMB-06 is a bispecific antibody that targets B-cell maturation antigen (BCMA) expressed on tumor cells and CD3 on T-cells, potentially leading to activation of cytotoxic T-lymphocytes (CTL) and CTL-dependent killing of tumor cells expressing BCMA, and antitumor activity (NCI Drug Dictionary, Journal for ImmunoTherapy of Cancer 2023;11). |
|
ENB003
|
|
ENB-003|ENB 003|Vodudeutentan Sodium |
|
ENB003 is an an antagonist that selectively binds to endothelin B receptor (ETBR) and inhibits downstream signaling, which potentially relieves tumor immunosuppression and inhibits proliferation of tumor cells expressing ETBR (Clin Cancer Res 2009;15(14):4521-4528; NCI Drug Dictionary). |
|
EO2040
|
|
EO-2040|EO 2040 |
|
EO2040 is a cancer peptide vaccine comprising microbiome-derived peptides homologous to tumor-associated antigens (TAA) and a CD4-positive T-cell epitope universal cancer peptide 2 (UCP2) emulsified with an immunoadjuvant, which potentially induces a cytotoxic T-cell response against tumor cells expressing the TAA (NCI Drug Dictionary). |
|
EO2463
|
|
EO 2463|EO-2463 |
|
EO2463 is a cancer vaccine comprised of microbiome-derived peptides homologous to tumor-associated antigens (TAA), which when presented by dendritic cells may lead to activation of T-cell mediated immune response against the TAAs expressed on tumor cells (NCI Drug Dictionary). |
|
EO4010
|
|
EO-4010|EO 4010 |
|
EO4010 is a cancer peptide vaccine composed of bacterial-derived peptides that are homologous to tumor-associated antigens (TAA), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
|
EP0031
|
|
EP-0031|EP 0031|A400|A-400|A 400|KL590586 |
RET Inhibitor
53
|
EP0031 inhibits RET, potentially leading to decreased growth of tumors expressing RET fusions and mutations, and resulting in antitumor activity (NCI Drug Dictionary, J Clin Oncol 41, 2023 (suppl 16; abstr 3007)). |
|
EP0042
|
|
EP 0042|EP-0042 |
AURK Inhibitor (Pan)
12
FLT3 Inhibitor
69
|
EP0042 inhibits FLT3 and Aurora kinase, potentially leading to impaired chromosome segregation and decreased proliferation of FLT3- or Aurora kinase-overexpressing tumor cells (NCI Drug Dictionary). |
|
ERAS-601
|
|
ERAS 601|ERAS601 |
SHP2 Inhibitor
20
|
ERAS-601 inhibits SHP2, potentially resulting in decreased cell growth and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2669). |
|
ERAS-801
|
|
ERAS801|ERAS 801 |
EGFR Inhibitor (Pan)
63
|
ERAS-801 is an EGFR inhibitor with improved blood-brain barrier penetrating ability, potentially leading to inhibition of growth of EGFR-overexpressing tumor cells (NCI Drug Dictionary). |
|
ES002023
|
|
ES-002023|ES 002023 |
CD39 Antibody
5
|
ES002023 is a monoclonal antibody targeting ENTPD1 (CD39), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
|
ESR1 peptide-pulsed DC1 vaccine
|
|
Autologous native ESR1-pulsed alternating with mutated ESR1-pulsed DC1 Vaccine |
|
ESR1 peptide-pulsed DC1 vaccine comprises autologous dendritic cells pulsed with wild-type ESR1 or mutant ESR1, which are delivered in an alternating manner and potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing ESR1 (NCI Drug Dictionary). |
|
ET140202
|
|
ET-140202 |
|
ET140202 consists of autologous T-cells engineered to express a T-cell receptor mimetic antibody that recognizes alpha-fetoprotein (AFP) combined with HLA-A02, which may result in antitumor activity of cells expressing AFP (NCI Drug Dictionary). |
|
ET140203
|
|
ET 140203|ET-140203 |
|
ET140203 are autologous T lymphocytes that have been engineered to express a T-cell receptor mimetic (TCRm) construct that targets an undisclosed tumor-associated antigen, potentially leading to cytotoxic T-cell mediated tumor cell killing (NCI Drug Dictionary). |
|
ETBX-021
|
|
ETBX021|ETBX 021 |
HER2 (ERBB2) Vaccine
15
|
ETBX-021 is a virally based vaccine that infects cells and induces expression of a ERBB2 (HER2) to activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary). |
|
ETBX-071
|
|
ETBX 071|ETBX071|Adenoviral PSA Vaccine ETBX-071 |
|
ETBX-071 is an engineered adenovirus vaccine that expresses human prostate specific antigen (PSA) in infected cells, which potentially activates cytotoxic T-lymphocytes against tumor cells expressing PSA (NCI Drug Dictionary). |
|
EU101
|
|
EU 101|EU-101 |
TNFRSF9 Antibody
36
|
EU101 is an agonistic monoclonal antibody that targets CD137 (4-1BB; TNFRSF9), resulting in increased CD137 signaling and potentially leading to inhibition of T-regulatory cells and induction of a cytotoxic T-lymphocyte (CTL)- and NK cell-mediated antitumor response, resulting in tumor cell killing (NCI Drug Dictionary). |
|
EVX-02
|
|
EVX 02|EVX02 |
|
EVX-02 is a DNA vaccine encoding for melanoma patient-specific tumor associated antigens (TAA), which may lead to a cytotoxic T-lymphocyte response against TAA-expressing tumor cells (NCI Drug Dictionary). |
|
Elenestinib
|
|
BLU-263|BLU 263|BLU263 |
KIT Inhibitor
57
|
Elenestinib (BLU-263) inhibits KIT D816V, which potentially leads to decreased cell proliferation (Blood (2022) 140 (Supplement 1): 6877–6878; NCI Drug Dictionary). |
|
Eltrombopag
|
Promacta |
|
|
Eltrombopag is a thromobopoeitin receptor agonist that causes increased proliferation and differentiation of megakaryocytic cells and increased platelet production (NCI Drug Dictionary). |
|
EndoTAG-1
|
|
LipoPac|MBT-0206|Cationic Liposome-Encapsulated Paclitaxel |
|
EndoTAG-1 is comprised of paclitaxel encapsulated in cationic liposomes that preferentially targets endothelial cells, which inhibits microtubule disassembly, potentially leading to decreased cell proliferation and increased apoptosis (NCI Drug Dictionary). |
|
Etoposide
|
Vepesid |
EPEG|Eposin|VP-16|VP-16-213 |
TOPO2 inhibitor
5
|
Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
|
Evixapodlin
|
|
GS4224|GS 4224|GS-4224 |
Immune Checkpoint Inhibitor
150
PD-L1 Inhibitor
15
|
Evixapodlin (GS-4224) is a small molecule that binds to PD-L1 and inhibits its interaction with PD-1, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
|
Exemestane
|
Aromasin |
|
Aromatase Inhibitor
3
|
Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary). |
|
FH-MCVA2TCR
|
|
|
|
FH-MCVA2TCR cells are autologous T-lymphocytes that are engineered to express a T-cell receptor that targets MCPyV, which potentially results in an anti-tumor immune response and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
FH-TCR-TMSLN
|
|
FH-TCR TMSLN |
MSLN Immune Cell Therapy
11
|
FH-TCR-TMSLN are autologous T-lymphocytes engineered to express a T-cell receptor (TCR) targeting MSLN, which potentially induce killing of tumor cells expressing MSLN (J Clin Oncol 41, no. 4_suppl (February 01, 2023) TPS779), NCI Drug Dictionary). |
|
FL-101
|
|
FL 101|FL101|Anti-IL-1 Beta Monoclonal Antibody FL-101 |
|
FL-101 is a monoclonal antibody that targets interleukin-1 beta (IL-1b) and blocks its binding to the IL-1 receptor, potentially resulting in decreased IL-1b downstream signaling and inflammatory response, and inhibition of tumorigenesis and angiogenesis (NCI Drug Dictionary). |
|
FL115
|
|
FL 115|FL-115|L-15(N72D)/IL-15Ra-sFc fusion protein complex |
|
FL115 is a long-acting form of IL-15 comprising a IL-15 variant complexed with a soluble IL-15 receptor alpha Fc domain, which potentially induces activation of NK and memory T cells and enhances antitumor immune response (NCI Drug Dictionary). |
|
FOG-001
|
|
FOG 001|FOG001 |
CTNNB1 Inhibitor
28
|
FOG-001 inhibits the interaction between beta-catenin (CTNNB1) and TCF, resulting in decreased Wnt pathway signaling and potentially leading to decreased tumor growth (J Clin Oncol 42, 2024 (suppl 16; TPS3175), NCI Drug Dictionary) |
|
FRalphaDC vaccine
|
|
FRaDC vaccine|Multi-epitope folate receptor alpha-loaded dendritic cell vaccine |
FOLR1-targeted Therapy
24
|
FRalphaDC vaccine comprises autologous dendritic cells loaded with multi-epitope peptides derived from FOLR1 (FRalpha), which may induce an immune response against FOLR1-expressing tumor cells (NCI Drug Dictionary). |
|
FSI-189
|
|
FSI189 |
SIRPA Antibody
7
|
FSI-189 is an antibody that targets SIRPA and inhibits the interaction between SIRPA and CD47 on tumor cells, which may lead to the activation of macrophages and phagocytic activity of tumor cells (NCI Drug Dictionary). |
|
Filgrastim
|
Neupogen |
G-CSF |
|
Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). |
|
FluBHPVE6E7
|
|
|
|
FluBHPVE6E7 is a cancer vaccine comprising an influenza viral vector with a C-terminal deletion of the NS1 gene and expressing HPV16 and HPV17, which potentially induces a cytotoxic T-lymphocyte (CTL) response against HPV16/17-expressing tumor cells (NCI Drug Dictionary). |
|
Fludarabine
|
Fludara |
FAMP|Fludarabine phosphate |
|
Fludara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) |
|
Fluoxymesterone
|
Halotestin |
Androfluorene |
Hormone - Anti-estrogens
31
|
Halotestin (fluoxymesterone) is a synthetic derivative of testosterone that suppresses estrogen and can potentially result in anti-tumor activity (NCI Drug Dictionary). |
|
Flutamide
|
Eulexin |
Flutamide USP25 |
Hormone - Anti-androgens
58
|
Eulexin (flutamide) is a nonsteroidal antiandrogen that competitively blocks androgen receptors. Eulexin prevents receptor activation and translocation to the nucleus, thus preventing androgen-dependent DNA and protein synthesis, which may prevent tumor cell growth (NCI Drug Dictionary). |
|
Fostamatinib
|
Tavalisse |
R788|R935788 |
SYK Inhibitor
15
|
Fostamatinib (R788) binds and inhibits Syk kinase thus interfering with mast cell, macrophage, and B-cell activation as well as downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis (NCI Drug Dictionary). |
|
GAd-209-FSP
|
|
|
|
GAd-209-FSP is a great ape adenovirus (GAd) priming vaccine that encodes neoantigens derived from frameshift peptides (FSP), which potentially stimulates immune response leading to tumor cell lysis (NCI Drug Dictionary). |
|
GB1275
|
|
GB-1275|GB 1275 |
|
GB1275 is a CD11b agonist with high immunomodulatory activity and promotes anti-tumor immune responses (NCI Drug Dictionary). |
|
GD2Bi-aATC
|
|
anti-CD3 x hu3F8 bispecific antibody-armed ATC |
|
GD2Bi-aATC are autologous T-cells that have been armed with bispecific antibodies that target both GD2 and CD3, resulting in cytotoxicity of GD2-expressing tumor cells by cross-linking activated T-cells to GD2-positive tumor cells, and may also enhance CTL-mediated response tumor cells (NCI Drug Dictionary). |
|
GDC-7035
|
|
GDC7035|GDC 7035|RG 6620|RG-6620|RG6620 |
KRAS G12D Inhibitor
25
|
GDC-7035 inhibits KRAS G12D, potentially resulting in decreased growth of tumor cells overexpressing KRAS G12D (NCI Drug Dictionary). |
|
GEN-001
|
|
GEN 001|GEN001 |
Microbiome
9
|
GEN-001 is a microbiome therapy derived from a single strain of bacteria isolated from healthy donors that, upon delivery, may produce metabolites that increase expression of interleukins (IL7 and IL15) and activate dendritic cells and macrophages, potentially resulting in the induction of cytotoxic immune response against tumor cells (NCI Drug Dictionary). |
|
GEN1044
|
|
GEN 1044|GEN-1044|DuoBody-CD3x5T4|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044 |
5T4 (TPBG) Antibody
8
CD3 Antibody
123
|
GEN1044 is a recombinant bispecific antibody that targets the human T-cell co-receptor CD3 and the oncofetal antigen 5T4 (TPBG), potentially leading to a cytotoxic T-cell response and inhibition of tumor cell cell proliferation (NCI Drug Dictionary). |
|
GEN1053
|
|
BNT 313|BNT-313|BNT313|GEN 1053|GEN-1053 |
|
GEN1053 is a hexamer-forming antibody that targets CD27, potentially leading to increased CD27-dependent signaling, expansion of immune cells, and activation of cytotoxic T-lymphocyte (CTL) mediated antitumor immune response (NCI Drug Dictionary). |
|
GEN2
|
|
GEN 2|GEN-2 |
|
GEN2 comprises a non-replicating retroviral vector expressing herpes simplex virus thymidine kinase (HSV-TK) and GM-CSF, which potentially enhances antitumor immune response and induces tumor cell death (Cancer Res (2024) 84 (6_Supplement): 7250, NCI Drug Dictionary). |
|
GIM-122
|
|
GIM122|GIM 122 |
|
GIM-122 is a dual-functioning monoclonal antibody with undisclosed targets, which potentially inhibits tumor cell proliferation (NCI Drug Dictionary). |
|
GIM-531
|
|
GIM 531|GIM531 |
|
GIM-531 is a small molecule regulatory T-cell (Treg) inhibitor, which potentially reduces Treg-mediated immunosuppression and increases antitumor immune response (NCI Drug Dictionary). |
|
GNKG168
|
|
GNKG 168|CpG ODN GNKG-168 |
TLR9 Agonist
9
|
GNKG168 is a synthetic oligodeoxynucleotide that binds to and activates TLR9, which may lead to downstream signaling of various pathways, potentially stimulating innate immunity, and inducing cytotoxic T-lymphocytes and antibody-dependent cellular cytotoxicity (NCI Drug Dictionary). |
|
GNX102
|
|
GNX-102|GNX 102 |
|
GNX102 is a monoclonal antibody targeting the Lewis B and Lewis Y glycans, which may lead to antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing these glycans (NCI Drug Dictionary). |
|
GRN-1201
|
|
|
|
GRN-1201 is a peptide cancer vaccine that targets four tumor associated antigens restricted to HLA-A2 to increase the activation of tumor-specific T cells (NCI Drug Dictionary). |
|
GRN-300
|
|
GRN 300|GRN300|ARN 3261|ARN-3261|ARN3261 |
|
GRN-300 inhibits salt inducible kinases 2 (SIK2) and 3 (SIK3), which may lead to anti-tumor activity (NCI Drug Dictionary). |
|
GRT-C901
|
|
GRTC901|GRT C901 |
|
GRT-C901 is a personalized priming cancer vaccine that encodes patient tumor-specific neoantigens, potentially resulting in increased anti-tumor immune response against neoantigen-expressing tumor cells (NCI Drug Dictionary). |
|
GRT-C903
|
|
GRTC903|GRT C903 |
|
GRT-C903 is a neoantigen cancer vaccine, which activates cytotoxic T-lymphocyte to kill cancer cells (NCI Drug Dictionary). |
|
GRT-R902
|
|
mRNA-based TSNA boosting vaccine GRT-R902|GRTR902|GRT R902 |
|
GRT-R902 is a personalized boosting cancer vaccine comprising mRNA for patient tumor-specific neoantigens, potentially resulting in increased anti-tumor immune response against neoantigen-expressing tumor cells (NCI Drug Dictionary). |
|
GRT-R904
|
|
GRTR904|GRT R904 |
|
GRT-R904 is a neoantigen cancer vaccine, which activates cytotoxic T-lymphocyte to kill cancer cells (NCI Drug Dictionary). |
|
GS-0201
|
|
GS0201 |
PARP-1 Inhibitor
13
|
GS-0201 selectively inhibits PARP1, which potentially results in accumulation of DNA damage and tumor cell apoptosis (NCI Drug Dictionary). |
|
GS-9911
|
|
GS 9911|GS9911 |
|
GS-9911 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). |
|
GSK4524101
|
|
GSK 4524101|GSK-4524101 |
|
GSK4524101 inhibits DNA polymerase theta, which may prevent the repair of DNA-double stranded breaks, resulting in decreased tumor cell proliferation (Cancer Res (2024) 84 (7_Supplement): CT169, NCI Drug Dictionary). |
|
GSK5764227
|
|
GSK 5764227|GSK-5764227|HS-20093|HS20093|HS 20093|Risvutatug rezetecan |
CD276 Antibody
22
|
GSK5764227 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which may induce apoptosis and inhibit proliferation of tumor cells expressing CD276 (B7-H3) (Cancer Res (2025) 85 (8_Supplement_2): CT195, NCI Drug Dictionary). |
|
GSK6097608
|
|
GSK-6097608|GSK 6097608|Anti-CD96 Monoclonal Antibody GSK6097608|Nelistotug |
|
GSK6097608 is a monoclonal antibody targeting the tumor transmembrane protein, CD96, which may lead to inhibition of downstream signaling upon binding to CD96-expressing immune cells, thereby restoring T cell and NK cell function, and potentially resulting in an antitumor immune response (NCI Drug Dictionary). |
|
Ganitumab
|
|
AMG-479 |
IGF-1R Inhibitor
17
|
Ganitumab (AMG-479) is a recombinant antibody that binds to and inhibits IGF-1R. Inhibition of IGF-1R prevents activation of the downstream PI3K/Akt pathway, which may inhibit proliferation and induce apoptosis of tumor cells (NCI Drug Dictionary). |
|
Gemcitabine
|
Gemzar |
Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 |
Chemotherapy - Antimetabolite
14
|
Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
|
Givastomig
|
|
ABL111|TJ-CD4B|CLDN18.2 x 4-1BB BsAb TJ-CD4B|TJ033721 |
CLDN18.2 Antibody
24
|
Givastomig is a bispecific antibody that targets claudin 18.2 (CLDN18.2) and TNFRSF9 (4-1BB), which potentially results in activation of immune cells and antitumor activity (Ann Oncol (2024) 35 (suppl_2): S689, NCI Drug Dictionary). |
|
Gonadorelin
|
|
Dirigestran|GnRH|LHRHA|AY-24031 |
Hormone Antineoplastics
2
|
Gonadorelin is a synthetic version of gonatotropin-releasing hormone (GnRH) that binds GnRH receptors and induces gonatotropic hormone release, and leads to down-regulation of GnRH receptor expression and reduced hormone release following sustained exposure (NCI Drug Dictionary). |
|
HB-201
|
|
HB201|HB 201|HPV E6/E7-encoding arenavirus vaccine HB-201 |
|
HB-201 consists of lymphocytic choriomeningitis virus that is engineered to express an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
|
HB-202
|
|
HB202|HB 202 |
|
HB-202 is a replication-defective arenavirus-based cancer vaccine that expresses an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
|
HB-302/HB-301
|
|
HB-300|HB300|HB 300 |
|
HB-302/HB-301 is a combination of two arenaviruses engineered to express prostatic acid phosphatase (PAP) and prostate specific antigen (PSA), which potentially results in enhanced antitumor activity against PSA- and PAP- expressing prosate cancer cells (NCI Drug Dictionary). |
|
HC-1119
|
|
HC 1119|HC1119|D3-ENT|Deuterated Enzalutamide|N-trideuteromethyl Enzalutamide |
Hormone - Anti-androgens
58
|
HC-1119 is a deuterated version of enzalutamide that inhibits androgen receptor (AR) by blocking its nuclear translocation and DNA-binding activity, which potentially results in enhanced apoptosis and reduced growth of AR expressing tumor cells (Journal of Clinical Oncology 2018 36:15_suppl, e17021; NCI Drug Dictionary). |
|
HER-2/neu intracellular domain protein
|
|
HER-2 ICD Peptide|HER-2-neu ICD Protein |
|
HER-2/neu intracellular domain protein is the cytoplasmic domain of the Her-2 protein, which may enhance the T-cell response against Her-2 expressing tumor cells when administered with trastuzumab (NCI Drug Dictionary). |
|
HER3-primed DC1 vaccine
|
|
Anti-HER3 DC Vaccine |
|
HER3-primed DC1 vaccine is a cancer vaccine comprising patient-derived dendritic cells targeted against ERBB3 (HER3), which potentially enhances anti-tumor immune response against ERBB3 (HER3)-expressing tumor cells (NCI Drug Dictionary). |
|
HF158K1
|
|
HF-158K1|HF 158K1 |
|
HF158K1 is an immunoliposome containing doxorubicin and TL01, an ERBB2 (HER2)-targeted trastuzumab Fab fragment conjugated lipid, which delivers doxirubicin to ERBB2 (HER2)-expressing tumor cells and potentially inhibits DNA replication (NCI Drug Dictionary). |
|
HH30134
|
|
HH-30134|HH 30134 |
AXL Inhibitor
30
FLT3 Inhibitor
69
Trk Receptor Inhibitor (Pan)
33
|
HH30134 is a multi-kinase inhibitor with activity against AXL, FLT3, and NTRKs, potentially resulting in decreased tumor cell growth (NCI Drug Dictionary). |
|
HLX301
|
|
HLX 301|HLX-301 |
PD-L1/PD-1 antibody
137
TIGIT Antibody
21
|
HLX301 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-L1 (CD274), thereby inhibiting the binding of TIGIT with its ligands CD112 and CD155 and the activation of the PD-L1 receptor, potentially leading to increased antitumor immune response (NCI Drug Dictionary, J Clin Oncol 2025 43: 16_suppl, 2647). |
|
HLX60
|
|
HLX-60|HLX 60 |
|
HLX60 is a monoclonal antibody that targets the TGFbeta activator GARP (LRRC32), preventing the release of TGFbeta1, which potentially results in increased antitumor response (NCI Drug Dictionary). |
|
HMPL-306
|
|
HMPL 306|HMPL306 |
IDH Inhibitor (Pan)
3
|
HMPL-306 specifically inhibits mutant IDH1/2, resulting in decreased conversion of alpha-ketoglutarate into 2-hydroxyglutarate, and potentially leading to inhibition of of IDH1/2 mutant tumor cell proliferation (NCI Drug Dictionary, J Clin Oncol 2025 43: 16_suppl, 2013). |
|
HMPL-453
|
|
HMPL453|HMPL 453 |
FGFR Inhibitor (Pan)
26
|
HMPL-453 binds and inhibits FGFR -1, -2, and -3, which may result in the inhibition of FGFR mediated signal transduction pathways and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
HMPL-523
|
|
|
SYK Inhibitor
15
|
HMPL-523 inhibits SYK, resulting in decreased tumor cell proliferation and migration (NCI Drug Dictionary). |
|
HPVST cells
|
|
Autologous HPV-16/18 E6/E7-specific TGF-beta-resistant T Lymphocytes |
|
HPVST cells are autologous T cells that are stimulated with HPV-16/18-loaded dendritic cells and are also engineered to express a dominant-negative TGF-beta receptor II that inhibits TGF-beta signaling, which potentially results in increased T cell response against HPV-16/18-positive tumor cells (NCI Drug Dictionary). |
|
HS-130
|
|
HS130|HS 130 |
|
HS-130 is a cancer vaccine, expressing a fusion of the OX40 ligand (TNFSF4) to an immunoglobulin, to activate an anti-tumor immune response (NCI Drug Dictionary). |
|
HSK29116
|
|
HSK-29116|HSK 29116 |
BTK inhibitor
39
|
HSK29116 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition in BTK-expressing tumor cells (NCI Drug Dictionary). |
|
HTI-1066
|
|
HTI1066|HTI 1066 |
MET Antibody
39
|
HTI-1066 is a monoclonal antibody against MET in conjugation with a cytotoxic agent, which may specifically target Met-positive tumor cells (NCI Drug Dictionary). |
|
HX009
|
|
HX 009|HX-009 |
CD47 Antibody
31
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
HX009 is a bispecific antibody that targets both PD-1 (PDCD1) on T lymphocytes and CD47 expressed on tumor cells, potentially leading to activation of macrophages, increased phagocytosis of CD47-positive cancer cells, and activation of effector T cell and cytotoxic T-lymphocyte (CTL) mediated antitumor responses (NCI Drug Dictionary). |
|
Hemay022
|
|
|
EGFR Inhibitor (Pan)
63
|
Hemay022 inhibits EGFR, potentially resulting in decreased growth of EGFR over expressing tumors (NCI Drug Dictionary). |
|
Histrelin acetate
|
Vantas |
Supprelin |
|
Histrelin acetate is an analog of gonadotropin-releasing hormone (GnRH), which binds to and activates GnRH receptors, resulting in reduced testosterone production in males, and thus may inhibit growth of androgen-receptor positive tumors (NCI Drug Dictionary). |
|
HuCART19-IL18
|
|
Autologous Anti-CD19 CAR IL-18-expressing T Cells |
CD19 Immune Cell Therapy
74
|
HuCART19-IL18 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and to secrete IL18, which may increase anti-tumor immune response and induce cytotoxicity against CD19-expressing tumor cells (Hematol. Oncol. 2023; 41: 35-37, NCI Drug Dictionary). |
|
HuJCAR014
|
|
Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014 |
CD19 Antibody
22
|
HuJCAR014 comprises CD4+ and CD8+ autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that consists of an anti-CD19 fragment linked to the 4-1BB (CD137) signaling domain and truncated human epidermal growth factor receptor, which has potential cytotoxic activity against CD19-expressing tumor cells (NCI Drug Dictionary). |
|
Hydroxychloroquine
|
Plaquenil |
HCQ |
|
Plaquenil (hydroxychloroquine sulfate) increases intralysosomal pH, resulting in inhibition of autophagic protein degradation and accumulation of autophagosomes, which potentially leads to cell death in autophagy-dependent tumor cells (NCI Drug Dictionary). |
|
Hydroxyurea
|
Droxia |
Carbamohydroxamic Acid|Hydroxycarbamide |
|
Droxia (hydroxyurea) inhibits ribonucleoside diphosphate reductase, resulting in cell cycle arrest (NCI Drug Dictionary). |
|
IACS-6274
|
|
IACS6274|IACS 6274|IPN60090|IPN-60090|IPN 60090 |
Glutaminase Inhibitor
3
|
IACS-6274 (IPN60090) inhibits glutaminase-1 (GLS1), which prevents the conversion of glutamine to glutamate, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary). |
|
IBI110
|
|
IBI 110|IBI-110|negalstobart |
LAG3 Antibody
19
|
IBI110 is a monoclonal antibody that targets LAG3 on tumor infiltrating lymphocytes, and prevents the interaction between LAG3 and MHC II molecules expressed on antigen-presenting cells and tumor cells, potentially leading to increased cytotoxic T lymphocyte-mediated antitumor immune response and inhibition of tumor growth (NCI Drug Dictionary). |
|
IBI133
|
|
IBI-133|IBI 133 |
|
IBI133 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting ERBB3 (HER3) linked to a DNA topoisomerase I inhibitor, which may induce apoptosis and inhibit proliferation of ERBB3 (HER3)-expressing tumor cells (NCI Drug Dictionary). |
|
IBI188
|
|
IBI-188|IBI 188|letaplimab |
CD47 Antibody
31
|
IBI188 (letaplimab) is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, potentially leading to phagocytosis of tumor cells, activation of cytotoxic T-cells (Blood (2022) 140 (Supplement 1): 4045-4046, NCI Drug Dictionary). |
|
IBI3003
|
|
IBI-3003|IBI 3003 |
CD3 Antibody
123
TNFRSF17 Antibody
22
|
IBI3003 is a T-cell engager targeting GPRC5D and TNFRSF17 (BCMA) on tumor cells and CD3 on T-cells, which potentially induces a cytotoxic T-cell response against tumor cells expressing GPRC5D and TNFRSF17 (BCMA) (NCI Drug Dictionary). |
|
IBI3004
|
|
IBI-3004|IBI 3004 |
CEACAM5 Antibody
12
|
IBI3004 is a bispecific antibody targeting CEACAM5 and TRAILR2 (DR5), which potentially induces apoptosis in tumor cells expressing CEACAM5 (NCI Drug Dictionary). |
|
IBI3005
|
|
IBI-3005|IBI 3005 |
EGFR Antibody
74
HER3 (ERBB3) Antibody
29
|
IBI3005 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a camptothecin derivative, which potentially induces cell cycle arrest and apoptosis in tumor cells expressing EGFR and ERBB3 (HER3) (NCI Drug Dictionary). |
|
IBI343
|
|
IBI-343|IBI 343 |
CLDN18.2 Antibody
24
|
IBI343 is an antibody-drug conjugate (ADC) comprising an anti-Claudin18.2 (CLDN18.2) monoclonal antibody linked to the topoisomerase I inhibitor exatecan, which potentially induces apoptosis in tumor cells expressing CLDN18.2 and results in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3037), NCI Drug Dictionary). |
|
IBI354
|
|
IBI-354|IBI 354 |
HER2 (ERBB2) Antibody-Drug Conjugate
36
|
IBI354 is an antibody-drug conjugate (ADC) comprising the ERBB2 (HER2) antibody trastuzumab linked to a toposiomerase I inhibitor, which potentially induces cell cycle arrest and apoptosis in Erbb2 (Her2)-expressing tumor cells and results in antitumor activity (NCI Drug Dictionary, Ann Oncol (2024) 35 (suppl_2): S467-468). |
|
IBI363
|
|
IBI-363|IBI 363 |
PD-L1/PD-1 antibody
137
|
IBI363 is a bispecific antibody fusion protein comprised of a monoclonal antibody that targets PD-1 (PDCD1) linked to a modified form of IL-2, which potentially leads to decreased PD-1 signaling, elevated IL-2-dependent signaling, and restoration of the anti-tumor immune response (NCI Drug Dictionary). |
|
IBRX-042
|
|
IBRX 42|IBRX042|hAd5-HPV E6.ETSD-IRES-E7.ETSD vaccine IBRX-042 |
|
IBRX-042 is a cancer vaccine comprising an adenoviral vector engineered to express HPV16-derived E6 and E7 proteins, which potentially induces a cytotoxic T-lymphocyte (CTL) response against HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
|
IC19/1563
|
|
IC19 1563|IC19-1563|Autologous CAR-T cells IC19/1563 |
CD19 Immune Cell Therapy
74
|
IC19/1563 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially induce toxicity in tumor cells expressing CD19 (NCI Drug Dictionary). |
|
ICP-105
|
|
ICP105|ICP 105 |
FGFR4 Inhibitor
10
|
ICP-105 inhibits FGFR4, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary). |
|
IDP-023
|
|
IDP 023|IDP023 |
|
IDP-023 comprises a preparation of allogeneic g-NK cells, which potentially induces tumor cell lysis and increases antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
|
IFN-B
|
Betaseron |
|
|
Betaseron (IFN-B) is recombinant interferon beta, which induces interferon-regulated gene expression, potentially resulting in immune response and decreased proliferation (NCI Drug Dictionary). |
|
IL-12 gene
|
|
Plasmid IL-12 |
|
IL-12 gene is the plasmid DNA encoding interleukin 12 (IL-12) which induces IL-12 expression when introduced into tumor cells and subsequently leads to anti-tumor immune response (NCI Drug Dictionary). |
|
IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM cells
|
|
IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells |
IL13RA2 Immune Cell Therapy
7
|
IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM cells are autologous naïve and memory T cells (TN/MEM) engineered to express a chimeric antigen receptor (CAR) targeting interleukin-13 receptor alpha 2 (IL13Ra2), and containing the CD137 co-stimulatory signaling domain fused to CD3-zeta, and a truncated form of CD19, which may induce killing of to IL13Ra2-expressing tumor cells (NCI Drug Dictionary). |
|
IMA-203
|
|
IMA203|IMA 203|ACTengine IMA203 |
|
IMA-203 is a preparation of autologous T-cells engineered to express T-cell receptors (TCR) that target tumor-associated antigens, which potentially results in enhanced immune response against tumor cells (NCI Drug Dictionary). |
|
IMA101 T cells
|
|
ACTolog IMA101|IMA101 |
|
IMA101 T cells are autologous cytotoxic T lymphocytes that are expanded ex vivo and injected back into the patient with the potential to recognize specific tumor-associated antigens on cancer cells and subsequently, induce cell death (NCI Drug Dictionary). |
|
IMA202
|
|
IMA-202|IMA 202 |
|
IMA202 is a TCR engineered T-cell therapy, which consists of autologous patient-derived T-cells that are modified to express T-cell receptors that recognizes patient-specific tumor associated antigens (NCI Drug Dictionary). |
|
IMC-002
|
|
IMC002|IMC 002 |
CD47 Antibody
31
|
IMC-002 is a monocloncal antibody that targets CD47 on tumor cells and inhibits its interaction with signal regulatory protein alpha on phagocytic cells, which may lead to immune cell activation and tumor cell phagocytosis (NCI Drug Dictionary). |
|
IMCnyeso
|
|
|
|
IMCnyeso is a bispecific T-cell receptor based therapy that targets NY-ESO-1 and LAGE-1A and also binds to CD3, potentially resulting in increased immune response against NY-ESO1-expressing and LAGE-1A-expressing tumor cells (NCI Drug Dictionary). |
|
IMSA101
|
|
IMSA-101|IMSA 101 |
STING1 Agonist
21
|
IMSA101 is a cyclic GMP-AMP analog that functions as a STING1 agonist, which potentially activates immune cells resulting in enhanced antigen presentation and anti-tumor immune response (NCI Drug Dictionary). |
|
IMX-110
|
|
IMX110|IMX 110 |
|
IMX-110 is a nanoparticle formulation of curcumin and doxorubicin, which may decrease tumor cell growth and induce tumor cell apoptosis (NCI Drug Dictionary). |
|
INBRX-105
|
|
INBRX105|INBRX 105|ES 101|ES-101|ES101 |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
TNFRSF9 Antibody
36
|
INBRX-105 (ES 101) is a bispecific antibody that binds to TNFRSF9 (CD137) and PD-L1 (CD274), potentially resulting in enhanced anti-tumor immunity and tumor cell lysis (NCI Drug Dictionary). |
|
INCAGN01876
|
|
INCAGN1876|INCAGN-1876|INCAGN 1876 |
GITR Antibody
7
|
INCAGN01876 is an activating monoclonal antibody that binds to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), which leads to activation of GITR and potentially results in activation of anti-tumor immunity (NCI Drug Dictionary). |
|
INCB099280
|
|
INCB 099280|INCB-099280|INCB 99280|INCB-99280|INCB99280 |
Immune Checkpoint Inhibitor
150
PD-L1 Inhibitor
15
|
INCB099280 is a small molecule inhibitor of CD274 (PD-L1) that prevents binding to PDCD1 (PD-1), potentially inducing an anti-tumor immune response (J ImmunoTherapy Cancer 2022;10, NCI Drug Dictionary). |
|
INO-5151
|
|
INO5151|INO 5151 |
|
INO-5151 is a combination of DNA plasmids encoding Interleukin-12 (INO-9012 formulation) and prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) (INO-5150 formulation) to activate a cytotoxic T-lymphocyte for an anti-tumor response (NCI Drug Dictionary). |
|
IOV-4001
|
|
IOV 4001|IOV4001 |
|
IOV-4001 are autologous tumor infiltrating lymphocytes engineered to knockout PD-1 (PDCD1), which potentially increase antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). |
|
IPN01194
|
|
IPN-01194|IPN 01194 |
ERK Inhibitor (pan)
21
|
IPN01194 inhibits ERK1 and ERK2, resulting in decreased downstream signaling and potentially leading to decreased tumor cell proliferation (NCI Drug Dictionary). |
|
IRX5183
|
|
IRX-5183 |
|
IRX5183 is an agonist of retinoic acid receptor alpha (RARalpha), which increases RARalpha signaling, potentially resulting in increased apoptosis and differentiation and decreased proliferation of tumor cells (NCI Drug Dictionary). |
|
ITIL-306
|
|
ITIL 306|ITIL306|Autologous CoStAR-TILs ITIL-306 |
|
ITIL-306 comprises autologous tumor infiltrating lymphocytes engineered to express a costimulatory antigen receptor targeting FOLR1 as well as the CD28 and CD40 costimulatory domains, which potentially induce killing of FOLR1-expressing tumor cells and enhance antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). |
|
IVS-3001
|
|
IVS 3001|IVS3001 |
|
IVS-3001 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting HLA-G, which potentially enhance antitumor immune response (NCI Drug Dictionary). |
|
IVX037
|
|
IVX-037|IVX 037 |
|
IVX037 is an oncolytic RNA virus that selectively infects tumor cells by targeting tumor-specific receptors, potentially leading to induction of cytotoxicity and tumor cell death (NCI Drug Dictionary). |
|
Ieramilimab
|
|
LAG-525|LAG525|IMP-701 |
Immune Checkpoint Inhibitor
150
LAG3 Antibody
19
|
Ieramilimab (LAG525) is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary). |
|
Ifosfamide
|
Cyfos |
Z4942 |
Chemotherapy - Alkylating
18
|
Cyfos (ifosfamide) is an alkylating agent, which cross-links DNA, thereby inhibiting DNA replication (NCI Drug Dictionary). |
|
Infliximab
|
Remicade |
Avakine|cA2|Remsima |
|
Remicade (infliximab) is a monoclonal antibody that targets tumor necrosis factor alpha (TNF-alpha), potentially resulting in increased or decreased apoptosis (NCI Drug Dictionary). |
|
Interleukin-12
|
|
Ro 24-7472|NM-IL-12|Edodekin alfa |
|
Interleukin-12 (NM-IL-12) is a recombinant version of Interleukin-12 (IL-12), which may decrease tumor angiogenesis (NCI Drug Dictionary). |
|
Iomab-B
|
|
I 131 MOAB BC8|131-I Apamistamab|Iodine I 131-apamistamab |
|
Iomab-B (131-I apamistamab) comprises an antibody targeting CD45 conjugated to iodine 131 (I-131), which delivers I-131 to CD45-expressing cells, potentially resulting in increased death of CD45-expressing tumor cells (NCI Drug Dictionary). |
|
JAB-2485
|
|
JAB2485|JAB 2485 |
Aurka Inhibitors
27
|
JAB-2485 inhibits Aurora Kinase A (AURKA), potentially resulting in decreased cell division and increased apoptosis of AURKA-expressing tumor cells (NCI Drug Dictionary). |
|
JAB-3068
|
|
JAB3068|JAB 3068 |
SHP2 Inhibitor
20
|
JAB-3068 targets SHP2 (PTPN11) to inhibit MAPK signaling, which may decrease tumor cell proliferation (NCI Drug Dictionary). |
|
JAB-8263
|
|
JAB8263|JAB 8263 |
BET Inhibitor (Pan)
33
|
JAB-8263 is a BET inhibitor that that binds BRD2, BRD3, BRD4, and BRDT and prevents their interaction with acetylated histones, thereby leading to altered chromatin modeling and gene expression patterns, and potentially resulting in inhibition of tumor cell growth (NCI Drug Dictionary). |
|
JBH492
|
|
JBH 492|JBH-492|Anti-CCR7 ADC JBH492 |
|
JBH492 is an antibody-drug conjugate consisting of an antibody that targets CC chemokine receptor 7 present on tumor cells and conjugated to the maytanisoid DM4, which may lead to inhibition of tumor cell proliferation (NCI Drug Ductionary). |
|
JCAR014
|
|
|
|
JCAR014 is composed of autologous CD8 and CD4+ memory T-cells expressing a chimeric antigen receptor (CAR) comprised of a CD19 scFv-4-1BB-CD3zeta fusion protein and truncated EGFR, which may stimulate anti-tumor immunity (NCI Drug Dictionary). |
|
JNJ-64041809
|
|
JNJ-809|Opolimogene Capmilisbac|ADU-741 |
|
Opolimogene Capmilisbac (JNJ-64041809) is an attenuated strain of Listeria monocytogenes encoding multiple tumor antigens which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
|
JNJ-64052781
|
|
Duvortuxizumab|MGD011 |
CD19 Antibody
22
|
JNJ-64052781 (duvortuxizumab) is an antibody-like protein that binds to both CD3 and CD19, resulting in cross-linking of tumor B-cells and cytotoxic T-lymphocytes, potentially leading to immune response against B-cell malignancies (NCI Drug Dictionary). |
|
JNJ-64264681
|
|
JNJ 64264681|JNJ64264681 |
BTK inhibitor
39
|
JNJ-64264681 is a BTK inhibitor that blocks signaling through the BCR signaling pathway, potentially resulting in growth inhibition of tumor cells over expressing BTK (NCI Drug Dictionary). |
|
JNJ-75229414
|
|
JNJ75229414|JNJ 75229414 |
|
JNJ-75229414 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets KLK2, which potentially induce toxicity against tumor cells expressing KLK2 (NCI Drug Dictionary). |
|
JNJ-78306358
|
|
JNJ 78306358|JNJ78306358 |
CD3 Antibody
123
|
JNJ-78306358 is a bispecific antibody that targets HLA-G expressed on tumor cells and the T-lymphocyte antigen CD3, potentially leading to activation of a cytotoxic T-lymphocyte response against tumor cells (NCI Drug Dictionary). |
|
JNJ-80948543
|
|
JNJ 80948543|JNJ80948543 |
CD3 Antibody
123
|
JNJ-80948543 is an antibody that targets an undisclosed tumor-associated antigen (TAA) and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and tumor cell killing (NCI Drug Dictionary). |
|
JNJ-86974680
|
|
JNJ 86974680|JNJ86974680 |
Adenosine Targeting
24
|
JNJ-86974680 is an antagonist of the adenosine receptor A2AR (ADORA2A) expressed on T-lymphocytes, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT137; NCI Drug Dictionary). |
|
JNJ-87189401
|
|
JNJ 87189401|JNJ87189401 |
CD28 Antibody
13
PSMA Antibody
24
|
JNJ-87189401 is a bispecific antibody that targets PSMA on tumor cells and CD28 expressed on T-cells, which potentially induces T-cell activation and tumor cell death in PSMA-expressing tumors (Ann Oncol (2024) 35 (Suppl_2): S1000; NCI Drug Dictionary). |
|
JNJ-87704916
|
|
JNJ87704916|JNJ 87704916 |
|
JNJ-87704916 is a recombinant oncolytic herpes simplex virus type 1 (HSV-1), which potentially induces tumor cell lysis and an antitumor immune response (NCI Drug Dictionary). |
|
JS006
|
|
JS-006|JS 006|TAB006|TAB 006|TAB-006 |
TIGIT Antibody
21
|
JS006 is a monoclonal antibody that binds to TIGIT and inhibits ligand interaction, potentially leading to increased antitumor immune response (NCI Drug Dictionary). |
|
JS009
|
|
JS-009|JS 009|TAB009|TAB-009|TAB 009 |
PVRIG Antibody
5
|
JS009 is a monoclonal antibody that binds to PVRIG (CD112R) expressed on cytotoxic T-lymphocytes and NK cells and blocks its interaction with CD112, which potentially induces antitumor immune response and decreases tumor cell proliferation (NCI Drug Dictionary). |
|
JSKN003
|
|
JSKN 003|JSKN-003 |
HER2 (ERBB2) Antibody
80
HER2 (ERBB2) Antibody-Drug Conjugate
36
|
JSKN003 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting two epitopes of ERBB2 (HER2) linked to a topoisomerase inhibitor, which potentially induces cell cycle arrest and apoptosis of ERBB2 (HER2)-expressing tumor cells and results in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3038), NCI Drug Dictionary). |
|
JV-213
|
|
JV213|JV 213 |
|
JV-213 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD79B, which potentially induces toxicity in CD79B-expressing tumor cells (NCI Drug Dictionary). |
|
JYP0322
|
|
JYP-0322|JYP 0322 |
ROS1 Inhibitor
23
|
JYP0322 selectively inhibits ROS1, with activity against ROS1 G2032R, which potentially leads to decreased proliferation of ROS1-positive tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT052, NCI Drug Dictionary). |
|
JZP341
|
|
JZP 341|JZP-341|PF745|PF-745|PF 745 |
|
JZP341 is a recombinant form of Erwinia asparaginase, which potentially reduces levels of asparagine leading to inhibition of protein synthesis and decreased tumor cell proliferation (NCI Drug Dictionary). |
|
KAND567
|
|
KAND-567|KAND 567|AZD8797|AZD-8797|AZD 8797 |
|
KAND567 is a small molecule inhibitor of CX3CR1, which inhibits DNA damage repair and enhances sensitivity to chemotherapeutic agents, potentially leading to decreased tumor cell viability (PMID: 33810010, NCI Drug Dictionary). |
|
KHK2455
|
|
KHK-2455|KHK 2455 |
IDO1 Inhibitor
13
|
KHK2455 inhibits IDO1, which results in reduced levels of kynurenine, potentially leading to increased immune cell activation and and immune response against tumor cells (NCI Drug Dictionary). |
|
KITE-197
|
|
KITE197|KITE 197 |
|
KITE-197 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) for an undisclosed target (NCI Drug Dictionary). |
|
KITE-439
|
|
KITE 439 |
|
KITE-439 consists of autologous T-cells engineered to express a T-cell receptor that recognizes HLA-A*02:01-restricted human papillomavirus type 16 isoform E7 (HPV16 E7) protein, potentially resulting in antitumor activity of cells expressing HPV16 E7 (NCI Drug Dictionary). |
|
KITE-718
|
|
KITE 718 |
|
KITE-718 comprises autologous T-cells engineered to express a T-cell receptor that recognizes MAGE-A3 and MAGE-A6, which may decrease growth of MAGE-A3 and MAGE-A6-expressing tumor cells (NCI Drug Dictionary). |
|
KN026
|
|
KN-026|KN 026 |
HER2 (ERBB2) Antibody
80
|
KN026 is a bispecific ERBB2 (HER2) antibody that inhibits Erbb2 (Her2) heterodimerization, potentially resulting in decreased downstream signal activation and induction of cytotoxicity against Erbb2 (Her2)-overexpressing tumor cells (NCI Drug Dictionary). |
|
KPG-818
|
|
KPG818|KPG 818 |
|
KPG-818 targets cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex, and modifies its E3 ligase activity, which may lead to proteosomal degradation of T cell transcriptional repressors, potentially resulting in activation of immune response and decreased tumor cell proliferation (NCI Drug Dictionary). |
|
KQB198
|
|
KQB-198|KQB 198 |
SOS1 Inhibitor
17
|
KQB198 inhibits SOS1, potentially leading to decreased downstream KRAS signaling and reduced growth of tumor cells expressing KRAS (NCI Drug Dictionary). |
|
KQB365
|
|
KQB-365|KQB 365 |
KRAS Inhibitor
31
|
KQB365 inhibits mutant KRAS, which potentially induces apoptosis and decreases proliferation in tumor cells harboring KRAS mutations (NCI Drug Dictionary). |
|
KSQ-001EX
|
|
KSQ 001EX|KSQ001EX |
|
KSQ-001EX comprises autologous T-lymphocytes engineered to harbor inactivation of SOCS1, which potentially induces cytotoxicity in tumor cells and enhances antitumor immune response (Cancer Res (2024) 84 (6_Supplement): 20, NCI Drug Dictionary). |
|
LAT010
|
|
LAT-010|LAT 010 |
|
LAT010 is an antibody fusion protein comprising an anti-IL2 antibody linked to the cytokine IL-2, which potentially activates NK cells and CD8-positive T-cells and induces antitumor activity (NCI Drug Dictionary). |
|
LAVA-1207
|
|
LAVA 1207|LAVA1207 |
PSMA Antibody
24
|
LAVA-1207 is a bispecific gamma delta T-cell engager (TCE) antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and Vdelta2 expressed on T-lymphocytes, which potentially leads to increased antitumor immune response and tumor cell killing (NCI Drug Dictionary). |
|
LB1908
|
|
LB-1908|LB 1908 |
CLDN18.2 Immune Cell Therapy
4
|
LB1908 are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting Claudin 18.2 (CLDN18.2), which potentially induce toxicity in tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
|
LB2102
|
|
LB-2102|LB 2102 |
|
LB2102 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting DLL3, which potentially induce toxicity in DLL3-expressing tumor cells (NCI Drug Dictionary). |
|
LEU011
|
|
LEU-011|LEU 011 |
|
LEU011 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting NKG2D ligands (NKG2DLs), which potentially induces toxicity in tumor cells expressing NKG2DLs (NCI Drug Dictionary). |
|
LM-102
|
|
LM102|LM 102 |
CLDN18.2 Antibody
24
|
LM-102 is a monoclonal antibody that targets CLDN18.2, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary) |
|
LM-108
|
|
LM 108|LM108 |
CCR8 Antibody
13
|
LM-108 is a monoclonal antibody that targets CCR8 expressed on regulatory T cells and inhibits downstream signaling, potentially leading to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2504), NCI Drug Dictionary). |
|
LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes
|
|
LMP/BARF1/EBNA1-specific CTLs|LMP1/BARF1/EBNA-1 MABEL CTLs |
|
LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes are T-cells that recognize the Epstein-Barr virus proteins LMP, BARF1, and EBNA1, potentially resulting in increased anti-tumor immune response against cells expressing these proteins (NCI Drug Dictionary). |
|
LMY-920
|
|
LMY920|LMY 920|Autologous BAFF-expressing CAR T Cells |
|
LMY-920 comprises autologous CD4- and CD8-positive T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing the B-cell activating factor (BAFF) ligand, which potentially induce cytotoxicity against tumor cells expressing BAFF-R (TNFRSF13C), BCMA (TNFRSF17), or TACI (TNFRSF13B) (NCI Drug Dictionary). |
|
LN-145
|
|
LN145 |
|
LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary). |
|
LNK01002
|
|
LNK 01002|LNK-01002|LNK-1000318 |
|
LNK01002 inhibits multiple kinases, potentially resulting in antitumor activity (NCI Drug Dictionary). |
|
LNS8801
|
|
LNS 8801|LNS-8801|GPER agonist LNS8801 |
|
LNS8801 is a selective G-protein coupled estrogen receptor (GPER) agonist, which activates GPER signaling and suppresses tumor-associated gene expression, potentially leading to the inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
LTT462
|
|
LTT 462|LTT-462|rineterkib |
ERK Inhibitor (pan)
21
|
LTT462 inhibits ERK, resulting in decreased downstream signaling, and reduced ERK-dependent proliferation and survival of tumor cells (NCI Drug Dictionary). |
|
LUNA18
|
|
LUNA 18|LUNA-18 |
RAS Inhibitor (Pan)
14
|
LUNA18 is a cyclic peptide that inhibits Ras, potentially leading to decreased proliferation of Ras-expressing tumor cells (PMID: 36109865, NCI Drug Dictionary). |
|
LV20.19 CAR-T cells
|
|
Autologous CAR-20/19-T cells|4-1BB-CD3zeta LV20.19 CAR T cells |
CD19 Immune Cell Therapy
74
CD20 Immune Cell Therapy
16
|
LV20.19 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) comprising single chain variable fragments targeting CD19 and CD20 coupled to CD3zeta and TNFRSF9 (CD137; 4-1BB) signaling domains, which potentially induce antitumor activity (PMID: 33020647, NCI Drug Dictionary). |
|
LVGN7409
|
|
LVGN-7409|LVGN 7409 |
CD40 Antibody
16
|
LVGN7409 is an agonist antibody targeting CD40, which may lead to activation of downstream signaling and T-cell activity (NCI Drug Dictionary). |
|
LY01005
|
|
LY-01005|LY 01005 |
Hormone - Anti-androgens
58
|
LY01005 is a extended release formulation of Goserelin, which is a synthetic analog of lutenizing hormone-releasing hormone (NCI Drug Dictionary). |
|
LY3022855
|
|
IMC-CS4 |
CSF1R Antibody
5
|
LY3022855 (IMC-CS4) is a monoclonal antibody against colony stimulating factor 1 receptor (CSF1R), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells over expressing CSF1R (NCI Drug Dictionary). |
|
LY3076226
|
|
LY-3076226 |
FGFR3 Antibody
5
|
LY3076226 is comprised of an FGFR3-directed monoclonal antibody conjugated to a toxic compound, which may result in death of FGFR3-expressing tumor cells (NCI Drug Dictionary). |
|
LY3321367
|
|
LY 3321367|LY-3321367 |
Immune Checkpoint Inhibitor
150
TIM-3 Antibody
9
|
LY3321367, is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
|
LY3435151
|
|
LY 3435151|LY-3435151 |
|
LY3435151 is an antibody that targets and binds to CD226, a cell surface glycoprotein, potentially leading to the activation of the antitumor immune response (NCI Drug Dictionary). |
|
LY4170156
|
|
LY-4170156|LY 4170156 |
FOLR1-targeted Therapy
24
|
LY4170156 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against FOLR1 (folate receptor alpha; FRa) linked to the topoisomerase I inhibitor exatecan, which may induce apoptosis and inhibit proliferation of tumor cells expressing FOLR1 (FRa) (J Clin Oncol (2024) 42:16_suppl, 3023, NCI Drug Dictionary). |
|
LZM009
|
|
LZM-009|LZM 009 |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
LZM009 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
|
Lanraplenib
|
|
GS-9876 |
SYK Inhibitor
15
|
Lanraplenib inhibits Syk, resulting in decreased B-cell receptor (BCR) signaling and potentially leading to decreased tumor cell activation and proliferation (NCI Drug Dictionary). |
|
Lenograstim
|
|
Glycosylated Recombinant G-CSF|Neutrogin|Granocyte |
|
Lenograstim is a recombinant analog of glycosylated granulocyte colony-stimulating factor (G-CSF), which binds and activates G-CSF receptors, leading to activation of neutrophil progenitor proliferation and differentiation (NCI Drug Dictionary). |
|
Leuprolide
|
Lupron |
Leuprorelin |
|
Lupron (leuprolide) is an agonist of gonadotropin releasing hormone (GnRH), which results decreased testosterone production in males and decreased estradiol production in females, potentially leading to decreased growth of androgen-positive tumors (NCI Drug Dictionary). |
|
Lilotomab
|
|
HH1 |
CD37 Antibody
9
|
Lilotomab is a murine antibody that targets CD37, which potentially results in enhanced antibody-dependent cell-mediated cytotoxicity response against tumor cels expressing CD37 (NCI Drug Dictionary). |
|
Liothyronine sodium
|
Triostat |
Cytomel |
|
Triostat (liothyronine sodium) is a synthetic version of T3, which induces thyroid hormone responsive gene expression to promote normal development and growth (NCI Drug DIctionary). |
|
Lirafugratinib
|
|
RLY4008|RLY 4008|RLY-4008 |
FGFR2 Inhibitor
24
|
Lirafugratinib binds to and inhibits FGFR2, selectively targeting primary oncogenic FGFR2 mutations and leads to decreased FGFR2-dependent signaling, potentially resulting in inhibition of tumor cell proliferation (NCI Drug Dictionary; Journal of Clinical Oncology 39, no. 15_suppl). |
|
Lomonitinib
|
|
ZE46 0134|ZE46-0134|ZE46 0134 |
FLT3 Inhibitor
69
IRAK4 Inhibitor
8
|
Lomonitinib (ZE46-0134) is an inhibitor of FLT3 and IRAK4, with activity against FLT3-ITD mutations and FLT3 F691L, which reduces downstream signaling and potentially inhibits tumor cell proliferation (Blood (2024) 144 (Supplement 1): 1396, NCI Drug Dictionary). |
|
Long peptide vaccine 7
|
|
LPV7 |
|
Long peptide vaccine 7 is a cancer vaccine that contains synthetic peptides based on cancer-testis antigens and melanocytic differentiation proteins, which may induce an anti-tumor immune response (NCI Drug Dictionary). |
|
Lutetium Lu 177-DOTA
|
|
177Lu-DOTA|Lu-177-DOTA |
|
Lutetium Lu 177-DOTA is a radioconjugate comprising the radionuclide Lutetium-177 linked to the chelating agent DOTA, which potentially delivers beta radiation (NCI Drug Dictionary). |
|
M032
|
|
M 032|M-032|NSC 733972 |
|
M032 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12, which may result in increased anti-tumor immune response and decreased tumor cells proliferation (PMID: 33524948; NCI Drug Dictionary). |
|
M1231
|
|
M-1231|M 12231 |
EGFR Antibody
74
MUC1 Antibody
8
|
M1231 is an antibody-drug conjugate (ADC) consisting of a bispecific antibody against MUC1 and EGFR conjugated to an anti-microtubule agent, which may result in decreased proliferation of tumor cells expressing MUC1 and EGFR (NCI Drug Dictionary). |
|
MAGE-A1-specific TCR cells
|
|
MAGE-A1-specific TCR-transduced autologous T cells |
|
MAGE-A1-specific TCR cells consist of autologous T-lymphocytes that are engineered to express a T-cell receptor that recognizes the human melanoma antigen 1 (MAGE-A1), which potentially inhibits growth of MAGE-A1-expressing tumor cells (NCI Drug Dictionary). |
|
MB-102
|
|
CD123CAR-CD28-CD3zeta-EGFRt-expressing T lymphocytes|CD123 CAR-T |
CD123 (IL3RA) Immune Cell Therapy
5
|
MB-102 is comprised of engineered T cells expressing chimeric antigen receptor consisting of CD123, CD28 fused to CD3 zeta, and a truncated EGFR (EGFRt), which may induce cytotoxic immune response against CD123-positive tumor cells (NCI Drug Dictionary). |
|
MB-106
|
|
MB 106|MB106 |
CD20 Immune Cell Therapy
16
|
MB-106 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD20, and containing CD28 co-stimulatory and TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CD20 (Blood (2021) 138 (Supplement 1): 3872; NCI Drug Dictionary). |
|
MB-CART19.1
|
|
MBCART19.1|MB CART19.1|Autologous CD19 CAR-expressing CD4/CD8 pos T-cells |
CD19 Immune Cell Therapy
74
|
MB-CART19.1 consists of CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing 4-1-BBz, which potentially inhibits tumor growth (Blood (2021) 138 (Supplement 1): 3836; NCI Drug Dictionary). |
|
MCARH125
|
|
MCARH-125|MCARH 125 |
TNFRSF17 Immune Cell Therapy
28
|
MCARH125 are autologous T-cells engineered to express a chimeric antigen receptor (CAR) that targets the B-cell maturation antigen (BCMA; TNFRSF17), which potentially induce cytotoxicity in tumor cells expressing BCMA (NCI Drug Dictionary). |
|
MCY-M11
|
|
anti-mesothelin mRNA-transfected autologous PBMCs MCY-M11 |
|
MCY-M11 consists of autologous peripheral blood mononuclear cells modified to express an mRNA construct that encodes a mesothelin-targeting chimeric antigen receptor (CAR), which potentially induces phagocytosis and increases cytotoxicity against tumor cells expressing mesothelin (NCI Drug Dictionary; J Clin Oncol 2020 38:15_suppl, 3014). |
|
MDA autologous tumor-infiltrating lymphocytes
|
|
MDA-TILs|Autologous MDA TILs |
|
MDA autologous tumor-infiltrating lymphocytes are patient-derived T-lymphocytes expanded with interleukin-2 (IL-2) and a CD137 (4-1BB) agonistic antibody, and then reintroduced, which potentially results in tumor cell killing (NCI Drug Dictionary). |
|
MDG1011
|
|
MDG 1011|MDG-1011 |
|
MDG1011 is T lymphocytes engineered to express preferentially expressed antigen in melanoma (PRAME)-specific TCR coupled to the CD3 signaling complex, which may induce death of PRAME-expressing tumor cells (NCI Drug Dictionary). |
|
MDNA55
|
|
PRX-321|PRX321 |
|
MDNA55 (PRX-321) is a fusion protein that includes IL-4 fused to a truncated form of Pseudomonas exotoxin, which once internalized by tumor cells expressing IL-4 receptors may lead to apoptosis (NCI Drug Dictionary). |
|
MDPK67b
|
|
MDPK-67b|MDPK 67b |
|
MDPK67b is a serpin-type inhibitor that inhibits kallikrein-related peptidases, including KLK2, KLK4, and KLK14, which potentially results in decreased cell proliferation and inhibition of tumor growth (PMID: 24571737, PMID: 14728688, NCI Drug Dictionary). |
|
MELITAC 12.1 Peptide Vaccine
|
|
|
|
MELITAC 12.1 peptide vaccine is a cancer vaccine that contains both melanoma peptides and helper peptides, which may stimulate an immune response against melanoma tumor cells (NCI Drug Dictionary). |
|
MEN2312
|
|
MEN-2312|MEN 2312 |
|
MEN2312 inhibits the histone acetyltransferase KAT6, which potentially results in altered gene expression and decreased proliferation in tumors overexpressing KAT6 (NCI Drug Dictionary). |
|
MG 98
|
|
MG98|MG-98 |
DNMT1 inhibitor
4
|
MG 98 is an oligonucleotide antisense that inhibits DNMT1, thereby resulting in altered expression of DNMT1 targeted genes due to decreased methylation and thus, potentially resulting in tumor growth inhibition (NCI Drug Dictionary). |
|
MGY825
|
|
MGY 825|MGY-825 |
|
MGY825 inhibits NFE2L2, KEAP1, and CUL3, which potentially leads to decreased tumor cell proliferation (NCI Drug Dictionary). |
|
MK-0482
|
|
MK 0482|MK0482 |
|
MK-0482 binds to ILT3 and prevents binding of ILT-3 ligands, leading to inhibition of ILT-3 dependent signaling, which may lead to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2046), NCI Drug Dictionary). |
|
MK-1084
|
|
MK 1084|MK1084|Calderasib |
KRAS G12C inhibitor
36
|
MK-1084 is a selective inhibitor of KRAS G12C, which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation, and antitumor activity (NCI Drug Dictionary, Ann Oncol 34 (2023): S466-S467). |
|
MK-1200
|
|
MK1200|MK 1200|SKB 315|SKB-315|SKB315 |
CLDN18.2 Antibody
24
|
MK-1200 is an antibody-drug conjugate (ADC) comprising an antibody targeting CLDN18.2 linked to a DNA topoisomerase I inhibitor, which potentially induces apoptosis in CLDN18.2--expressing tumor cells (NCI Drug Dictionary). |
|
MK-1308
|
|
MK1308|MK 1308|Quavonlimab |
CTLA4 Antibody
33
Immune Checkpoint Inhibitor
150
|
MK-1308 is a monoclonal antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response and decreased tumor growth (NCI Drug Dictionary). |
|
MK-1966
|
|
MK 1966 |
|
MK-1966 down-regulates IL-10 activity and enhances anti-tumor immunity (NCI Drug Dictionary). |
|
MK-4830
|
|
MK4830|MK 4830 |
Immune Checkpoint Inhibitor
150
LILRB2 Antibody
12
|
MK-4830 is a monoclonal antibody that targets LILRB2 (ILT4), which may relieve LILRB2 (ILT4)-mediated immunosuppression in the tumor microenvironment and enhance antitumor activity (PMID: 34598945, NCI Drug Dictionary). |
|
MK-7684A
|
|
MK-7684/MK-3475|Vibostolimab/Pembrolizumab |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
TIGIT Antibody
21
|
MK-7684A is a co-formulation of the immune checkpoint inhibitor Keytruda (pembrolizumab) and MK-7684 (Vibostolimab), an antibody directed against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which may lead to the activation of immune response against tumor cells (NCI Drug Dictionary). |
|
MOR210
|
|
TJ210|MPR 210|MOR-210|TJ 210|TJ-210|TJ210001|WBP2191 |
|
MOR210 (TJ210) is a human antibody against complement component fragment 5a receptor (C5aR1, CD88), which may block C5aR1 signaling and induce anti-tumor immune response (NCI Drug Dictionary). |
|
MQ710
|
|
MQ-710|MQ 710 |
|
MQ710 is a cancer vaccine comprising a modified vaccinia virus Ankara engineered with deletion of the viral E5R gene and to express FLT3L and OX40L, which potentially increases interferon signaling and cytokine release, reduces immunosuppression, and enhances antitumor immune response (NCI Drug Dictionary). |
|
MRG004A
|
|
MRG-004A|MRG 004A |
|
MRG004A is an antibody-drug conjugate consisting of an anti-tissue factor (TF) monoclonal antibody conjugated to monomethyl auristatin E (MMAE), which may lead to G2/M cell cycle arrest and apoptosis of tumor cells (NCI Drug Dictionary). |
|
MT-101
|
|
MT 101|MT101 |
CD5 Immune Cell Therapy
4
|
MT-101 are autologous monocytes engineered to express a chimeric antigen receptor (CAR) targeting CD5, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD5 (NCI Drug Dictionary). |
|
MT-201-GBM
|
|
MT 201-GBM|MT201-GBM |
|
MT-201-GBM is a vaccine comprised of autologous monocytes containing mRNA encoding a fusion protein of pp65 and lysosome-associated membrane protein (LAMP), which may lead to an increased T-cell response against tumor cells expressing pp65 (NCI Drug Dictionary). |
|
MT-401
|
|
MT401|MT 401|Zelenoleucel |
|
MT-401 are allogeneic multi-tumor-associated antigen (MultiTAA)-specific T lymphocytes, which may target TAA-expressing tumor cells for cell killing (NCI Drug Dictionary). |
|
MUC1 peptide-Poly-ICLC vaccine
|
|
|
|
MUC1 peptide-Poly-ICLC vaccine is a cancer vaccine comprising MUC1 peptide and poly-ICLC, which potentially enhances immune response against MUC1-expressing tumor cells (NCI Drug Dictionary). |
|
MVA-209-FSP
|
|
|
|
MVA-209-FSP is a neoantigen booster vaccine against frameshift peptides found in mismatch repair deficient and MSI-high tumors (NCI Drug Dictionary). |
|
MVA-BN-CV301
|
|
MVA-BN CV301|MVA BN CV301|MVA-BN-CV-301 |
|
MVA-BN-CV301 is a priming cancer vaccine derived from a modified vaccinia Ankara-Bavarian Nordic (MVA-BN) virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Drug Dictionary). |
|
MVR-C5252
|
|
MVR C5252|MVRC5252|C5252|C-5252|C 5252 |
PD-L1/PD-1 antibody
137
|
MVR-C5252 is an oncolytic herpes simplex virus type 1 modified to express IL-12 and an antibody targeting PDCD1 (PD-1), which potentially activates an anti-tumor immune response (Cancer Res (2025) 85 (8_Supplement_2): CT056, NCI Drug Dictionary). |
|
Medroxyprogesterone
|
Depo-Provera |
CBP-1011 |
Hormone - Anti-estrogens
31
|
Depo-Provera (medroxyprogesterone) is a synthetic progesterone derivative that acts as an anti-estrogen by binding to and activating nuclear receptors, stimulating downstream signaling and potentially resulting in decreased growth of estrogen-sensitive tumor cells (NCI Drug Dictionary). |
|
Mitomycin C
|
Mitozytrex |
|
Chemotherapy - Alkylating
18
|
Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary). |
|
Mitoxantrone
|
Novantrone |
CL 232315 |
TOPO2 inhibitor
5
|
Novantrone (mitoxantrone) binds to and inhibits topoisomerase II, leading to DNA double strand breaks and decreased DNA repair (NCI Drug Dictionary). |
|
Molgramostim
|
Macrogen |
Leucomax|Molgradex|SCH 39300|SCH-39300 |
|
Macrogen (molgramostim) is a recombinant form of human granulocyte colony-stimulating factor (G-CSF), which potentially enhances proliferation, differentiation, and activity of hematopoietic progenitor cells (NCI Drug Dictionary). |
|
NANT-008
|
Cynviloq |
nant-paclitaxel|micellar nanoparticle-encapsulated NANT-008 |
|
NANT-008 is comprised of polymeric micellar nanoparticles of paclitaxel, which binds to microtubules and blocks cell division (NCI Drug Dictionary). |
|
NBM-BMX
|
|
NBM BMX |
|
NBM-BMX inhibits histone deacetylase type 8 (HDAC8), which may lead to increased histone acetylation, cell cycle arrest, and apoptosis in tumor cells (NCI Drug Dictionary). |
|
NC-4016
|
|
DACH-platin micelle NC-4016|DACH-Pt/m NC-4016 |
Chemotherapy - Platinum
7
|
NC-4016 is comprised of polymeric micellar nanoparticles of 1,2-diaminocyclohexane platinum, which cause cross-linking of DNA leading to apoptosis (NCI Drug Dictionary). |
|
NDI-101150
|
|
NDI 101150|NDI101150 |
MAP4K1 Inhibitor
8
|
NDI-101150 inhibits MAP4K1 (HPK1), which may prevent immunosuppression in the tumor microenvironment, potentially inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells and resulting in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3083); NCI Drug Dictionary). |
|
NECVAX-NEO1
|
|
NECVAX NEO1|NECVAXNEO1 |
|
NECVAX-NEO1 is a personalized neoantigen cancer vaccine comprising an expression plasmid encoding patient-derived neoantigens, which may induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
|
NEV801
|
|
NEV-801|NEV 801 |
TOPO Inhibitor (Pan)
3
|
NEV801 is a multi-target inhibitor that selectively blocks the activity of topoisomerase I and II and activates transcription of HIF-1 and VEGF, thereby potentially resulting in anti-tumor activity (NCI Drug Dictionary). |
|
NGFR-transduced autologous T lymphocytes
|
|
|
|
NGFR-transduced autologous T lymphocytes are autologous T-lymphocytes engineered to express nerve growth factor receptor, which may result in an antitumor immune response and killing of tumor cells expressing nerve growth factor (NCI Drug Dictionary). |
|
NGM120
|
|
NGM-120|NGM 120|GFRAL Antagonistic Monoclonal Antibody NGM120 |
|
NGM120 is a monoclonal antibody that targets glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), which inhibits binding of its ligand GDF15 and downstream signaling (NCI Drug Dictionary). |
|
NK-like CTLs
|
|
autologous NK-like CTLs|autologous aDC1-induced CTLs |
|
NK-like CTLs (nCTLs) are autologous T-lymphocytes that are treated with autologous alpha-type-1 dendritic cells that have been exposed to patient-specific tumor antigens, which potentially results in natural killer-like activity and increased tumor cell lysis (NCI Drug Dictionary). |
|
NLM-001
|
|
NLM001|NLM 001 |
|
NLM-001 inhibits the Hedgehog pathway, potentially resulting in increased infiltration of immune cells into tumors (NCI Drug Dictionary). |
|
NM1F
|
|
NM 1F|NM-1F |
PVRIG Antibody
5
|
NM1F is a monoclonal antibody that binds to PVRIG (CD112R) expressed on cytotoxic T-lymphocytes and NK cells and prevents its interaction with CD112, which potentially results in increased antitumor immune response and decreased tumor cell proliferation (NCI Drug Dictionary). |
|
NM21-1480
|
|
NM21 1480|NM211480|ND 021|ND-021|ND021 |
|
NM21-1480 is a recombinant, trispecific monovalent antibody-based molecule that targets PD-L1, 4-1BB, and human serum albumin, potentially resulting in activation of T cell immune responses and enhanced T cell-mediated cytotoxicity, leading to inhibition of tumor cell proliferation (NCI Drug Dictionary, Cancer Research 80(16), Abstr 2276). |
|
NM6603
|
|
NM 6603|NM-6603 |
|
NM6603 is a small molecule targeting retinoid X receptor alpha (RXRA), which potentially inhibits TGFbeta signaling, reduces immunosuppression, and decreases tumor cell proliferation (NCI Drug Dictionary). |
|
NMS-03597812
|
|
NMS 03597812|NMS03597812 |
|
NMS-03597812 inhibits PERK, potentially leading to apoptosis of tumor cells and decreased tumor growth (NCI Drug Dictionary). |
|
NPX887
|
|
NPX-887|NPX 887 |
|
NPX887 is a monoclonal antibody that targets HHLA2 (B7-H7) and inhibits its interaction with KIR3DL3 while preserving the interaction with TMIGD2, which potentially enhances T and NK cell-mediated antitumor response (Ann Oncol (2024) 35 (Suppl_2): S708-709, NCI Drug Dictionary). |
|
NRC-2694-A
|
|
NRC-2694A|NRC2694A|NRC 2694A|NRC-2694|NRC 2694 |
EGFR Inhibitor (Pan)
63
|
NRC-2694-A inhibits EGFR, potentially resulting in increased tumor cell death (NCI Drug Dictionary). |
|
NT-112
|
|
NT112|NT 112 |
|
NT-112 comprises autologous T lymphocytes engineered to express an HLA-C*08:02-restricted T-cell receptor (TCR) targeting KRAS G12D, which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing KRAS G12D and inhibits tumor growth (Clin Oncol 42, 2024 (suppl 16; e14533, NCI Drug Dictionary). |
|
NU-0129
|
|
SNA NU-0129 |
|
NU-0129 comprises sphericle nucleic acid gold nanoparticles made up of siRNAs that specifically target BCL2L12, thereby blocking translation of BCL2L12 and subsequently, resulting in apoptotic activity (NCI Drug Dictionary). |
|
NUV-1511
|
|
NUV1511|NUV 1511 |
|
NUV-1511 is a drug-drug conjugate comprising an undisclosed tumor-targeted therapy linked to an undisclosed chemotherapeutic agent, which potentially induces tumor cell killing (NCI Drug Dictionary). |
|
NY-ESO-1 TCR/IL-15 NK cells
|
|
Allogeneic anti-NY-ESO-1 TCR-transduced IL-15-expressing CB-derived NK cells |
|
NY-ESO-1 TCR/IL-15 NK cells are allogeneic natural killer (NK) cells derived from cord blood that are engineered to express a T-cell receptor (TCR) targeting NY-ESO-1 and to express IL-15, which potentially induce toxicity in tumor cells expressing NY-ESO-1 (NCI Drug Dictionary). |
|
Nab-paclitaxel
|
Abraxane |
ABI-007|Paclitaxel Protein-bound |
Chemotherapy - Taxane
3
|
Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
|
NeoAg-mBRAF
|
|
NeoAg mBRAF|BRAF 585-614 (V600E)|BRAF585-614-V600E|BRAF 585-614 V600E |
|
NeoAg-mBRAF is a peptide consisting of aa 585-614 of the Braf protein with the BRAF V600E mutation, which may lead to cytotoxic T-lymphocyte mediated immune response against BRAF V600E-expressing tumor cells (NCI Drug Dictionary). |
|
NeoVax melanoma vaccine
|
|
|
|
NeoVax melanoma vaccine combines patient-derived melanoma neoantigen with the immunostimulant poly-ICLC, which stimulates anti-tumor immune response against tumor cells expressing the neoantigen (NCI Drug Dictionary). |
|
Neratinib
|
Nerlynx |
HKI-272|PB272 |
HER2 Inhibitor
45
|
Nerlynx (neratinib) inhibits the ERBB2 (HER2) receptor as well as EGFR, resulting in decreased proliferation of HER2 and EGFR expressing tumor cells (PMID: 15173008). Nerlynx (neratinib) is FDA approved for use in patients with early stage ERBB2 (HER2)-positive breast cancer following Herceptin (trastuzumab)-based therapy, and in combination with Xeloda (capecitabine) in patients with advanced/metastatic ERBB2 (HER2)-positive breast cancer who have received two or more anti-ERBB2 (HER2) regimens (FDA.gov). |
|
Nidanilimab
|
|
CAN04|CAN 04|CAN-04|Nadunolimab |
|
Nidanilimab is a humanized monoclonal antibody that targets ll1rap, which inhibits downstream signaling and blocks activation of NFkappa-B, thereby potentially inducing antibody-dependent cellular cytotoxicity, leading to decreased proliferation and increased death of tumor cells expressing IL1RAP (NCI Drug Dictionary). |
|
Nilutamide
|
Nilandron |
Anandron |
Hormone - Anti-androgens
58
|
Nilandron (nilutamide) is a nonsteroidal antiandrogen, binding to the androgen receptor and blocking agonists, thereby inhibiting androgen-dependent tumor growth (NCI Drug Dictionary). |
|
OBI-833
|
|
Globo H-CRM197 vaccine |
|
OBI-833 is a vaccine consists of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
|
OBX-115
|
|
OBX 115|OBX115|CytoTIL15 |
|
OBX-115 comprises tumor-infiltrating lymphocytes (TILs) engineered to express membrane-bound IL-15 (mbIL15), which potentially induce tumor cell killing and lead to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 9515), NCI Drug Dictionary). |
|
OMO-103
|
|
OMO 103|OMO103 |
c-MYC Inhibitor
12
|
OMO-103 inhibits MYC, potentially leading to decreased tumor cell proliferation (NCI Drug Dictionary). |
|
ONC 841
|
|
ONC841|ONC-841 |
|
ONC 841 is a monoclonal antibody targeting Siglec10, which potentially activates immune cells and relieves Siglec-10-mediated inhibition of tumor cell phagocytosis, leading to increased tumor cell killing (NCI Drug Dictionary). |
|
ONCT-808
|
|
ONCT808|ONCT 808 |
ROR1 Immune Cell Therapy
5
|
ONCT-808 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets ROR1, potentially resulting in cytotoxicity against tumor cells expressing ROR1 (NCI Drug Dictionary). |
|
ONO-4685
|
|
ONO4685|ONO 4685 |
CD3 Antibody
123
PD-L1/PD-1 antibody
137
|
ONO-4685 is a bispecific antibody that targets PDCD1 (PD-1) and CD3, which has potential anti-tumor activity (NCI Drug Dictionary). |
|
ONT-10
|
|
|
|
ONT-10 is a cancer vaccine that consists of encapsulated glycoprotein MUC1 and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A, which may lead to immune stimulation and antitumor effects (NCI Drug Dictionary). |
|
OVM-200
|
|
OVM200|OVM 200 |
|
OVM-200 is a cancer vaccine comprised of peptides derived from survivin, which may induce cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells expressing survivin (NCI Drug Dictionary). |
|
Oncoquest-L vaccine
|
|
autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine |
|
Oncoquest-L vaccine is a cancer vaccine comprising liposomal-encapsulated patient-specific proteins combined with IL-2, which may induce immune response against tumors expressing those proteins (NCI Drug Dictionary). |
|
Onfekafusp alfa
|
|
Fibromun|L19-TNF-alpha|L19TNF |
|
Onfekafusp alfa comprises TNFalpha linked to a single chain variable fragment targeting fibronectin extra-domain B, which may increase antitumor immune response (NCI Drug Dictionary). |
|
Onvatilimab
|
|
CI 8993|CI8993|CI-8993|JNJ 61610588|JNJ61610588|JNJ-61610588 |
VSIR Antibody
6
|
Onvatilimab (CI-8993) is a monoclonal antibody that targets and binds to VSIR (VISTA; PD-1H) on immune cells leading to decreased VSIR-mediated signaling and potentially resulting in activation of anti-tumor immune response and inhibition of tumor cell growth (NCI Drug Dictionary). |
|
Oratecan
|
|
Irinotecan/P-glycoprotein Inhibitor HM30181AK |
|
Oratecan is a combination drug containing irinotecan and the P-glycoprotein (P-gp) efflux pump inhibitor HM30181AK, which may decrease efflux of irinotecan leading to increased intracellular accumulation, potentially leading to increased DNA damage and tumor cell death (NCI Drug Dictionary). |
|
Orelabrutinib
|
|
ICP-022|ICP022|ICP 022 |
BTK inhibitor
39
|
Orelabrutinib (ICP-022) inhibits BTK, potentially resulting in decreased growth of BTK-expressing tumor cells (NCI Drug Dictionary). |
|
Ovapuldencel-T
|
|
AVOVA-1 |
|
Ovapuldencel-T is a cancer vaccine consisting of autologous dendritic cells loaded with autologous tumor antigens, which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
|
PBA-0405
|
|
PBA 0405|PBA0405 |
ROR1 Antibody
8
|
PBA-0405 is an NK-cell engager targeting ROR1, which potentially results in NK cell-mediated killing of tumor cells expressing ROR1 (NCI Drug Dictionary). |
|
PBCAR269A
|
|
Allogeneic Anti-BCMA-CAR T-cells PBCAR269A |
TNFRSF17 Immune Cell Therapy
28
|
PBCAR269A are allogeneic T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeted against B-cell maturation antigen (BCMA), potentially resulting in increased death of tumor cells expressing BCMA (NCI Drug Dictionary). |
|
PBF 999
|
|
PBF-999|PBF999 |
Adenosine Targeting
24
|
PBF 999 inhibits both adenosine A2A receptor (A2AR) and phosphodiesterase 10A (PDE-10A), which potentially leads to activation of immune response and inhibition of tumor cell growth (NCI Drug Dictionary). |
|
PCUR-101
|
|
PCUR101|PCUR 101|PLUMBAGIN |
|
PCUR-101 is a synthetic form of the medicinal plant derivative, plumbagin, which may lead to inhibition of PKCe, STAT3, AKT, and EMT markers, potentially resulting in antitumor activity (NCI Drug Dictionary). |
|
PEPIDH1M vaccine
|
|
PEPIDH1M |
|
PEPIDH1M vaccine is a peptide vaccine based on isocitrate dehydrogenase 1 (IDH1) harboring the R132H point mutation, which may induce a host immune response against tumor cells expressing IDH1 R132H (NCI Drug Dictionary). |
|
PF-06688992
|
|
PF06688992|PF 06688992 |
|
PF-06688992 is an antibody drug conjugate consisting of a monoclonal antibody to ganglioside GD3 and a chemotherapeutic agent (NCI Drug Dictionary) |
|
PF-06936308
|
|
PF 06936308|PF 06936308 |
|
PF-06936308 is a replication defective serotype 68 chimpanzee adenovirus (AdC68) that expresses three undisclosed tumor associated antigens, potentially inducing a cytotoxic immune response against tumor cells expressing those antigens (NCI Drug Dictionary). |
|
PF-06939999
|
|
PF06939999|PF 06939999 |
PRMT5 Inhibitor
21
|
PF-06939999 is an inhibitor that blocks PRMT5 methyltransferase activity, resulting in decreased histone H2A, H3, and H4 arginine mono- and di-methylation, which potentially leads to modulation of gene expression resulting in decreased tumor cell growth (NCI Drug Dictionary). |
|
PF-06952229
|
|
PF06952229|PF 06952229 |
TGFBR1 inhibitor
16
|
PF-06952229 is an inhibitor of the transforming growth factor-beta receptor 1 (TGFBR1), which results in stimulation of the immune system (NCI Drug Dictionary). |
|
PF-07104091
|
|
PF 07104091|PF07104091 |
CDK2 Inhibitor
31
|
PF-07104091 inhibits CDK2, which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
PF-07220060
|
|
PF 07220060|PF07220060|Atirmociclib |
CDK4 Inhibitor
19
|
PF-07220060 inhibits CDK4 and may lead to cell cycle arrest and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
PF-07260437
|
|
PF 07260437|PF07260437 |
B7-H4 (VTCN1) Antibody
13
CD3 Antibody
123
|
PF-07260437 is a bispecific antibody targeting B7H4 and CD3, which potentially activates a cytotoxic T-cell response against tumor cells expressing B7H4 (NCI Drug Dictionary). |
|
PF-07263689
|
|
PF07263689|PF 07263689 |
|
PF-07263689 is a modified oncolytic vaccinia virus, which may selectively infect tumor cells and induce cell death (NCI Drug Dictionary). |
|
PF-07820435
|
|
PF07820435|PF 07820435 |
STING1 Agonist
21
|
PF-07820435 is a STING agonist that activates the STING pathway in immune cells, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
|
PF-07826390
|
|
PF 07826390|PF07826390 |
LILRB2 Antibody
12
|
PF-07826390 is a bispecific antibody that targets LILRB1 and ILT4 (LILRB2), which potentially results in reduced ILT4 (LILRB2)- and ILT2-dependent immune suppression and enhanced antitumor immune response (NCI Drug Dictionary). |
|
PF-07934040
|
|
PF 07934040|PF07934040|PF-4040|PF4040|PF 4040 |
KRAS Inhibitor
31
|
PF-07934040 inhibits mutant KRAS, which potentially induces apoptosis and decreases proliferation of tumor cells harboring KRAS mutations (NCI Drug Dictionary). |
|
PF-07985045
|
|
PF 07985045|PF07985045|PF-5045|PF 5045|PF5045 |
KRAS Inhibitor
31
|
PF-07985045 is a pan-KRAS inhibitor, which potentially induces apoptosis and decreases proliferation in tumor cells harboring KRAS mutations (NCI Drug Dictionary). |
|
PGG beta-glucan
|
|
Imprime PGG|Odetiglucan |
|
Imprime PGG (PGG beta-glucan) binds to and promotes cytotoxicity of neutrophils bound to tumor cells via complement receptor 3 (CR3) (NCI Drug Dictionary). |
|
PHN-010
|
|
PHN010|PHN 010 |
|
PHN-010 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
|
PMD-026
|
|
PMD 026|PMD026 |
|
PMD-026 inhibits RSK 1-4, which may lead to cell cycle arrest and apoptosis (NCI Drug Dictionary). |
|
PNT2002
|
|
PNT-2002|PNT 2002|177Lu-PNT2002|[Lu-177]-PSMA-I and T|Zadavotide guraxetan |
|
PNT2002 is a radioconjugate consisting of a PSMA-targeting ligand (PNT2002) attached to the radioisotope Lu 177, that binds to tumor cells expressing PSMA, potentially resulting in tumor cell death (NCI Drug Dictionary). |
|
PRJ1-3024
|
|
PRJ1 3024|PRJ13024 |
MAP4K1 Inhibitor
8
|
PRJ1-3024 inhibits MAP4K1 (HPK1), which may reduce immunosuppression in the tumor microenvironment and result in induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (J Clin Oncol 42, 2024 (suppl 16; abstr 2590), NCI Drug Dictionary). |
|
PRT1419
|
|
PRT 1419|PRT-1419 |
MCL1 Inhibitor
18
|
PRT1419 is an inhibitor of myeloid cell leukemia 1 (MCL1) that blocks inactivation of pro-apoptotic proteins by Mcl1, which may lead to apoptosis of tumor cells overexpressing Mcl1 (NCI Drug Dictionary). |
|
PRT543
|
|
PRT-543|PRT 543 |
PRMT5 Inhibitor
21
|
PRT543 is an inhibitor of PRMT5, which inhibits PRMT5 methyltransferase activity, leading to decreased histone H2A, H3, and H4 arginine mono and di-methylation and altered expression of genes involved in cellular processes, thereby potentially resulting in decreased tumor cell growth (NCI Drug Dictionary). |
|
PT199
|
|
PT-199|PT 199 |
CD73 Antibody
14
|
PT199 is a monoclonal antibody that targets CD73, which potentially results in increased antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 4259; NCI Drug Dictionary). |
|
PUR001
|
|
PUR-001|PUR 001 |
Adenosine Targeting
24
|
PUR001 is a monoclonal antibody that targets CD39, which may relieve adenosine-mediated immune suppression in the tumor microenvironment, resulting in enhanced antitumor immune response (NCI Drug Dictionary). |
|
Paclitaxel
|
Taxol |
7-Epipaclitaxel |
Antimicrotubule Agent
14
BCL2 Family Inhibitor
6
|
Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
|
Peg-interferon alfa-2a
|
Pegasys |
peginterferon alfa-2a|pegylated interferon alfa-2a|PEG-IFNA2a |
|
Pegasys (peg-interferon alfa-2a) comprises interferon alfa-2a conjugated to polyethylene glycol (PEG), which may decrease tumor cell proliferation and enhance anti-tumor immune response (NCI Drug Dictionary). |
|
Pegaspargase
|
Oncaspar |
PEG-asparaginase|PEG-ASP |
|
Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary). |
|
Pegcetacoplan
|
|
APL2|APL-2|APL 2 |
|
Pegcetacoplan binds to and inhibits C3 and C3b, resulting in decreased activation of the complement pathway and potentially leading to reduced inflammation and cell lysis (PMID: 33464651, NCI Drug Dictionary) |
|
Pegfilgrastim
|
Neulasta |
GCSF-SD01 |
|
Neulasta (Pegfilgrastim) is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary). |
|
Pegtomarginase
|
|
A20CL|PT01|PT-01|PT 01 |
|
Pegtomarginase is a modified form of the enzyme arginase linked to polyethylene glycol, which may lead to decreased arginine levels in the blood resulting in inhibition of cancer cell proliferation (NCI Drug Dictionary). |
|
Pegylated liposomal doxorubicin
|
Doxil |
ATI-0918|CAELYX|liposomal doxorubicin |
Chemotherapy - Anthracycline
13
|
Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
|
Pembrolizumab and berahyaluronidase alfa-pmph
|
Keytruda Qlex |
MK 3475A|MK3475A|MK-3475A |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is a co-formulation of Keytruda (pembrolizumab) and berahyaluronidase alfa, which potentially enhances antitumor immune response (J Clin Oncol 2025 43: 16_suppl, TPS7090, NCI Drug Dictionary). Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is FDA-approved for use in adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of Keytruda (Pembrolizumab) (FDA.gov). |
|
Pemetrexed Disodium
|
Alimta |
LY231514|Ciambra|pemetrexed |
Chemotherapy - Antimetabolite
14
|
Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
|
Pimivalimab
|
|
JTX4014|JTX 4014|JTX-4014 |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
Pimivalimab (JTX-4014) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary). |
|
Pirotinib
|
|
KBP-5209|KBP5209 |
HER inhibitor (Pan)
6
|
Pirotinib (KBP-5209) inhibits EGFR, ERBB2 (HER2), and ERBB4 (HER4), potentially resulting in decreased tumor growth (NCI Drug Dictionary). |
|
Pooled Mutant KRAS-Targeted Long Peptide Vaccine
|
|
KRAS Peptide Vaccine |
KRAS Inhibitor
31
|
Pooled mutant KRAS-targeted long peptide vaccine is a mixture of long tumor-specific mutant KRAS peptides, which potentially induces a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KRAS (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): CT036). |
|
Pralatrexate
|
FOLOTYN |
|
|
Pralatrexate is folate analogue inhibitor of dihydrofolate reductase that is selective for cells expressing RFC-1 (which may be overexpressed on cancer cells). Pralatrexate causes depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death (NCI Drug Dictionary). |
|
Prednisone
|
Adasone |
Dehydrocortisone |
|
Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
|
Proscavax
|
|
PSA/IL-2/GM-CSF Vaccine|Prostatac |
|
Proscavax is a cancer vaccine comprising prostate specific antigen (PSA), IL-2, and GM-CSF, which potentially enhances immune response against tumor cells expressing PSA, leading to reduced tumor cell growth (NCI Drug Dictionary). |
|
Pterostilbene
|
|
|
|
Pterostilbene is a stilbenoid that potentially functions as an antioxidant by preventing cellular damage induced by reactive oxygen species, and may have anti-inflammatory and pro-apoptotic effects (NCI Drug Dictionary). |
|
Quinacrine
|
Acrichine |
Quinacrine Dihydrochloride |
|
Acrichine (quinacrine) inhibits the transcription and activity of NF-kappaB, which may result in the induction of tumor suppressor p53 transcription and tumor cell apoptosis (NCI Drug Dictionary). |
|
R289
|
|
R906289 monosodium |
IRAK1/4 Inhibitor
2
|
R289 is a prodrug of R835, an inhibitor of IRAK1 and IRAK4, which potentially leads to decreased production of proinflammatory cytokines and immune cell-mediated cell killing (NCI Drug Dictionary). |
|
RAPA-201
|
|
RAPA 201|RAPA201 |
|
RAPA-201 are autologous rapamycin-resistant T cells, which potentially induce tumor cell killing (NCI Drug Dictionary). |
|
RC118
|
|
RC 118|RC-118 |
|
RC118 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting an undisclosed tumor-associated antigen linked to a cytotoxic agent, which potentially induces tumor cell killing (NCI Drug Dictionary). |
|
REC-1245
|
|
REC 1245|REC1245 |
|
REC-1245 is a molecular glue degrader that induces DCAF15-dependent proteasomal degradation of RBM39, which potentially results in altered gene expression, reduced DNA damage response, and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
REGN5093
|
|
REGN-5093|REGN 5093|davutamig |
MET Antibody
39
|
REGN5093 is a bispecific MET antibody that targets two different epitopes on MET, potentially leading to degradation of MET and decreased tumor cell growth (PMID: 37059804, NCI Drug Dictionary). |
|
REGN5668
|
|
REGN 5668|REGN-5668 |
CD28 Antibody
13
MUC16 Targeted Therapy
11
|
REGN5668 is a bispecific monoclonal antibody that targets both CD28 and MUC16 (CA125), resulting in cross-linking of CD28-positive T-cells to MUC16-expressing tumor cells, potentially leading to enhanced cytotoxic response against MUC16-positive tumor cells (NCI Drug Dictionary). |
|
REGN6569
|
|
REGN-6569|REGN 6569 |
GITR Antibody
7
|
REGN6569 is a monoclonal antibody that binds to and activates the glucocorticoid-induced tumor necrosis factor receptor (GITR, TNFRSF18) expressed on immune cells, potentially leading to activation and proliferation of effector T cells and anti-tumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2650, NCI Drug Dictionary). |
|
RLY-5836
|
|
RLY 5836|RLY5836 |
PIK3CA inhibitor
27
|
RLY-5836 is a mutant-selective PIK3CA inhibitor, which potentially induces apoptosis and inhibits growth of tumor cells expressing mutant PIK3CA (Cancer Res (2024) 84 (9_Supplement): PO3-20-04, NCI Drug Dictionary). |
|
RO6874281
|
|
RG 7461|RG7461|Simlukafusp alfa|RO-6874281 |
|
RO6874281 (Simlukafusp alfa) is a fusion protein consists of a human anti-fibroblast activation protein-alpha (FAP) antibody and an engineered interleukin-2, which may stimulate local immune response against FAP-positive tumor cells (NCI Drug Dictionary). |
|
RO7121661
|
|
RG 7769|RG7769|RG-7769|RO-7121661|RO 7121661|Lomvastomig |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
TIM-3 Antibody
9
|
RO7121661 is a bispecific antibody that binds to PD-1 (CD279) and TIM-3 and inhibits ligand interaction, potentially resulting in the activation of cytotoxic T-lymphocytes and increased tumor cell death (NCI Drug Dictionary). |
|
RO7172508
|
|
RG6123|RG-6123|RG 6123|RO-7172508|RO 7172508 |
|
RO7172508 (RG6123) targets the tumor specific antigen, carcinoembryonic antigen (CEA), to induce cell death (NCI Drug Dictionary). |
|
RO7283420
|
|
RO-7283420|RO 7283420|RG6007|RG-6007|RG 6007|HLA-A2-WT1 x CD3 RG6007 |
CD3 Antibody
123
|
RO7283420 is a T-cell receptor-like T-cell engaging bispecific antibody (T-BsAb) that targets a 9-amino acid peptide derived from Wilms tumor 1 (WT1) and CD3 expressed on T-lymphocytes, which potentially leads to a cytotoxic T-lymphocyte response against tumor cells expressing WT1 (NCI Drug Dictionary). |
|
RO7284755
|
|
RO-7284755|RO 7284755|PD1-IL2v |
Immune Checkpoint Inhibitor
150
PD-L1/PD-1 antibody
137
|
RO7284755 consists of an alternate form of the cytokine IL-2 (IL-2v) fused to an antibody against PD-1, which may inhibit PD-1-mediated immune suppression and lead to activation of anti-tumor immune response (NCI Drug Dictionary). |
|
RO7293583
|
|
RO-7293583|RO 7293583 |
CD3 Antibody
123
|
RO7293583 binds to both PRSS1 (TRP1) and CD3, potentially leads to the activation of CD3-expressing cytotoxic T lymphocytes (CTLs) and CTL-mediated killing of TYRP1-expressing tumor cells (NCI Drug Dictionary). |
|
RO7428731
|
|
RO-7428731|RO 7428731 |
CD3 Antibody
123
|
RO7428731 is a bispecific antibody that targets EGFR variant III (EGFRvIII) and CD3, resulting in cross-linking of tumor cells and cytotoxic T-lymphocytes, and potentially leading to increased killing of EGFRvIII-expressing tumor cells (NCI Drug Dictionary). |
|
RO7443904
|
|
RO-7443904|RO 7443904|RG6333|RG-6333|RG 6333 |
CD19 Antibody
22
CD28 Antibody
13
|
RO7443904 is a bispecific antibody that targets both CD19 and CD28, resulting in cross-linking of CD28-positive T-cells to CD19-expressing tumor cells, potentially leading to enhanced cytotoxic response against CD19-positive tumor cells (NCI Drug Dictionary). |
|
RO7444973
|
|
RO-7444973|RO 7444973 |
|
RO7444973 is a bispecific T-cell engaging antibody that targets MAGE-A4 and CD3, which potentially leads to activation and targeting of cytotoxic T-lymphocytes to tumor cells expressing MAGE-A4, resulting in tumor cell killing (NCI Drug Dictionary). |
|
RO7496353
|
|
RO-7496353|RO 7496353|SOF 10|SOF10|SOF-10|RG 6440|RG 6440|RG6440 |
|
RO7496353 is a monoclonal antibody targeting TGFb1, which potentially induces increased antitumor immune response, decreased tumor cell proliferation, and cytotoxicity against tumor cells (NCI Drug Dictionary). |
|
RO7515629
|
|
RO 7515629|RO-7515629|RG 6353|RG-6353|RG6353 |
CD3 Antibody
123
|
RO7515629 is a bispecific antibody targeting HLA-G and CD3 that redirects cytotoxic T-lymphocytes towards tumor cells expressing HLA-G, potentially resulting in increased tumor cell killing (NCI Drug Dictionary). |
|
RO7617991
|
|
RO-7617991|RO 7617991 |
CD3 Antibody
123
|
RO7617991 is a bispecific T-cell engaging antibody that targets MAGE-A4 and CD3, which potentially leads to activation and targeting of cytotoxic T-lymphocytes to tumor cells expressing MAGE-A4, resulting in tumor cell killing (NCI Drug Dictionary). |
|
RO7656594
|
|
RO-7656594|RO 7656594|GDC-2992|GDC2992|GDC 2992 |
Hormone - Anti-androgens
58
|
RO7656594 is an androgen receptor (AR) degrader, which potentially inhibits proliferation of tumor cells overexpressing AR (NCI Drug Dictionary). |
|
RP-1664
|
|
RP1664|RP 1664 |
|
RP-1664 inhibits PLK4, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary). |
|
RP-3467
|
|
RP3467|RP 3467 |
|
RP-3467 inhibits DNA polymerase theta (POLQ), which may prevent the repair of DNA-double stranded breaks, resulting in increased apoptosis and decreased proliferation of tumor cells (NCI Drug Dictionary). |
|
RP-6306
|
|
RP6306|RP 6306|Lunresertib |
PKMYT1 Inhibitor
4
|
RP-6306 is a PKMYT1 inhibitor, which may decrease CDK1 phosphorylation, leading to cell cycle arrest, apoptosis, and decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT262, NCI Drug Dictionary). |
|
RP1
|
|
Vusolimogene Oderparepvec|HSV-1 Engineered RP1|HSV-1 Oncolytic Viral Strain RP1 |
|
RP1 is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain that expresses a fusogenic glycoprotein (GALV-GP-R-) and GM-CSF, which potentially induces an anti-tumor immune response and tumor cell lysis (Cancer Res (2024) 84 (7_Supplement): CT003, NCI Drug Dictionary). |
|
RP2
|
|
RP-2|RP 2 |
|
RP2 is an oncolytic virus engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and an antibody-like molecule targeted against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which may lead to activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
|
RP3
|
|
RP 3|RP-3 |
|
RP3 is an oncolytic virus engineered to express a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) targeting antibody, CD40 ligand, and tumor necrosis factor ligand superfamily member 9 (TNFSF9), which may result in activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
|
RPTR-168
|
|
RPTR168|RPTR 168 |
|
RPTR-168 are autologous T lymphocytes that are targeted against multiple tumor associated antigens (TAAs) and attached to the interleukin IL-12, which bind to tumor cells expressing the TAAs, potentially leading to cytotoxic T-cell mediated killing of these cells and the activation of the anti-tumor immune response (NCI Drug Dictionary). |
|
RSC-1255
|
|
RSC 1255|RSC1255 |
RAS Inhibitor (Pan)
14
|
RSC-1255 inhibits Ras, including mutant Ras, potentially leading to inhibition of tumor cell proliferation (NCI Drug Dictionary). |
|
RTX-240
|
|
RTX 240|RTX240 |
|
RTX-240 is a therapy comprised of allogeneic red blood cells (RBCs) engineered to express a fusion protein consisting of the cytokine IL-15 and the IL-15 receptor alpha and TNFSF9 (4-1BBL), which may lead to activation of immune cells and antibody-dependent cell mediated cytotoxicity (ADCC) induced tumor cell killing (NCI Drug Dictionary; Journal for ImmunoTherapy of Cancer 2020;8). |
|
Radium Ra 223 dichloride
|
Xofigo |
BAY 88-8223|alpharadin|BAY88-8223|Radium 223 Dichloride |
|
Radium Ra 223 dichloride is a radium-based radiopharmaceutical that targets bone via incorporation into bony matrix, and results in DNA double strand breaks and tumor regression in bone (NCI Drug Dictionary). |
|
Radvax
|
|
Autologous Tumor Vaccine Plus Polysaccharide-derived Delta Inulin Adjuvant |
|
Radvax is an autologous tumor vaccine comprising a patient-derived tumor cell lysate and polysaccharide-derived adjuvant, which potentially induces an enhanced antitumor immune response (NCI Thesaurus). |
|
Ranibizumab
|
Lucentis |
rhuFab V2 |
VEGF Antibody
17
|
Lucentis (Ranibizumab) is a monoclonal antibody that binds VEGF-A, preventing receptor binding and potentially resulting in decreased growth of blood vessels (NCI Drug Dictionary). |
|
RiMO-401
|
|
RiMO401|RiMO 401 |
IDO1 Inhibitor
13
|
RiMO-401 inhibits IDO1, which results in reduced levels of kynurenine, potentially leading to increased immune cell activation and immune response against tumor cells (NCI Drug Dictionary). |
|
Rituximab Hyaluronidase
|
|
Rituxan Hycela|Rituximab and Hyaluronidase Human|Rituximab/Hyaluronidase |
CD20 Antibody
28
|
Rituximab Hyaluronidase consists of a preparation of the CD20 antibody Rituxan (rituximab) combined with hyaluronidase, which upon delivery leads to break down of tissue hyaluronan by the hyaluronidase component, resulting in increased rituximab absorption and potentially resulting in enhanced complement-dependent and antibody-dependent cytotoxicity against CD20-positive tumor cells (NCI Drug Dictionary). |
|
S-588210
|
|
S 588210|S588210|S-488210/S-488211 |
|
S-588210 is a cancer vaccine comprised of an injectable formulation of S-488210 and S-488211 that together contain five different HLA-A*02:01-restricted peptides, which may lead to a cytotoxic T-lymphocyte response against tumor cells and decreased tumor growth (NCI Drug Dictionary). |
|
S095035
|
|
S 095035|S-095035 |
MAT2A Inhibitor
5
|
S095035 inhibits MAT2A, which potentially decreases proliferation in MTAP-deficient tumor cells (NCI Drug Dictionary). |
|
SA53-OS
|
|
SA53 OS|SA53OS|SA53-MDM2 |
MDM2 Inhibitor
23
|
SA53-OS binds MDM2 and blocks its interaction with p53, thereby restoring p53 activity, which may result in increased tumor cell apoptosis (NCI Drug Dictionary). |
|
SAR428926
|
|
|
|
SAR428926 is a antibody-drug conjugate that contains an anti-lysosome-associated membrane protein 1 (LAMP1) monoclonal antibody linked to the cytotoxic anti-microtubule agent DM4, which inhibits growth of LAMP1-expressing tumor cells (NCI Drug Dictionary). |
|
SAR440234
|
|
SAR-440234|SAR 440234 |
CD123 (IL3RA) Antibody
14
|
SAR440234 is a bispecific T-cell engager (BiTE) antibody that targets the CD3 antigen on T-cells and CD123 (IL3RA) on tumor cells, which may result in increased T-cell activation, and enhanced anti-tumor response leading to tumor cell killing (NCI Drug Dictionary). |
|
SAR445419
|
|
SAR 445419|SAR-445419|KDS 1001|KDS-1001|KDS1001 |
|
SAR445419 are allogeneic ex vivo-expanded natural killer (NK) cells, which potentially induce killing of tumor cells (NCI Drug Dictionary). |
|
SC-005
|
|
SC005|SC 005 |
|
SC-005 is an antibody drug conjugate to an undisclosed tumor associated antigen and cytotoxic agent (NCI Drug Dictionary). |
|
SC-CAR4BRAIN
|
|
|
CD276 Immune Cell Therapy
12
IL13RA2 Immune Cell Therapy
7
|
SC-CAR4BRAIN are autologous CD4+ and CD8+ T-lymphocytes engineered to express four chimeric antigen receptors (CARs) that target B7-H3, EGFR, ERBB2 (HER2), and interleukin-13 receptor alpha 2 (IL13Ra2), which potentially induce toxicity in B7-H3, EGFR, ERBB2 (HER2), and IL13Ra2-expressing tumor cells (NCI Drug Dictionary). |
|
SC262
|
|
SC-262|SC 262 |
CD22 Immune Cell Therapy
13
|
SC262 comprises allogeneic CD4+ and CD8+ T-lymphocytes engineered to express CD47 and a chimeric antigen receptor (CAR) targeting CD22, and with disruption of MHC class I and class II molecule expression, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD22 (NCI Drug Dictionary). |
|
SC291
|
|
SC 291|SC-291|Allogeneic HIP Anti-CD19 CAR-T Cells SC291 |
CD19 Immune Cell Therapy
74
|
SC291 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19, which may induce a cytotoxic immune response against CD19-expressing tumor cells (NCI Drug Dictionary). |
|
SCRI-CAR22v2
|
|
SCRI-CAR22v|SCRICAR22v2 |
CD22 Immune Cell Therapy
13
|
SCRI-CAR22v2 cells are T-cells engineered to express a chimeric antigen receptor (CAR) that targets CD22, which may potentially inhibit growth of CD22-expressing tumor cells (NCI Drug Dictionary). |
|
SCRI-CARB7H3(s)x19
|
|
|
CD19 Immune Cell Therapy
74
CD276 Immune Cell Therapy
12
|
SCRI-CARB7H3(s)x19 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) and CD19, truncated EGFR (EGFRt), and undisclosed costimulatory domains, which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) and CD19 (NCI Drug Dictionary). |
|
SG301
|
|
SG-301|SG 301 |
CD38 Antibody
21
|
SG301 is a monoclonal antibody that targets CD38, which potentially results in increased tumor cell lysis (NCI Drug Dictionary). |
|
SGN-CD47M
|
|
SGN CD47M|SGNCD47M |
CD47 Antibody
31
|
SGN-CD47M is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against CD47 conjugated to an undisclosed toxin, which potentially results in tumor cell killing (NCI Drug Dictionary). |
|
SGN-EGFRd2
|
|
SGN EGFRd2|SGNEGFRd2|LAVA1223|LAVA 1223|LAVA-1223 |
EGFR Antibody
74
|
SGN-EGFRd2 is a bispecific gamma delta T-cell engager targeting EGFR and the Vdelta2 TCR expressed on Vgamma9Vdelta2 T-cells, which potentially induces an antitumor immune response (NCI Drug Dictionary). |
|
SGN1
|
|
SGN-1|SGN 1|SalMet-Vec |
|
SGN1 is a strain of Salmonella enterica engineered to harbor mutations in the MSBB and PURI genes and to express L-methioninase, which potentially reduces tumor methionine levels and inhibits umor growth (PMID: 36077761, NCI Drug Dictionary). |
|
SH3809
|
|
SH 3809|SH-3809 |
SHP2 Inhibitor
20
|
SH3809 is a PTPN11 (SHP2) inhibitor, which potentially blocks MAPK signaling leading to tumor growth inhibition (NCI Drug Dictionary). |
|
SIM0237
|
|
SIM-0237|SIM 0237 |
PD-L1/PD-1 antibody
137
|
SIM0237 comprises a monoclonal antibody targeting CD274 (PD-L1) linked to the IL-15/IL-15 receptor sushi domain complex, which potentially enhances antitumor immune response (NCI Drug Dictionary). |
|
SIRPant-M
|
|
SI-101|SIRPantM|SI101|SI 101 |
|
SIRPant-M are autologous macrophages activated ex vivo and engineered to have depletion of SIRPa, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (Blood (2023) 142 (Supplement 1): 4856, NCI Drug Dictionary). |
|
SKI-G-801
|
|
FLT3 kinase inhibitor SKI G-801|SKI G-801|G-801|G-749 HCl |
Aurkb Inhibitors
21
Aurkc Inhibitors
3
AXL Inhibitor
30
FGFR1 Inhibitor
28
FGFR3 Inhibitor
21
FLT3 Inhibitor
69
MERTK Inhibitor
13
RET Inhibitor
53
VEGFR1 Inhibitor
6
|
SKI-G-801 is a multi-kinase inhibitor that has activity against wild-type and mutant forms of FLT3, which blocks FLT3 signaling and potentially inhibits proliferation of FLT3-overexpressing tumor cells, and has additional activity against AXL, potentially leading to decreased tumor cell metastasis, as well as MER, RET, VEGFR1, FMS, FGFR1, FGFR3, AURKB, and AURKC (NCI Drug Dictionary; Cancer Res 2019;79(13 Suppl):Abstract nr 2010). |
|
SL-172154
|
|
SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154 |
|
SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
|
SM-020
|
|
SM 020|SM020 |
Akt Inhibitor (Pan)
22
|
SM-020 is a topical inhibitor of AKT, which decreases Pi3k/Akt pathway signaling and potentially inhibits tumor cell proliferation (NCI Drug Dictionary). |
|
SNV4818
|
|
SNV-4818|SNV 4818 |
PIK3CA inhibitor
27
|
SNV4818 selectively inhibits mutations at PIK3CA H1047, which results in decreased downstream signaling and potentially leads to decreased growth of tumor cells (NCI Drug Dictionary). |
|
SNX281
|
|
SNX-281|SNX 281 |
STING1 Agonist
21
|
SNX281 acts as an agonist to stimulator of interferon genes (STING, TMEM173), which activates the immune system by stimulating cells in the tumor microenvironment, potentially resulting in a cytotoxic T-lymphocyte response against tumor cells (NCI Drug dictionary). |
|
SON-DP
|
|
|
|
SON-DP is a transcription factor that induces pluripotent reprogramming in tumor cells, potentially leading to reversion of tumor cells to a normal cell phenotype (NCI Drug Dictionary). |
|
SOT102
|
|
SOT-102|SOT 102|SO N102|SO-N102|SON102 |
CLDN18.2 Antibody
24
|
SOT102 is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2)-targeted antibody linked to a derivative of the cytotoxic anthracycline PNU-159682, which potentially leads to impaired DNA replication and protein synthesis, resulting in killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
|
SPL-108
|
|
SPL108|SPL 108 |
|
SPL-108 targets the CD44 antigen on cancer stem cells to prevent tumor cell proliferation (NCI Drug Dictionary). |
|
SQZ-PBMC-HPV
|
|
|
|
SQZ-PBMC-HPV are autologous peripheral blood mononuclear cells that are engineered to express antigens specific to HPV16 type E6 and E7, which may result in enhanced immune response against HPV16 E6 and E7-expressing tumor cells NCI Drug Dictionary). |
|
SQZ-eAPC-HPV
|
|
|
|
SQZ-eAPC-HPV are antigen-presenting cells engineered with mRNAs encoding HPV16 E6 and E7 antigens, CD86, and membrane bound IL-2 and IL-12, which may lead to a a cytotoxic T-lymphocyte (CTL)-mediated response against HPV16 E6/E7-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2022;10; NCI Drug Dictionary). |
|
STI-1492
|
|
STI 1492|STI1492 |
|
STI-1492 are allogeneic T-cells engineered to knockout TCR alpha and express a dimeric antigen receptor targeting CD38 and containing 4-1BB and CD3-zeta signaling domains, which potentially induce toxicity against tumor cells expressing CD38 (NCI Drug Dictionary). |
|
STM-416
|
|
STM 416|STM416 |
TLR7 Agonist
14
TLR8 Agonist
10
|
STM-416 is an injectable hydrogel formulation of resiquimod, a TLR7/8 agonist, which potentially enhances antitumor immune response and induces tumor cell lysis (PMID: 39735340, NCI Drug Dictionary). |
|
STM434
|
|
STM 434|STM-434 |
|
STM434 is a fusion protein comprising the extracellular domain of activin type II B receptor (ACVR2B) linked to a Fc chain that binds to activin-A and blocks activation of ACVR2B signaling, which potentially inhibits proliferation, survival and migration of activin-A overexpressing cancer cells (NCI Drug Dictionary). |
|
STP707
|
|
STP-707|STP 707 |
|
STP707 is a siRNA-based polypeptide nanoparticle consisting of siRNAs that target TGF-beta 1 and COX-2, leading to decreased TGF-beta 1 and COX-2 signaling, potentially resulting in enhanced antitumor immune response and decreased tumor growth (NCI Drug Dictionary). |
|
SYN004
|
|
|
EGFR Antibody
74
|
SYN004 is a monoclonal antibody that binds to and inhibits EGFR signaling, leading to potential anti-tumor activity (NCI Drug Dictionary). |
|
SYNB1891
|
|
SYNB-1891|SYNB 1891 |
|
SYNB1891 is a non-pathogenic strain of Escherichia coli that express STING (TMEM173), in order to stimulate the anti-tumor response of the innate immune system (NCI Drug Dictionary). |
|
Safimaltib
|
|
JNJ67856633|JNJ 67856633|JNJ-67856633 |
MALT1 Inhibitor
6
|
Safimaltib inhibits the activity of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), resulting in decreased NF-kappaB and JAK/STAT signaling, which potentially leads to increased apoptosis and decreased growth of MALT1-expressing tumor cells (PMID: 39894894, NCI Drug Dictionary). |
|
Sodium cridanimod
|
|
Virexxa|XBIO-101|Camedon|Neovir |
|
Sodium cridanimod (Virexxa) is the sodium salt of the small molecule cridanimod, which may increase progesterone receptor expression, potentially resulting in increased sensitivity to progestin therapy (NCI Drug Dictionary). |
|
Sym024
|
|
Sym-024|Sym 024|S095024 |
CD73 Antibody
14
|
Sym024 is a monoclonal antibody against CD73, which may inhibit the conversion of AMP to adenosine, reducing adenosine-mediated immunosuppression (Cancer Res (2024) 84 (6_Supplement): 3737, NCI Drug Dictionary). |
|
SynKIR-110
|
|
SynKIR110|SynKIR 110 |
MSLN Immune Cell Therapy
11
|
SynKIR-110 comprises autologous T-lymphocytes engineered to express a killer cell immunoglobulin-like receptor (KIR)-based chimeric antigen receptor (CAR) targeting MSLN, which potentially induce killing of tumor cells expressing MSLN (NCI Drug Dictionary). |
|
T3011
|
|
T 3011|T-3011 |
|
T3011 is an oncolytic herpes simplex virus-1 (HSV-1), engineered to express the cytokine IL-12 and an antibody against PD-1, which may block the immune checkpoint, and lead to inhibition of tumor cell proliferation (NCI Drug Dictionary) |
|
T3P-Y058-739
|
|
T3PY058739|T3P Y058739|T3PY 058739 |
|
T3P-Y058-739 is an attenuated bacterial strain carrying undisclosed type 1 Interferon and Toll-like receptor payloads, which potentially increases anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
|
TAK-280
|
|
TAK 280|TAK280|MVC280|MVC-280|MVC 280 |
CD276 Antibody
22
CD3 Antibody
123
|
TAK-280 is a conditional bispecific redirected activation T-cell engager targeting CD276 (B7-H3) and CD3, which is activated in the tumor microenvironment and redirects cytotoxic T-lymphocytes towards tumor cells expressing CD276 (B7-H3), potentially resulting in increased tumor cell killing (J Clin Oncol 2025 43: 16_suppl, TPS2684, NCI Drug Dictionary). |
|
TAK-500
|
|
TAK 500|TAK500 |
STING1 Agonist
21
|
TAK-500 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting an undisclosed tumor-associated antigen and the STING agonist TAK-676, which may result in increased STING pathway activation and anti-tumor immune response (NCI Drug Dictionary). |
|
TAK-676
|
|
TAK 676|TAK676|Dazostinag disodium |
STING1 Agonist
21
|
TAK-676 is a STING agonist, which activates the STING pathway in immune cells, potentially leading to increased antitumor immune response (Ann Oncol 35 (2024): S678-S679; NCI Drug Dictionary). |
|
TAR-200
|
|
GemRIS|TAR 200 |
Chemotherapy - Antimetabolite
14
|
TAR-200 comprises gemcitabine delivered through an intravesical delivery system that results in gradual release of gemcitabine, which inhibits DNA synthesis and potentially leads to increased tumor cell apoptosis (NCI Drug Dictionary). |
|
TARA-002
|
|
TARA002|TARA 002 |
|
TARA-002 consists of a lyophilized preparation of group A Streptococcus pyogenes treated with benzylpenicillin, which potentially enhances antitumor immune response (J Clin Oncol 41, 16_suppl TPS4618), NCI Drug Dictionary). |
|
TBX-3400
|
|
TBX3400|TBX 3400 |
|
TBX-3400 comprises autologous peripheral blood mononuclear cells that are treated with TBX-4000, a recombinant fusion protein consisting of the HIV TAT protein transduction domain fused to MYC, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
|
TBio-4101
|
|
TBio4101|TBio 4101 |
|
TBio-4101 are tumor-derived autologous tumor infiltrating lymphocytes (TILs), which may induce killing of tumor cells (NCI Drug Dictionary). |
|
TC-510
|
|
TC 510|TC510 |
MSLN Immune Cell Therapy
11
|
TC-510 are autologous T-lymphocytes engineered to express both an anti-mesothelin (MSLN) antibody fused to the N-terminus of the CD3-epsilon subunit of the T-cell receptor complex as well as a PD-1:CD28 switch receptor, which potentially induce activation of T-lymphocytes, decrease PD-1/PD-L1 pathway-dependent T-cell suppression, and induce killing of tumor cells expressing MSLN (NCI Drug Dictionary). |
|
TEV-56278
|
|
TEV56278|TEV 56278 |
PD-L1/PD-1 antibody
137
|
TEV-56278 is an antibody-cytokine fusion protein comprising an anti-PDCD1 (PD-1) antibody and attenuated IL-2, which potentially enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_2): CT198, NCI Drug Dictionary). |
|
TGF-beta-imprinted NK cells
|
|
|
|
TGF-beta-imprinted NK cells are natural killer cells that have been imprinted by TGF-beta during activation and expansion, which potentially leads to increased secretion of pro-inflammatory cytokines and enhanced antitumor immune response (NCI Drug Dictionary). |
|
TGFBR2 KO CAR27/IL-15 NK cells
|
|
Allogeneic TGFBR2 KO CAR27/IL-15-expressing NK cells |
CD70 Immune Cell Therapy
11
|
TGFBR2 KO CAR27/IL-15 NK cells are allogeneic natural killer cells engineered to express a chimeric antigen receptor (CAR) targeting CD70, to express IL-15, and with TGFBR2 deletion, which potentially induce cytotoxicity in tumor cells expressing CD70 (NCI Drug Dictionary). |
|
TGFbDNRII-transduced autologous TILs
|
|
|
|
TGFbDNRII-transduced autologous TILs are patient-derived tumor infiltrating lymphocytes engineered to express a dominant negative version of transforming growth factor beta receptor (TGFbDNRII), which potentially results in enhanced anti-tumor immune activity (NCI Drug Dictionary). |
|
TL-895
|
|
TL895|TL 895 |
|
TL-895 is a tyrosine kinase inhibitor that binds to tyrosine kinases in tumor cells, potentially leading to inhibition of tumor cell proliferation, tumor angiogenesis, and inflammatory immune response (NCI Drug Dictionary). |
|
TORL-2-307-ADC
|
|
TORL 2-307-ADC|TORL2-307-ADC |
|
TORL-2-307-ADC is an antibody-drug conjugate (ADC) comprising an antibody that targets an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
|
TORL-2-307-MAB
|
|
|
|
TORL-2-307-MAB is a monoclonal antibody that targets an undisclosed tumor-associated antigen (NCI Drug Dictionary). |
|
TSC-204-A0201
|
|
TSC 204-A0201|TSC204-A0201 |
|
TSC-204-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-A*02:01, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of MAGE-A1-expressing tumor cells (NCI Drug Dictionary). |
|
TSC-204-C0702
|
|
TSC204-C0702|TSC 204-C0702 |
|
TSC-204-C0702 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-C*07:02, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing MAGE-A1 (NCI Drug Dictionary). |
|
TSMA-based SLP vaccine
|
|
Personalized Synthetic Long Peptide Vaccine|Personalized SLP Vaccine |
|
TSMA-based SLP vaccine is a personalized synthetic long peptide (20-35 amino acid) vaccine derived from multiple patient-specific tumor-specific mutant antigens (TSMA), which may induce cytotoxic immune response against tumor cells expressing TSMAs (NCI Drug Dictionary). |
|
TT-01488
|
|
TT01488|TT 01488 |
BTK inhibitor
39
|
TT-01488 inhibits BTK, including the BTK mutation C481S, potentially leading to decreased tumor cell growth (NCI Drug Dictionary). |
|
TVI-Brain-1
|
|
TVI-Brain 1|TVI-Brain1 |
|
TVI-Brain-1 are activated autologous T-cells prepared from cells isolated following administration of a personalized cancer vaccine, which potentially induce antitumor immunity and decrease tumor growth (NCI Drug Dictionary). |
|
Tabelecleucel
|
|
ATA129|ATA 129|EBV-CTL|Tab-cel |
|
Tabelecleucel (ATA129) is a preparation of donor-derived EBV-specific cytotoxic T-cells, which may decrease growth of EBV-positive tumors (NCI Drug Dictionary). |
|
Tacrolimus
|
Hecoria |
FK-506|Prograf|Advagraf |
|
Tacrolimus binds to FKBP-12 and inhibits calcineurin activity, resulting in immunosuppression (NCI Drug Dictionary). |
|
Temozolomide
|
Temodar |
Methazolastone|TMZ |
Chemotherapy - Alkylating
18
|
Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
|
Testosterone cypionate
|
Depo-Testosterone |
Depotest|Depovirin|Pertestis |
|
Testosterone cypionate is made up of an eight carbon ester form, whcih inhibits the secretion of gonadotropin and blocks the generation of estrogen (NCI Drug Dictionary). |
|
Thiostrepton
|
|
RSO-021|RSO 021|RSO021 |
|
Thiostrepton (RSO-021) inhibits mitochondrial thioredoxin-dependent peroxide reductase (PRX-3), potentially resulting in an increase in intracellular hydrogen peroxide and tumor cell death (NCI Drug Dictionary). |
|
TmPSMA-02 CAR-T cells
|
|
TmPSMA 02|TmPSMA-02 |
|
TmPSMA-02 CAR-T cells are autologous T-lymphocytes engineered to express a CD2 endodomain-containing chimeric antigen receptor (CAR) targeting PSMA, a dominant negative form of TGFBR2, and a PD-1-CD28 switch receptor, which may induce toxicity against PSMA-expressing tumor cells (J Clin Oncol 40, no. 6_suppl (February 16, 2022) 158, NCI Drug Dictionary). |
|
Topotecan
|
Hycamtin |
Topotecan Hcl |
|
Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
|
TransCon IL-2 beta/gamma
|
|
TransCon IL-2b/g |
|
TransCon IL-2 beta/gamma is a hydrogel based formulation of an IL-2 variant, which may lead to activation of cytotoxic T-lymphocytes and NK cells, and increased antitumor immune response, potentially resulting in tumor cell death (NCI Drug Dictionary). |
|
TransCon TLR7/8 Agonist
|
|
Resiquimod Hydrogel-based Sustained-release formulation |
TLR7 Agonist
14
TLR8 Agonist
10
|
TransCon TLR7/8 Agonist is a hydrogel based formulation of an imidazoquinolinamine and resiquimod, which acts as an agonist of TLR 7 and TLR8, which potentially activates the antitumor immune response and may lead to tumor cell lysis (NCI Drug Dictionary). |
|
Trastuzumab rezetecan
|
|
SHR A1811|SHRA1811|SHR-A1811 |
HER2 (ERBB2) Antibody
80
HER2 (ERBB2) Antibody-Drug Conjugate
36
|
Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to the camptothecin derivative rezetecan, which potentially induces DNA damage and apoptosis in ERBB2 (HER2)-expressing tumor cells and inhibits tumor growth (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): LB031). |
|
UBX-303061
|
|
UBX303061|UBX 303061 |
BTK inhibitor
39
|
UBX-303061 is a chimeric BTK degrader composed of an ligand for E3 ubiquitin ligase linked to a BTK-binding ligand, which induces proteasomal degradation of BTK, potentially leading to decreased growth of tumor cells overexpressing BTK (NCI Drug Dictionary). |
|
UCARTCS1A
|
|
UCART CS1A|UCART-CS1A|Allogeneic TALEN Gene-edited UCARTCS1A |
SLAMF7 Immune Cell Therapy
5
|
UCARTCS1A is a preparation of allogeneic T-lymphocytes engineered with TALEN to express a chimeric antigen receptor (CAR) that targets CS1 (SLAMF7), which potentially induces cytotoxicity and may result in lysis of tumor cells expressing CS1 (NCI Drug Dictionary). |
|
UCD19 CAR T cells
|
|
|
CD19 Immune Cell Therapy
74
|
UCD19 CAR T cells are autologous peripheral blood lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, which potentially leads to killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
|
UCT-03-008
|
|
UCT 03-008|UCT03-008 |
|
UCT-03-008 inhibits the kinase activity of an undisclosed target, potentially leading to decreased cell proliferation in tumor cells overexpressing the target (NCI Drug Dictionary). |
|
UF-KURE19
|
|
UF KURE19|UFKURE19 |
CD19 Immune Cell Therapy
74
|
UF-KURE19 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, potentially resulting in cytotoxicity in tumor cells expressing CD19 (NCI Drug Dictionary). |
|
USL311
|
|
USL-311|USL 311 |
CXCR4 Inhibitor
15
|
USL311 is a CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may inhibit proliferation and migration of tumor cells expressing CXCR4 (NCI Drug Dictionary). |
|
V938
|
|
V 938|V-938 |
|
V938 is a recombinant Newcastle disease virus strain engineered to express IL-12, which may induce tumor cell lysis and enhance antitumor immune response (NCI Drug Dictionary). |
|
VAC85135
|
|
VAC-85135|VAC 85135 |
|
VAC85135 is a cancer vaccine comprising a viral vector expressing neoantigens, which may result in the induction of a cytotoxic T-lymphocyte (CTL) response against neoantigen-expressing tumor cells (NCI Drug Dictionary). |
|
VB10.16
|
|
DNA Vaccine VB10.16 |
|
VB10.16 is a DNA vaccine comprised of inactivated HPV16 E6 and E7 proteins attached to the chemokine macrophage inflammatory protein-1 alpha (MIP-1alpha), which may lead to activation of immune response and tumor cell lysis (Annals of Oncology 31 (2020): S645-S646; NCI Drug Dictionary). |
|
VBI-1901
|
|
VBI1901|VBI 1901 |
|
VBI-1901 is a vaccine comprising enveloped virus-like particles that contain GM-CSF linked to the cytomegalovirus antigens, glycoprotein B (gB) and phosphoprotein 65 (pp65), thereby potentially stimulating an immune attack against gB and pp65-expressing cancer cells (NCI Drug Dictionary). |
|
VCAR33
|
|
VCAR 33|VCAR-33 |
CD33 Immune Cell Therapy
5
|
VCAR33 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD33, which potentially induce antitumor activity (Blood (2023) 142 (Supplement 1): 4862; NCI Drug Dictionary). |
|
VEGFR1-1084
|
|
VEGFR1-A24-1084|OTS11101 |
|
VEGFR1-1084 is a FLT1 (VEGFR1) HLA-A*2402 allele-restricted peptide vaccine, which may stimulate a cytotoxic T-cell response against cells expressing FLT1 (VEGFR1), resulting in decreased tumor angiogenesis (PMID: 17020992, NCI Drug Dictionary). |
|
VSV-GP154
|
|
VSV GP154|VSVGP154 |
|
VSV-GP154 is a vesicular stomatitis virus (VSV) viral vector-based cancer vaccine containing pancreatic adenocarcinoma patient-derived tumor-associated antigen peptides, which preferentially replicates in tumor cells expressing KRAS G12V or KRAS G12D, potentially resulting in tumor cell killing (NCI Drug Dictionary). |
|
VSV-IFNbetaTYRP1
|
|
VSV-IFN-b/TYRP1|recombinant VSV-IFNbetaTYRP1 |
|
VSV-IFNbetaTYRP1 is a oncolytic vesicular stomatitis virus engineered to express interferon-beta (IFNbeta) and TYRP1, which potentially induces activation of immune cells and enhances the immune response against tumor cells expressing TYRP1 (NCI Drug Dictionary). |
|
VVD-130850
|
|
VVD 130850|VVD130850 |
STAT3 Inhibitor
26
|
VVD-130850 inhibits STAT3, which potentially results in decreased proliferation of STAT3-overexpressing tumor cells (NCI Drug Dictionary). |
|
Valacyclovir
|
Valtrex |
Acicloftal |
|
Valacyclovir is the prodrug of acyclovir, which is an antiviral agent that functions by inhibiting viral DNA polymerase (NCI Drug Dictionary). |
|
Vibostolimab
|
|
MK7684|MK 7684|MK-7684 |
Immune Checkpoint Inhibitor
150
TIGIT Antibody
21
|
Vibostolimab (MK-7684) acts as an antagonist to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
|
Vincristine Sulfate
|
Oncovin |
22-Oxovincaleukoblastine|vincristine |
|
Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary). |
|
WGI-0301
|
|
WGI 0301|WGI0301 |
Antisense Therapy
14
|
WGI-0301 is a lipid nanoparticle-based formulation of archexin, an antisense oligonucleotide targeting Akt, which inhibits Akt1 translation and potentially leads to decreased proliferation of Akt1-overexpressing tumor cells (NCI Drug Dictionary). |
|
WT1 sensitized T cells
|
|
|
|
WT1 sensitized T cells are T cells that have been sensitized to Wilms' Tumor Protein 1 (WT1), which have the potential to bind to WT1 expressing cells and induce cellular lysis (NCI Drug Dictionary). |
|
XB010
|
|
XB-010|XB 010 |
5T4 (TPBG) Antibody
8
|
XB010 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting 5T4 (TPBG) linked to monomethyl auristatin E (MMAE), which potentially induces cell cycle arrest and apoptosis in tumor cells expressing 5T4 (TPBG) (NCI Drug Dictionary). |
|
XB2001
|
|
XB-2001|XB 2001|Vilamakitug |
|
XB2001 is a monoclonal antibody that targets interleukin-1 alpha (IL1a), potentially resulting in decreased angiogenesis and reduced tumor formation (Ann Oncol (2024) 35 (suppl_1): S26, NCI Drug Dictionary). |
|
XL495
|
|
XL-495|XL 495 |
PKMYT1 Inhibitor
4
|
XL495 inhibits PKMYT1, which potentially induces mitotic arrest and apoptosis in tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1733, NCI Drug Dictionary). |
|
XmAb18087
|
|
XmAb 18087|XmAb-18087|Tidutamab |
CD3 Antibody
123
|
XmAb18087 (Tidutamab) is a bispecific monoclonal antibody that targets CD3 and somatostatin receptor 2 (SSTR2), which once bound to tumor cells expressing SSTR2, may elicit an immune response, resulting in cell death (NCI Drug Dictionary). |
|
XmAb18968
|
|
XmAb-18968|XmAb 18968 |
CD3 Antibody
123
CD38 Antibody
21
|
XmAb18968 is a bispecific T-cell engager that targets both CD38 and CD3, potentially leading to a cytotoxic T-lymphocyte mediated response against tumor cells expressing CD38 (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2515; NCI Drug Dictionary). |
|
XmAb22841
|
|
Pavunalimab |
CTLA4 Antibody
33
Immune Checkpoint Inhibitor
150
LAG3 Antibody
19
|
Pavunalimab (XmAb22841), is a bispecific antibody that targets CTLA4 and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
|
XmAb541
|
|
XmAb-541|XmAb 541 |
CD3 Antibody
123
CLDN6 Antibody
10
|
XmAb541 is a bispecific antibody targeting CLDN6 and CD3 that redirects cytotoxic T-lymphocytes towards tumor cells expressing CLDN6, potentially resulting in increased tumor cell killing (J Clin Oncol 2025 43: 5_suppl, TPS652, NCI Drug Dictionary). |
|
XmAb819
|
|
XmAb 819|XmAb-819|XmAb30819 |
CD3 Antibody
123
ENPP3 Antibody
5
|
XmAb819 is a bispecific antibody that targets ENPP3 and CD3, potentially resulting in increased T-cell response against tumor cells expressing ENPP3 (NCI Drug Dictionary). |
|
YH004
|
|
YH 004|YH-004 |
TNFRSF9 Antibody
36
|
YH004 is an agonistic monoclonal antibody that targets CD137 (4-1BB; TNFRSF9), resulting in increased CD137 signaling and potentially leading to inhibition of T-regulatory cells and induction of a cytotoxic T-lymphocyte (CTL)- and NK cell-mediated antitumor response, resulting in tumor cell killing (NCI Drug Dictionary). |
|
YL-15293
|
|
YL15293|YL 15293 |
KRAS G12C inhibitor
36
|
YL-15293 selectively inhibits KRAS G12C and leads to decreased downstream signaling, potentially resulting in anti-tumor activity (NCI Drug Dictionary). |
|
YL201
|
|
YL-201|YL 201 |
CD276 Antibody
22
|
YL201 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in tumor cells expressing CD276 (B7-H3) (Ann Oncol 35 (2024): S485, NCI Drug Dictionary). |
|
Yttrium Y 90 Basiliximab
|
|
90Y basiliximab |
|
Yttrium Y 90 Basiliximab consists of an anti-IL-2 receptor antibody (basiliximab) conjugated to radioactive yttrium Y 90, which binds to IL-2R and prevents IL-2 binding, as well as delivering cytotoxic radiation to IL-2R expressing cells, thereby potentially decreasing T-cell activation and immune response (NCI Drug Dictionary). |
|
ZL1201
|
|
ZL 1201|ZL-1201 |
CD47 Antibody
31
|
ZL1201 is a monoclonal anti-CD47 antibody that binds to the cell surface antigen CD47 and inhibits its interaction with signal regulatory protein alpha on phagocytic cells, and may lead to immune cell activation and tumor cell phagocytosis (NCI Drug Dictionary). |
|
ZN-A-1041
|
|
ZN-A 1041|ZN-A1041 |
HER2 Inhibitor
45
|
ZN-A-1041 inhibits ERBB2 (HER2)-mediated downstream signaling, potentially resulting in tumor cell death (NCI Drug Dictionary). |
|
ZN-c5
|
|
ZNc5|ZN c5 |
|
ZN-c5 is a selective estrogen receptor degrader, which prevents estrogen receptor mediated signaling (NCI Drug Dictionary). |
|
ZZ06
|
|
ZZ-06|ZZ 06 |
EGFR Antibody
74
|
ZZ06 is a monoclonal antibody targeting EGFR, which potentially inhibits EGFR signaling and tumor cell proliferation (NCI Drug Dictionary). |
|
cMet RNA CAR T cells
|
|
cMet CAR-mRNA electroporated autologous T lymphocytes |
MET Immune Cell Therapy
1
MET Inhibitor
59
|
cMet RNA CAR T cells are autologous T-cells transfected with RNA that codes for a chimeric antigen receptor comprised of a portion of anti-Met and CD3-zeta chain linked to CD-137, which targets T-cells to c-MET expressing tumor cells, resulting in selective toxicity (NCI Drug Dictionary). |
|
huCART19
|
|
huCTL019|CTL119|autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T cells |
CD19 Immune Cell Therapy
74
|
huCART19 comprise autologous T-cells engineered to express a humanized chimeric antigen receptor (CAR) that targets CD19, as well as CD3zeta chain and 4-1BB, which may result in increased T-cell response against CD19-expressing tumor cells (NCI Drug Dictionary, PMID: 38615142). |
|
iC9.CAR-CSPG4 T-cells
|
|
Autologous anti-CSPG4 CAR-iC9-expressing T-lymphocytes |
|
iC9.CAR-CSPG4 T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CSPG4 and also express inducible caspase-9, which potentially induce killing of tumor cells expressing CSPG4 (NCI Drug Dictionary). |
|
iCasp9M28z T cells
|
|
anti-mesothelin iCasp9M28z |
|
iCasp9M28z T cells are autologous T-cells that express a chimeric antigen receptor targeting mesothelin, which potentially enhances anti-tumor immune response against mesothelin-expressing tumor cells (NCI Drug Dictionary). |
|
mBTCvax
|
|
|
|
mBTCvax is a personalized cancer vaccine comprising patient tumor-derived neoantigen peptides combined with poly-ICLC, which may induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary) |
|
mDC3/8-KRAS vaccine
|
|
|
|
mDC3/8-KRAS vaccine is a cancer vaccine comprising patient-derived dendritic cells pulsed with patient-specific KRAS-mutant peptides, potentially resulting in increased anti-tumor immune response against KRAS-mutant tumor cells (NCI Drug Dictionary). |
|
mRNA 5671
|
|
mRNA-5671|V941|V 941 |
|
mRNA 5671 is a lipid nanoparticle encapsulated mRNA vaccine that targets KRAS G12D, G12V, G13D, and G12C, which potentially results in anti-tumor immune response (NCI Drug Dictionary). |
|
mRNA-2416
|
|
mRNA 2416 |
|
mRNA-2416 is a lipid nanoparticle-encapsulated mRNA encoding the ligand, TNFSF4 (OX40L, CD252), which upon translation binds to TNFRSF4 (OX40, CD134) expressed on T-lymphocytes, potentially leading to proliferation of T-cells and enhanced anti-tumor response (Cancer Res 2020;80(16 Suppl):Abstract nr CT032, NCI Drug Dictionary). |
|
pLADD
|
|
|
|
pLADD is a personalized live-attenuated double-deleted strain of listeria monocytogenes that is encoded with patient-specific neoantigens, which may elicit an immune response, resulting in antitumor activity (NCI Drug Dictionary). |
|
rHSC-DIPGVax
|
|
|
|
rHSC-DIPGVax is a peptide vaccine comprising 16 heat shock protein (HSP) neoepitopes associated with diffuse intrinsic pontine glioma and diffuse midline glioma, which potentially enhances cytotoxic T-lymphocyte (CTL) response against HSP neoepitope-expressing tumor cells (NCI Drug Dictionary). |